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Finding the balance - EpCAM signaling In health and disease Gruningen 
1 I Since the number of cell-cell adhesion proteins identified as substra s for regulated 
intramembrane proteolysis is increasing, it is crucial to re-interpret immunohist ical data and to 
consider signaling properties of proteolytic protein fragments. (Cancer Res. 2011, 71:303} 
2 I Localization of EpCAM's intracellular domain has been introduced as a distinctive marker for 
epithelial cancers. However, inconsistent immunostaining results demand mRNA assessment and 
antibody specificity validation to address the cleavage hypothesis. (SMC Cancer 2010, 10:331; PLoS 
ONE 2010, 5:e14130) 
3 I EpCAM and E-Cadherin are substrates of the same proteases. Therefore, loss of E-Cadherin­
mediated cell-cell adhesion and cleavage-induced signaling may predominantly account for the 
metastatic potential and aggressiveness of thyroid cancer (SMC Cancer 2012, 12:523; Cancer Res. 1993, 
53:4987). 
4 I As an outcome of 3.8 billion years of evolution, nature provides the most genius models for the 
development of new and sustainable technologies and designs. 
5 I Although basic research is the foundation of any applied research or commercial product, it is often 
met with incomprehension. 
6 I Exosomes are the future for gene therapy and drug delivery across the blood-brain barrier. 
7 I Following the diagnosis of Type 1 Diabetes and the initiation of insulin therapy, the "honeymoon 
phase" refers to the period in which the body's own insulin production still aids in blood glucose 
control. Since this is only temporal while diabetes progresses, "honeymoon" improperly implies that 
marriage is doomed to failure. 
BI Being critical towards data should always be prioritized above publishing; yet, it should not keep 
one from progressing. 
9 I Overnight live-cell imaging experiments sometimes only lead to the conclusion that the terms 
"Autofocus" and "Out of focus" are as interchangeable as they sound. 
D I The feeling of being fully integrated in a foreign country's society requires the ability to 
communicate in the native language. 
1 I Since the demand for organs exceeds availability, anyone that would embrace a donor organ in an 
emergency case should be willing to be a donor him-/herself. 
Z I Raising children in multiple languages is often considered a big challenge. However, even in Europe, 
where many assume that bilingualism is rare, every country has at least one linguistic minority 
whose members are typically bilingual. 
:1 I The word "Anspecken" (to gain weight) as the antonym of "Abspecken" (to slim down) should be 
included in German dictionaries. 
IJ I The absence of time consciousness may constitute the greatest quality of childhood. 
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1. GENERAL INTRODUCTION 
In multicellular organisms, epithelia line external and internal surfaces of the body. A 
major function of all epithelia is to form a barrier, preventing unrestricted exchange of 
materials between the organism and the external world. Simple epithelium consists of a 
tightly packed and organized monolayer of polarized cells and can generally be found in 
organs where absorption, secretion, or filtration occurs. Characteristic features of simple 
epithelia are microvilli or cilia on the apical side and high abundance of cell junctions 
(Fig. 1 ). Dysfunction of epithelia due to cellular or molecular abnormalities can give rise 
to a number of diseases, including cancer. So how is the epithelial integrity maintained? 
Cell adhesion - The epithelial barrier function is primarily determined by tight junctions 
(TJ; Zonula occ/udens; Fig. 1 ), which form an impermeable or regulated semi-permeable 
seal between the apical and basolateral side of the cells. Cell adhesion is important for 
cell polarity and for inhibition of cell proliferation and migration when epithelial cells 
adhere to neighboring cells, so-called contact inhibition1 • Contact inhibition is crucial 
for organogenesis and wound healing2 •3. In cancer, loss of contact inhibition can result 
in uncontrolled cell movement and proliferation, allowing cells to invade neighboring 
tissue and to metastasize4 . Cell adhesion is mediated by transmembrane proteins called 
cell adhesion molecules (CAMs). Classically, CAMs are subdivided into four major 
families: cadherins, selectins, integrins, and immunoglobulin(lg)-like CAMs (Fig. 1 ). 
Additionally, there are several CAMs that do not belong to any of these families5. In 
general, CAMs promote cell-cell adhesion or cell-matrix adhesion by homophilic or 
heterophilic interaction (Fig. 1 ). Although several CAMs have been reported to be 
involved in contact inhibition6.7, the mechanism is not fully understood4. Loss of contact 
inhibition in cancer cells might be the result of extracellular proteolytic cleavage, which 
has been described for a range of CAMs, leading to disruption of homophilic adhesion1 • 
EpCAM - One cell adhesion protein that does not fit into any of the "classical" adhesion 
molecule families is the so-called epithelial cell adhesion molecule (EpCAM, CD326). 
EpCAM was discovered in a screen for novel tumor-specific cell surface antigens in the 
1970's, in which monoclonal antibodies were generated by immunization of mice with 
cancer cells, leading to the production of antibody-secreting hybridomas8 . EpCAM is 
a glycoprotein of approximately 40 kDa that is highly expressed in epithelial cancers 
and at lower levels in normal epithelia. EpCAM's abundant expression on carcinoma 
led to its discovery by many research groups, and therefore received a variety of names 
(Table 1 ). Several of these names are still in use, making it more difficult to obtain a 
comprehensive picture of the properties of EpCAM9 • In 2007, it was therefore suggested 
to consistently use the name EpCAM as an abbreviation for the protein's ability to act as 
an epithelial-specific cell adhesion molecule and activating molecule9 • 
EpCAM in health and disease - Due to its frequent tumor-specific overexpression, 
EpCAM has been of significant interest for cancer diagnosis and therapy, and several 










(1) Tight junction 
(2) Adherens junction 
(3) Desmosome 
(4) Gap junction 
(5) Non-classical junctions 
(6) Focal adhesion, 
Hemi-desmosome 
Figure 1 I Cel l  adhesion molecules (CAMs) and junctional complexes are abundant in 
epithelial tissues. (1) Tight junctions form a seal between adjacent cells and are connected to actin 
filaments. (2) Adherens junctions are plaques of classical cadherins linked to the actin cytoskeleton. 
(3) Desmosomes are formed by desmosomal cadherins, linked to intermediate filaments. (4) Gap 
junctions connect the cytoplasm of two adjacent cells and are linked to microfilaments. (5) Selectins, 
lg-superfamily CAMs, but also other CAMs not belonging to the classical families can promote 
homophilic adhesion outside of junctions. lntegrins bind in a heterophilic manner. (6) Focal adhesions 
(linked to actin) and hemi-desmosomes (linked to intermediate filaments) are cell-matrix junctions 
that are formed by integrins. 
have been conducted9· 10. Apart from being targeted as a molecular biomarker, EpCAM also 
may play a functional role in tumor progression, and high expression of EpCAM is often 
associated with decreased patient survival9-1 6. Moreover, EpCAM has been identified as an 
additional marker for cancer stem cells in solid tumors17 • 18. High EpCAM expression occurs 
not only in carcinoma, but also in healthy tissue. Being expressed in stem/progenitor cells, 
EpCAM plays a morphoregulatory role in epithelial tissue development5• 19-21 . Here, high 
expression of EpCAM is associated with increased proliferation and correlates negatively 
with differentiation5 • 19·2 1 . Recently, mutations in the EpCAM gene have been discovered 
to be responsible for congenital tufting enteropathy (CTE)22, a rare autosomal recessive 
disease that affects the intestinal epithelium, leading to often lethal diarrhea in infants. 
EpCAM function - The name EpCAM originates from studies demonstrating that the 
protein ca� promote homophilic adhesion23; however, exogenous expression of EpCAM 
has also been shown to interfere with E-Cadherin-mediated cell adhesion, suggesting a 
role as a functional antagonist24. In addition, EpCAM has been suggested to be involved 
in a diversity of processes including cell proliferation, migration, adhesion, differentiation, 
10 
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Table 1: EpCAM's various names based on monoclonal antibodies or cDNA clones. 























n.a., mAb from immunization with colon adenocarcinoma cells 28 
Trophoblast cell-surface antigen 30 
n.a. (mAb) 32 
Carcinoma-associated glycoprotein 34 
n.a. (mAb) 36 
Human epithelium antigen 38 
Epithelial glycoprotein of M, 34,000 38 
Epithelial surf ace antigen 41 
Adenocarcinoma-associated antigen 42 
n.a. (mAb) 44 
Glycoprotein of 38 kDa 46 
n.a. (mAb) 29 
n.a. (mAb) 31 
n.a., mAb from immunization with gastric adenocarcinoma cells 33 
n.a. (mAb) 35 
n.a. (from cDNA clone) 37 
Epithelial glycoprotein-2 39 
Epithelial glycoprotein of Mr 40,000 40 











Tumor-associated calcium signal inducer 1 43 -- -
n.a. (derived from mAb FU-MK-1) 45 
Cluster of differentiation 326 47 
and cell signaling5•20 . Proliferation induced by EpCAM-overexpression has been shown to 
correlate with upregulation of cell cycle-related proteins25 . In 2009, two models of EpCAM 
signaling in cancer were proposed, one focusing on EpCAM as a new substrate for regulated 
intramembrane proteolysis (RIP)26, and the other one on the spatiotemporal localization of 
EpCAM and its association with a tight junction protein27. However, the molecular basis of 
EpCAM-mediated signaling in healthy tissue, cancer, and CTE is not yet fully understood. 
In this chapter, a general overview of the current knowledge on EpCAM is provided, 
focusing on functional and structural aspects and their implication in health and disease. 
2. EPCAM IN HEALTH & DISEASE 
a. EpCAM in normal tissue and during development 
(i) EpCAM expression - In healthy adult tissue, EpCAM is expressed at the basolateral 
cell membrane of simple, pseudo-stratified, and transitional epithelia. No expression 
1 1  
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can be detected in normal squamous stratified epithelia. In adult humans, EpCAM 
is expressed in most organs and glands, with the highest expression in the colon. In 
general, the levels of expression differ between tissue types. EpCAM is expressed neither 
in cells of lymphoid origin and bone-marrow-derived cells, nor in mesenchymal, muscular, 
and neuro-endocrine tissues38A8 (see Balzar et al. 199920 and Went et al. 200449 for an 
overview). In a number of epithelial tissues, active proliferation correlates with increased 
expression or de nova expression of EpCAM, whereas differentiation is associated with 
downregulation of protein expression (reviewed in Balzar et al. 199920) (Fig. 2). In the 
intestinal epithelium for example, a gradient of EpCAM expression can be observed from 
crypts to villi20. This expression pattern corresponds to high EpCAM levels in the intestinal 
stem cells, located in the crypts50, and decreasing levels when cells are differentiating. 
In addition to the gut, EpCAM can be found in progenitor cells of other organs: e.g., 
hepatocytes are EpCAM-positive during embryonic liver development, whereas in adults, 
EpCAM is only expressed during liver regeneration processes in cells resembling precursor 
cells21 . EpCAM's high expression in fetal epithelia in comparison to adult mature tissues34 
points to a dynamic regulation of its expression during morphogenesis19. In the human 
fetal pancreas, the highest levels of EpCAM can be found in developing islets budding 
from pancreatic ducts. In the adult pancreas, levels are low in differentiated islets but 
high in duct cells, which might represent endocrine progenitors1 9 . 
(ii) Stem cell marker - EpCAM's role in the switch between proliferation and 
differentiation is further suggested by EpCAM's identification as a surface marker 
for pluripotent human embryonic stem cells (hESCs)47•51 and murine embryonic stem 
cells (mESCs)52 . In undifferentiated hESCs, EpCAM is co-expressed with pluripotency 
markers Octamer 4 (OCT4) and Sex-determining region Y-Box 2 (SOX2)51 . Knock-down 
of EpCAM results in decreased cell proliferation and causes significant upregulation of 
endoderm- and mesoderm-associated genes. However, decreasing EpCAM levels by 
silencing did not significantly alter the expression of pluripotent markers. In mESCs, 
EpCAM expression has been found to be higher under self-renewal conditions than 
during differentiation52 . Induction of differentiation caused downregulation of EpCAM 
along with decreased expression of c-Myc and pluripotent markers SOX2, Oct3/4, and 
EpCAM 
Prof iferation Differentiation 
Figure 2 I EpCAM in the balance between cell proliferation and differentiation. High EpCAM 
levels are associated with cell proliferation, whereas low levels correspond to differentiation. 
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Stat3. Downregulation of EpCAM induced similar effects52 . Hence, EpCAM is likely 
involved in the maintenance of the undifferentiated state of ESCs (Fig. 2). 
(iii) Knock-down animal models - Due to the lack of genetic loss-of-function studies, 
the in vivo function of EpCAM remains poorly understood. Loss of EpCAM in the 
developing zebrafish led to compromised epithelial plasticity and adhesiveness, with 
hyper-proliferation as a secondary consequence, possibly due to the loss of contact 
inhibition53 . Compromised skin integrity also resulted in a higher susceptibility for 
bacterial infections and enhanced inflammation53 . Homozygous deficient EpCAM -/­
mice died in utero, revealing prominent placental abnormalities. EpCAM -/+ mice were 
viable and did not show abnormalities54 . So far, no conditional EpCAM knock-out mice 
or transgenic mice have been generated. Such mice would allow assessment of essential 
functions of EpCAM and also the investigation of diseases resulting from mutations in 
the EpCAM gene, such as CTE (see section 2c). 
b. EpCAM i n  cancer 
(i) Prognostic marker - EpCAM levels are increased on most epithelium-derived 
tumors. High expression levels of EpCAM usually correlate with poor prognosis, e.g. 
in breast and ovarian cancer as well as in pancreatic, urothelial, and gallbladder 
carcinoma1 1 -1 6 . Here, high EpCAM expression also often promotes cancer progression 
and metastasis. Exceptional cases are e.g. renal and thyroid carcinoma, where high 
levels of EpCAM have been shown to correlate with increased survival55•56 . In several 
other cancer types, EpCAM seems to play a dual role, either promoting or reducing 
cancer progression (for overviews of EpCAM as a prognostic marker see van der Gun et 
al. 201057 and Patriarca et al. 201258) .  EpCAM's prognostic value also has been assessed 
in combination with E-Cadherin and tight junction protein Claudin7, which are both 
functionally related to EpCAM (see section 4a). However, co-expression analysis did not 
improve EpCAM's prognostic value for the presence of nodal metastases in oral and 
oropharyngeal squamous cell carcinoma (OSCC) (Melchers et al. , in preparation). 
Since EpCAM might be subject to regulated proteolytic cleavage (see section 4c i), 
which involves ectodomain shedding, data regarding EpCAM expression based on 
immunohistochemistry should be interpreted with caution (see also chapter 2). Studies 
using an antibody against EpCAM's intracellular domain suggested that nuclear/ 
cytoplasmic EpCAM staining correlates with the aggressiveness of thyroid cancer and 
overall patient survival, and that this nuclear and cytoplasmic staining can be specifically 
found in epithelial cancers in contrast to normal tissue59•60 . Although we had similar 
staining results in OSCC material, we could not exclude artifacts due to non-specific 
binding of the primary antibody. 
(ii) Cancer therapy- Besides being of prognostic value, EpCAM is an attractive target for 
tumor therapy because of its tumor-specific overexpression. EpCAM has been used as a 
target for many immunotherapeutic approaches, including treatment with monoclonal 
antibodies1 0 and the development of cancer targeting antibodies61 . Furthermore, 
1 3  
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vaccination strategies62 , an EpCAM-specific antibody fragment fused to TRAIL (Tumor 
necrosis factor-related apoptosis-inducing ligand)63·64 , and toxin-conjugated antibody 
fragments65·66 have been developed. Since 2009, the anti-EpCAM trispecific antibody 
catumaxomab (Removab) has been approved for treatment of malignant ascites in 
cancer patients; other EpCAM-directed antibodies and antibody-based constructs are 
currently in clinical development9· 1 0 . 
(iii) Lynch syndrome - In addition to its direct involvement in tumor biology (see 
section 4), EpCAM plays an indirect role in Lynch syndrome (also known as hereditary 
nonpolyposis colorectal cancer; HNPCC). This term describes an autosomal dominant 
cancer predisposition syndrome in which patients are prone to develop colorectal 
adenocarcinoma (60 - 90%), endometrial carcinoma (20 - 60%), and various other 
cancers67-69 . Tumors observed in Lynch syndrome families are diagnosed at an unusual 
early age and can be multiple. Lynch syndrome is caused by mutations in mismatch 
repair genes, including MLH1  and MSH2 (mutL homolog 1 and mutS homolog 2). 
Mutations in MLH 1  and MSH2 account for about 80% of Lynch syndrome cases70 . 
Recently, heterozygous germline deletions in the EpCAM gene (epcam), located 
upstream of MSH2, have been shown to result in hypermethylation of the MSH2 
promoter region and subsequent loss of MSH2 expression69. Deletions of the last exons 
of epcam l ead to extended transcription into the downstream gene, resu l ting in an 
epcam-MSH2 fusion transcript and methylation induction of the MSH2 promoter69. 
19 different epcam deletions, all including the last two exons, have been identified 
in 45 Lynch syndrome families67 . epcam deletions account for approximately 20% of 
Lynch syndrome cases showing loss of mismatch protein expression but lacking the 
corresponding gene mutations70 . In total, deletions in epcam inactivate MSH2 in about 
1 % of individuals with Lynch syndrome. Due to high EpCAM expression levels in 
specific tissues, carriers of an epcam deletion have a high risk of colorectal carcinoma, 
whereas extra-colonic cancers are rarely found and the risk for endometrial cancer is 
reduced68•7 1 . In the latter case, the cancer risk seems to correlate with the size and 
location of the deletion in the EpCAM gene. Thus, genetic screening for EpCAM might 
allow optimization of cancer surveillance programs for Lynch syndrome families68 . 
Histological studies showed a lack of EpCAM expression in a number of tumors 
from patients with epcam germline deletions. Here, EpCAM was only absent in case 
of homozygous epcam deletion, resulting from the combination of a germline and a 
second somatic deletion72•73 . Absence of EpCAM in these tumors seems to disagree 
with the model of EpCAM being important in tumor development and progression. 
This raises the question whether EpCAM is overexpressed as a secondary effect and is 
only representing a tumor marker, or whether it actually plays an active role as a proto­
oncogene. In case of Lynch syndrome, the absence of mismatch repair proteins might 
be the dominant cause for the development of tumors, outrunning possible beneficial 
effects due to absence of EpCAM. Notably, only homozygous mutations in epcam resul t  
in loss of EpCAM expression and morphological abnormalities, as has been shown in 
knock-down mice (see section 2a iii) and CTE (see below). 
1 4  
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c. M utations of EpCAM cause congenital tufting enteropathy 
Apart from EpCAM's indirect role in Lynch syndrome, homozygous mutations in epcam have 
been identified in patients suffering from congenital tufting enteropathy (CTE)22• CTE is a rare 
autosomal recessive form of intractable diarrhea of infancy. Typically, patients develop chronic 
diarrhea within the first days after birth and show impaired growth. CTE is characterized by 
subtotal villous atrophy with crypt hyperplasia without evidence of inflammation. In the 
typical form, abnormalities are localized mainly in the intestinal epithelium and include 
disorganization of surface enterocytes with focal crowding, resembling tufts74• Most patients 
are dependent on parenteral nutrition to allow normal growth and development. The disease 
persists throughout life and imparts significant morbidity and mortality22 • CTE was first 
described in 199475 with an annual incidence of -1/100,000 live births in Western Europe. 
As a result of its severity and rarity, the pathogenesis of CTE remains poorly understood. 
In 2008, the genetic basis of CTE was uncovered: using single nucleotide 
polymorphism (SNP) genotyping in CTE patient material, Sivagnanam and colleagues22 •76 
identified several epcam mutations, resulting in a single amino acid exchange, truncation 
or partial deletion of the EpCAM protein. Another case study revealed a single basepair 
insertion, leading to a frame shift and premature truncation of EpCAM77 • Further studies 
revealed novel mutations resulting in premature stop codons and thereby truncation of 
the protein78•79 (see Fig. 1 in chapter 3). 
In a comprehensive analysis of all identified EpCAM mutants, we recently discovered that 
all the mutations in EpCAM result in absence of the protein from the plasma membrane 
(see chapter 3). This can be due to either secretion or degradation of the truncated protein, 
or to retention of the aberrant protein in the endoplasmic reticulum. Considering EpCAM's 
morphoregulatory role and its high expression in the intestinal crypts where the stem cells are 
located, absence of EpCAM might disturb normal intestinal development. Sivagnanam et al. 
speculate that EpCAM is involved in the development of the crypt villus axis, where epithelial 
cells originate from stem cells in the crypt and migrate to the tip of the villus22 . EpCAM's 
absence from the cell surface may not only preclude its adhesive function, but might also 
prevent EpCAM-mediated signaling, involving proteolytic cleavage and association with 
tetraspanins and other transmembrane proteins (see section 4c). 
Some cases of CTE have been reported as being associated with chronic arthritis77 or 
malformations, including eye-associated abnormalities80 • In a recent study, Roche and 
colleagues found that 10 out of 15 patients diagnosed with CTE exhibited ophthalmic 
functional disorders such as superficial punctate keratitis (SPK) and conjunctiva! 
erosive lesions, revealing that CTE might be a multifocal clinical disease81 • Besides the 
characteristic CTE features in the intestinal epithelium, also conjunctiva! tissues showed 
disorganization of the surface epithelium with focal crowding, resembling tufts81 • 
Disorganization of surface enterocytes with tuft-like crowding has been considered 
a unique diagnostic feature for CTE until recently. However, since the genes for several 
congenital diarrheal disorders have been identified and tufts have been found unreliable 
as a distinctive feature for CTE, genetic testing is crucial for a correct diagnosis and 
optimal treatment82 . 
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To uncover how EpCAM is involved in tumor progression and normal development, 
it is important to understand EpCAM's function and the mechanism of EpCAM signaling 
on the molecular level. The sections below provide an overview of EpCAM's structure, 
function, and EpCAM signaling as known to date. 
3 .  EpCAM :  GE N E, PROTE I N  & STRUCTUR E  
Human EpCAM is a polypeptide of 314 amino acids (aa), consisting of a large extracellular 
domain (N-terminal) of 242 aa, a single-spanning transmembrane domain of 23 aa and 
a short cytoplasmic domain of 26 aa (C-terminal)42 (Figs. 3 and 4). The gene encoding 
for human EpCAM is located on chromosome 2 (location 2p21) and has an estimated 
size of 14 kb20•83•84 . Comparison of the genomic and cDNA sequences has shown that 
the epcam gene consists of 9 coding exons: EpCAM's extracellular domain, including 
the signal peptide, is mainly encoded by exons 1 to 6, the transmembrane region by 
exon 7. The intracellular domain is encoded by exons 8 and 9 (last 13 amino acids) 20•84 
(Fig. 3). The EpCAM gene is conserved in many species, including chimpanzee, dog, 
cow, mouse, rat, chicken, and zebrafish. Moreover, the EpCAM protein seems to be 
highly conserved among higher vertebrates, e.g. human EpCAM showing 82% amino 
acid sequence homology with mouse EpCAM. 
(i) The extracellular domain of human EpCAM - EpCAM's extracellular domain 
starts with the signal peptide, which is cleaved off predominantly between alanine 23 
and glutamine 2442•83•85 (Fig. 4). N-terminal sequencing revealed a minor alternative 
cleavage of the signal peptide after residue 21 (1 %)85 • 
Different models of the tertiary structure of EpCAM's ectodomain have been developed, 
defining three motifs. Balzar and colleages have suggested that EpCAM's extracellular 
domain contains a tandem of epidermal growth factor(EGF)-like repeats (amino acids 27-59 
and 66- 1 35), which closely resemble the fourth and fifth EGF-like motif in the rod domain of 
nidogen, a basement membrane glycoprotein involved in cell-matrix adhesion86 . However, 




position l 23 27 59 66 






Figure 3 I Structure of the EpCAM encoding gene (A) a nd p rotein  (B). The EpCAM encodi ng 
gene (GA733-2, epcam) consists of 9 exons located on chromosome 2. The protein is encoded as 
ind icated. SP = signal peptide; TY = thyroglobulin-like domain; TM = transmembrane domain. 
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Figure 4 1  Amino acid sequence of EpCAM. 
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determination of the exact disulphide bond assignments of the protein by Chong and 
Speicher has revealed that the first motif in EpCAM's ectodomain shows a novel pattern of 
disulphide linkage that does not resemble an EGF-like domain85 • Furthermore, the second 
motif does not represent an EGF-like repeat, but is in fact, as presented in earlier studies, a 
thyroglobulin (TY) type 1 A repeat83·85•87 (Fig. 4). Thyroglobulin type 1 domains are conserved 
in a number of proteins and capable of binding and thereby inhibiting certain cathepsins 
(cysteine proteases), which are involved in cancer progression88•89 • Whether EpCAM plays a 
role as a substrate or inhibitor of cathepsins is not known. Following the TY-repeat, EpCAM's 
so-called third motif is cysteine-free and unrelated to known molecules. 
EpCAM contains three N-glycosylation sites at positions Asn74, Asn111  (both within 
TY-repeat) and Asn198 (Cysteine-free region; F ig .  4)41 •85•90 • In human and murine cell 
lines, point mutations have shown that all three N-glycosylation sites are glycosylated91 , 
whereas in insect cells, Asn11 1 and Asn74 are completely or partially glycosylated, while 
Asn198 is not glycosylated85 (Fig. 4). In mammalian cells, glycosylation of Asn1 98 seems 
to be of high importance for EpCAM's cell surface expression and protein stabil ity9 1 . 
Mutation of the Asn198 glycosylation si te led to decreased expression of EpCAM91 . 
Furthermore, elimination of all three glycosylation si tes reduced the half-life time of 
the prote in from 21 to 7 hours when compared to wt EpCAM91 . Since a number of 
cell surface molecules such as Notch, E-Cadherin, integrins, and CD44 are differentially 
glycosylated in carcinoma versus normal epithelia92·95, differential glycosylation of 
EpCAM might be an important factor causing differences in the function of EpCAM in 
healthy versus malignant tissue. In head and neck carcinoma, EpCAM has been shown 
to be hyperglycosylated in comparison to healthy tissue96. 
(ii) The intracellular domain - Following the transmembrane domain, which is 
involved in the association with tight junction protein Claudin727 (Fig. 4; see section 4c i i), 
EpCAM's short cytoplasmic domain consists of 26 aa of which 14 are charged. Using 
EpCAM mutants with deletions in the intracellular domain, Balzar and colleagues97 
determined two potential a-actinin binding sites at positions 289 to 296 and 304 to 
314 (Fig. 4), which are reportedly important for EpCAM's localization at cell-cell contacts 
and therefore for the cell adhesion properties of the molecule97 (see section 4a). At the 
(-term inus, amino acids Leu312, Asn313 and Ala314 display a putative PDZ binding 
site (Fig. 4). In most other cell-cell contact proteins, the hydrophobic (-terminal aa can 
interact with multi-PDZ domain proteins that are key in complex formation with signaling 
or structural proteins. Whether this is the case for EpCAM is currently not known. 
(iii) EpCAM cleavage - Proteolytic cleavage of EpCAM at multiple sites has been implicated 
in its function. Like many other transmembrane proteins, EpCAM contains a signal peptide 
which is cleaved off by a signal peptidase (see before; Fig. 4, arrow 1 ). Furthermore, EpCAM 
can be cleaved between Arg80 and Arg81, located in the second motif (TY-repeat) of the 
ectodomain41 •83•90 (Fig. 4, arrow 2). The cleaved peptide has a molecular weight of 6 kDa and 
remains attached to the 32 kDa part via the disulphide bond between Cys6 and Cys7 (Fig. 5). 
Notably, the majority of mAbs that recognize EpCAM on cancer cells bind specifically to this 
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6 kDa part, underlining its high immunogenicity90•98 . A number of proteases, including serine 
proteases trypsin and chymotrypsin, have been shown to be able to conduct this N-terminal 
cleavage of EpCAM90, which occurs in a variety of epithelial cancer cell lines originating e.g. 
from colon, ovarian, and breast cancer41 • Whether or not and to which extent N-terminal 
cleavage occurs depends on the presence and activity of the relevant proteases41 • Although 
EpCAM's limited N-terminal proteolytic cleavage was discovered more than three decades 
ago and suggested to be of functional importance90, the effects of this post-translational 
modification on EpCAM's structure and function are still unknown. 
While the two cleavage sites described above are the only truly identified, EpCAM 
might be cleaved by additional proteases which will be discussed below. Besides all 
these published cleavage events (this chapter), we identified novel proteolytic fragments 
(chapter 4). 
(iv) EpCAM's homologue TROP-2 - The only molecule known to be homologous 
to EpCAM is the GA733- 1 gene product TROP-2 (Trophob/ast cell-surface antigen-2), 
showing approximately 49% sequence identity and 67% similarity taking conserved 
substitutions into account20·83 . The most prominent regions of homology are the 
transmembrane region and a region in the extracellular domain that is homologous 
to the type 1 repeat of thyroglobulin . Like EpCAM, TROP-2 contains twelve cysteine 
residues . Remarkably, the positions of these cysteines as well as the overall distribution 
of hydrophilic and hydrophobic residues are conserved in both proteins83 . Instead of 
three, TROP-2 (36 kDa) contains four N-glycosylation sites, resulting in a total molecular 











- 32 k D  
- 6 k D  
Figure 5 I N-terminal  cleavage of EpCAM. (A) Schematic representation of EpCAM in its non­
cleaved ( 1 ) and cleaved state (2). After reduction of disulfide bonds (blue l ines), the cleaved part is no 
longer connected (3). Red arrow: Arg80/81 cleavage site. (B) Lysates of colon cancer cell line SW480 
were immunoprecipitated with antibody MH99, recognizing EpCAM motif 1 .  [35S]Methion i ne-labeled 
immunoprecipitates were analyzed u nder non-reducing ( 1 )  and reducing conditions (2) on 1 5% 
acrylamide gels (reproduced and adapted from Thampoe et al. 1 9884 1).  
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weight of 50 kDa. Two of these glycosylation sites are conserved in EpCAM83 . Whereas 
the conserved tyrosine residue present in both proteins has never been reported to 
be phosphorylated, TROP-2 has been found phosphorylated within the cytoplasmic 
domain at Ser303, which is not conserved in EpCAM99 • 1 00 . While phoshorylation of 
TROP-2 by protein kinase C may be essential for tumor growth promoting signaling of 
the protein1 00, it does not seem to play a role in EpCAM-mediated signaling. 
Like EpCAM, the TROP-2 protein is mainly expressed in epithelial tissue. Notably, 
expression levels are low in tissues with relatively high EpCAM expression, such as 
colon and lung tissue, whereas expression levels are relatively high in EpCAM-negative 
epithelium20 . Nevertheless, TROP-2 is overexpressed in a variety of late-stage epithelial 
carcinomas (pancreatic, colorectal, gastric and squamous cell-carcinoma of the oral 
cavity). Overexpression is associated with decreased patient survival as well as increased 
tumor aggressiveness and metastasis1 00, pointing to functional homology between 
TROP-2 and EpCAM. 
4. E PCAM F U N CTI O N  
a .  EpCAM and adhesion 
While EpCAM was discovered in a tumor-marker assay, its function remained elusive . 
Sequence homology to nidogen, a basement membrane protein mediating cell-matrix 
adhesion, suggested that EpCAM might be involved in cell-matrix or cell-cell adhesion86 . 
The name EpCAM -or epithelial cell adhesion molecule- was introduced by Litvinov and 
colleagues (1 994), who showed that EpCAM can mediate Ca2+-independent homophilic 
cell-cell adhesion in cells that normally lack cell-cell interactions23 • Expression of EpCAM 
in EpCAM-negative cells led to aggregation of cells and the formation of cell-cell 
contacts. In a mix of EpCAM-positive and EpCAM-negative L-cells, cell aggregates 
mainly consisted of EpCAM-positive cells (90%), pointing to homophilic adhesion. 
Using a range of EpCAM deletion mutants, Balzar et al. have demonstrated that all the 
motifs in EpCAM's extracellular domain are required for the formation of homophilic 
intermolecular binding and EpCAM accumulation at cell-cell adhesion sites98 . However, 
also the short intracellular domain, which might connect EpCAM with the actin 
cytoskeleton via a-actinin (see section 3b), is essential for EpCAM localization at cell-cell 
contacts and therefore for EpCAM's ability to mediate adhesion97 • Only the intact wt 
protein associated with a-actinin98 . 
While being able to mediate homophilic adhesion when introduced in cells that 
lack their own means of cell-cell interaction, EpCAM is neither structurally related to 
any of the four major families of CAMs24 nor associated with any classical junctional 
structure 1 °1 . In human colon epithelium as well as in epithelial cell lines, EpCAM could 
not be detected at tight junctions, desmosomes or cell-matrix adhesions, whereas it 
partly co-localized with E-Cadherin at the lateral membrane 1 0 1 . 
The reported effects of EpCAM in cell-cell adhesion are quite contradictory and 
need further explanation. In comparison to E-Cadherin, EpCAM is a relatively weak 
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cell-cell adhesion molecule23•24 . Unlike E-Cadherin expressing cells, which are tightly 
connected due to adherens junctions, EpCAM expressing cells are only loosely 
interconnected24 • Remarkably, when co-expressed in E-Cadherin expressing cells, 
EpCAM weakens E-cadherin-mediated intercellular adhesion24 . This weakening is not 
due to lower E-Cadherin levels or lack of its cell-surface localization, but results from 
reduced stability of E-Cadherin-mediated adhesion due to disturbance of E-Cadherin 
association with the cytoskeleton via cx-actinin24 • Other typical epithelial features, such 
as contact inhibition and polarization, are less strong in EpCAM-expressing cells when 
compared to E-Cadherin-expressing cells23 . 
Being part of adherens junctions, E-Cadherin is fundamental for the maintenance 
of the normal architecture of epithelial tissues102 . Loss of E-Cadherin expression can 
result in loss of cellular polarity and contact inhibition, unregulated growth and invasion 
of tumor cells in adjacent tissues1 03-1 08• In most epithelia, E-Cadherin and EpCAM are 
co-expressed during some stage of development. However, an increased or de nova 
expression of EpCAM is often associated with metaplastic or neoplastic changes, 
which can progress to malignancies24• 109• 1 10, while E-Cadherin has a tumor-suppressing 
and growth-inhibitory role6 • By weakening Cadherin-mediated cell-cell adhesion, 
EpCAM might induce higher tissue plasticity, which may promote cell proliferation and 
motility during morphogenesis, but -due to aberrant overexpression- also during the 
development and progression of malignancies. 
Concluding, although EpCAM is able to promote homophilic adhesion, it seems to 
be a functional antagonist of E-Cadherin. Hence, the name EpCAM is misleading. In 
regard to Cadherin-mediated adhesion, EpCAM's anti-adhesive effect might well be 
tightly regulated and coordinated during morphogenesis and tissue regeneration24 but 
out of control during carcinogenesis. 
b. EpCAM and pro l iferation 
Besides EpCAM's increased/de nova expression in metaplasia and neoplasia, its 
abundant overexpression on fast proliferating tumors points to a causal relationship 
and the involvement of EpCAM in growth control. Several in vitro and in vivo studies 
have shown that overexpression of EpCAM, or parts of it (see below), induces cell 
proliferation, whereas downregulation of EpCAM decreases cell proliferation25,26• 1 1 1 -1 1 3  
(Fig. 2). Induction of EpCAM in some in vitro models results in rapid upregulation of 
the oncogenic transcription factor c-Myc, and consequently in upregulation of cell 
cycle-related proteins Cyclin A and E as well as epidermal fatty acid binding protein25• 1 1 4 • 
Using EpCAM mutants, M0nz and colleagues have shown that EpCAM's intracellular 
domain is not only necessary but also sufficient to induce c-Myc upregulation25 . Whereas 
EpCAM-mediated induction of Cyclin A and E might be a secondary effect following 
upregulation of c-Myc, EpCAM has been shown to have a direct effect on Cyclin D1 at 
the transcriptional level1 1 3 • A current model of EpCAM's signaling mechanism suggests 
that EpCAM is subject to regulated intramembrane proteolysis (Fig. 6). Here, the 
cleaved intracellular domain seems to be responsible for the induction of EpCAM's 
target genes26• 1 1 3  (see below; Fig. 6). 
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c. M od els of EpCAM-med iated s ignaling 
(i) Regulated intramembrane proteolysis - The mechanism of EpCAM-induced 
proliferation in cancer cells might involve regulated intracellular membrane proteolysis 
(RIP)26 . RIP describes an evolutionary conserved mechanism combining regulated e.g. 
ligand-induced ectodomain shedding with the consecutive release of an intracellular 
domain (ICD) from transmembrane proteins1 1 5 (Fig. 6). Both the shed ectodomain 
and/or the ICD may activate signaling events. Matrix metalloproteases (MMPs) and the 
disintegrin-type metalloproteases (ADAMs, 'A disintegrin and metal!oprotease') are 
often involved in protein ectodomain shedding, whereas, in a second step, y-secretases 
including presenilin-1 and 2 (PS-1, PS-2) as active subunits are generating the soluble ICD. 
Besides proteins such as Notch and amyloid precursor protein (APP), a number of CAMs 
have been shown to undergo proteolytic cleavage, including E-Cadherin, CD44 and 
L 1-CAM1 • 1 1 6-1 1 9. While non-cleaved E-Cadherin, e.g., acts as a tumor suppressor, different 
proteolytic fragments of E-Cadherin have been shown to promote tumor progression1 20  . 
• • • 
extracellular 








• / nucleus 
FHL-2 Target genes 
intracellular 
Figure 6 I EpCAM as a substrate for regulated intra membrane proteo lysis (RIP) . Full-length EpCAM 
( 1 ) is cleaved by ADAM 1 7, releasing EpCAM's ectodomain (EpEX) (2) . EpEX might act as a homophilic 
ligand for non-cleaved EpCAM, inducing RIP (grey dotted arrow). Following the first cleavage step, 
EpCAM's cytoplasmic tail (EplCD) is released due to cleavage by PS-2 (3). EplCD associates with FHL-2 
and �-catenin and translocates to the nucleus (4), inducing transcription of EpCAM target genes via 
LEF- 1  consensus sites. Adapted from Maetzel et al. 200926• See main text for details and abbreviations. 
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The proteases implicated in RIP of EpCAM are metalloprotease ADAM17 (also 
known as TACE: tumor necrosis factor-a-converting enzyme) and a y-secretase 
containing PS-226 • The initial cleavage results in the release of a soluble fragment, called 
EpEX, which possibly acts as a homophilic ligand for non-cleaved EpCAM. The cleaved 
intracellular peptide EplCD might initiate signaling by association with �-catenin and 
four-and-a-half LIM domains protein 2 (FHL2). This complex may translocate to the 
nucleus, where it binds LEF-1 and DNA, resembling the canonical Wnt signaling pathway 
(Fig. 6). LEF-1 is known to be a major regulator of c-myc and Cyclin E, which represent 
Wnt target genes and also EpCAM's target genes26 . Notably, since EpCAM itself has 
been shown to be induced by Wnt signaling1 2 1 , EpCAM cleavage may trigger a positive 
feedback loop on its expression26. Theoretically, EpCAM's ability to weaken E-Cadherin 
mediated adhesion (discussed above) might lead to an increase in non-membrane 
bound �-catenin24 .m, which may be stabilized and protected from degradation due to 
association with EplCD and FHL-2 (Fig. 7). The fact that expression and regulation of 
ADAM 17 and presenilins as well as FHL2 differ between normal versus malignant tissue 
might explain EpCAM's different functional properties in health and disease26 • Although 
EpCAM is detectable at low levels in sera of cancer patients45• 1 23• 1 24, the used detection 
methods did not distinguish between full-length EpCAM and its cleaved ectodomain. 
Conclusions should be drawn with caution since EpCAM is also present on exosomes, 










Figure 7 I EpCAM signaling in cross-talk with E-Cadherin. EpCAM may weaken E-Cadherin­
mediated adhesion by interrupting the l i nk  between E-Cadherin and the act in cytoskeleton .  This 
might i n  turn result in increased ava i lab i l ity of non-bound �-caten in that may be stabi l ized by 
association with Ep lCD. Adapted from Maetzel et al. 200926• 
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(ii) Tetraspanin-enriched microdomains - Cell-to-cell contact has been identified as 
an initial trigger for the proteolytic processing described above and thereby induction of 
EpCAM-mediated proliferation 1 26 • However, not only EpCAM's presence and homophilic 
interaction at the cell surface, but also localization in specific subdomains of the plasma 
membrane might be highly important for signaling. Cell signaling is often facilitated by 
microdomains, for instance specialized cell-cell contacts2 (Fig. 1 ), but also other membrane 
microdomains, such as lipid rafts or so-called tetraspanin-enriched microdomains 
(TEMs), can serve as signaling platforms. TEMs are organized macromolecular complexes 
formed by tetraspanins, integral transmembrane proteins that can interact with other 
tetraspanins, certain lipids, and a variety of transmembrane and cytosolic proteins1 27• 1 29 • 
Although lipid rafts and TEMs exhibit some similarities, they can be distinguished by their 
distinct protein composition 1 27 • EpCAM has been identified as a new molecule in TEMs, 
forming a primary complex with tetraspanin CD91 30 • 
In metastasizing rat carcinoma cell lines, EpCAM has been found in a complex 
with tetraspanins CD9 and CO-029 (Tetraspanin8), as well as CD44 variant isoforms 
(CD44v4-7) (Fig. 8)1 3 1 , which are involved in tumor progression 1 32 . In contrast to CD9, 
which has a tumor-/metastasis-suppressing role, high levels of CO-029 correlate with 
metastasis and poor prognosis1 28•1 3 0• 1 33· 1 35 • Another protein in the EpCAM-CD44v­
tetraspanin complex has been identified as the tight j unction protein Claudin7, which 
directly binds to EpCAM via an AxxxG motif within the transmembrane domain27 • 1 36• 1 37 
(Fig. 4). Claudin7 recruits EpCAM into TEMs where it associates with CO-029 and 
CD44v6 1 37 (Fig. 8). The direct association with Claudin7 seems to be crucial for EpCAM­
specific functions: only in complex with Claudin7, EpCAM has been found to promote 
cell proliferation, apoptosis resistance, and tumorigenicity27 • 
Interestingly, also metalloproteases have been identified as members of the 
tetraspanin web; ADAM 10 for example associates with CD9 and other tetraspanins130• 1 38 . 
ADAM 10 and ADAM 17, which has been shown to be involved in EpCAM cleavage26 , 
are key players in ectodomain shedding or RIP 1 39· 1 41 • Tetraspanins might play a role 
as regulators of ADAM-induced ectodomain shedding138• 142 : Antibodies against 
tetraspanins, including CD9, specifically induced ADAM10- but not ADAM1 7-dependent 
cleavage of TNF-a and EGF in certain cell lines1 38 • Another study revealed that CD9 
negatively regulates ADAM17 activity1 43 . Fu rthermore, Tetraspanin12 has been shown 
to promote ADAM10-mediated cleavage of APP and the maturation of ADAM10 in 
some cell lines1 42 • Among the ADAM proteases, ADAM17 and ADAM10 are the most 
closely related 1 44 and often share substrates1 39• 1 4 1 • However, while a major fraction of 
ADAM 10 is localized in TE Ms, ADAM 17 seems to be sequestered to lipid rafts1 45 and 
has, except for one study1 43 , not been found to associate with tetraspanins138• 1 42 . The 
diverse localization of these two metalloproteases as well as their substrates might 
be an important factor in the regulation of ADAM-activity and substrate specificity. 
Notably, tetraspanins are not only involved in the regulation of ADAM activity, but were 
also shown to affect MMPs and to associate with y-secretases (reviewed in Yaflez-M6 










Figure 8 I EpCAM in tetraspanin-enriched microdomains (TEMs) .  EpCAM associates with 
Claudin-7 ( 1 )  and is recruited to TEMs (2), where it bu i lds a complex with tetraspanins CD9 and 
CO-029, and CD44v6 .  ADAM 1 0, a lso present in  TEMs, might be involved in activating EpCAM 
signa l ing as presented in Fig .  6 (3) . 
of RIP processes. Since EpCAM associates with tetraspanins CD9 and CO-029 in TEMs, 
ADAM 10 seems to be a likely candidate for the ectodomain cleavage of EpCAM (Fig. 8). 
However, further investigation is needed to elucidate whether tetraspanins play a role 
in the regulation of EpCAM signaling (chapter 5). 
5 .  CONCLUSIONS, REMARKS & FUTURE PERSPECTIVES 
Although EpCAM has been discovered as a tumor marker more than three decades ago 
and is since exploited as a tool for tumor diagnosis/prognosis and as a target for cancer 
therapy, it is still not fully understood how EpCAM is functionally involved in tumor 
biology. Only in recent years, models of EpCAM-mediated signaling on the molecular 
level emerged but still need to be further investigated. 
EpCAM certainly plays a role in the balance between proliferation and differentiation 
by being directly involved in cell proliferation and in the self-renewal of embryonic 
stem cells/progenitor cells as well as cancer stem cells. Post-translational modification 
of EpCAM such as glycosylation and proteolytic cleavage at various sites, as well as 
association with binding partners and localization in TEMs might be crucial for activation 
and regulation of EpCAM signaling. Importantly, to exhibit normal function, EpCAM 
needs to be present at the cell surface, where it can engage in homophilic adhesion and/ 
or interact with other cell surface proteins, including proteases. Differential expression 
levels of the various proteins interacting with EpCAM in malignant versus healthy tissue 
might explain differences in EpCAM function. Notably, EpCAM-induced proliferation 
is normally triggered by high expression or de nova expression, in cancer as well as in 
developing or regenerating tissue. EpCAM overexpression might be regulated at the 
level of gene transcription (Wnt pathway)12 1 . Since proteolytic cleavage of EpCAM's ICD 
might induce genes via Wnt, EpCAM itself may trigger a positive feedback loop on its 
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expression26. Furthermore, it has been shown that ablation/downregulation of tumor 
suppressor protein p53 is associated with an increase in EpCAM expression1 47 , which 
might explain EpCAM's frequent overexpression in tumors. 
To further determine EpCAM's function in normal development and the pathogenesis 
of diseases such as cancer and CTE, the next step might be the generation of conditional 
knock-out or transgenic mice. Understanding the mechanism of EpCAM-induced 
proliferation not only could improve cancer prognosis and therapy, but also might open 
new possibilities for tissue engineering and stem cell treatment. 
While crystals of EpCAM's unglycosylated ectodomain have been obtained recently, 
the three-dimensional structure is not yet available1 48 . Structural insight would aid in 
the understanding of EpCAM signaling by providing information about possible binding 
and cleavage sites. Furthermore, rational protein design approaches could aid in the 
development of cancer therapeutics targeting EpCAM. 
6 .  THESIS OU TLINE 
To understand the role of EpCAM in health and disease, we aimed to unravel the 
molecular basis of EpCAM-mediated proliferation. During our studies, we noticed 
that a number of publications on the localization of EpCAM in cancer tissue, based 
on antibodies targeting EpCAM's ICD, seemed to be unreliable. Comparing different 
antibodies, immunolabeling methods and fluorescent proteins to study EpCAM, we came 
across drastic differences in protein localization in living vs. fixed and immunostained 
cells that should be considered when using immunolabeling techniques in general. 
Chapter 2a presents and reviews artifacts arising from standard immunolabeling 
protocols, emphasizing the importance of live-cell controls. One way to avoid 
permeabilization-induced artifacts and to simultaneously obtain optimal ultrastructural 
information and resolution is to use "correlated light and electron microscopy" (CLEM) . 
Chapter 2b  introduces the various options of CLEM and presents a straightforward 
protocol to find back proteins/cells of interest, previously imaged live, subsequently 
by electron microscopy. The combination of fluorescent protein techniques and CLEM 
might offer new possibilities to identify membrane microdomains, such as TEMs, on 
the basis of uncompromised cellular ultrastructure. In Chapter 3, we used (amongst 
other techniques) immunostaining and fluorescent proteins in parallel to investigate the 
effects of EpCAM gene mutations found in CTE patients on the structure, localization 
and function of EpCAM. In Chapter 4, all EpCAM-derived proteolytic protein fragments, 
including new (-terminal peptides, are characterized, uncovering an alternative way 
of EpCAM proteolysis which might play a role in the activation of EpCAM signaling. 
Cleavage of EpCAM might be regulated by its spatiotemporal localization in membrane 
microdomains and association with other proteins. In Chapter 5, we investigated 
whether metalloprotease ADAM 1 0  is involved in EpCAM ectodomain shedding, 
focussing on the localization and interaction in TEMs. In addition, we addressed 
EpCAM's role as a cell adhesion molecule. A summary, general discussion and future 
perspectives in the field of EpCAM research are given in Chapter 6 .  
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• 
CHAPTER 2a 
F luorescent fusion prote ins  have revo lut ionized the exam ination of proteins i n  l ivi ng cel l s .  
Sti l l ,  stud ies us ing these proteins are met with critic ism because prote ins are modified 
and ectopical ly expressed, i n  contrast to immunofluorescence stud ies. However, 
i ntrod ucing immu noreagents ins ide cel l s  ca n cause protein extraction or reloca l ization,  
not reflecti ng the in vivo situation . Here we d iscuss pitfa l l s  of i m m unofl uorescence 
label ing that often receive l ittle attention and argue that immunosta i n i ng exper iments 
in dead, permea b i l i zed cel l s  should be complemented with l ive-cel l imag ing when 
scruti n iz ing protei n  loca l izat ion .  
36 
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Investigation of protein dynamics is fundamental to understanding the regulation of 
cell behavior. Snapshots of biomolecule dynamics in situ, defined as the study of a 
phenomenon where it appears, provide information about protein expression, subcellular 
distribution and colocalization with other proteins. These explorations, typically based on 
antibody labeling or fluorescent protein techniques, give insight into protein function 1 . 
Currently, sophisticated fluorescence-based techniques are being developed and 
implemented to localize proteins on the molecular scale2-tens of nanometers-and 
localization artifacts at this scale, owing to microscope instability or to the size of the 
detection reagents, are therefore being considered2 • But how well is protein localization 
preserved in the cell after standardized fixation and immunostaining procedures? 
Inherent to revealing the in situ localization of proteins is a reliable preservation 
of the ' in vivo' protein distribution after immunostaining: elimination of redistribution 
and/or extraction of proteins during sample preparation is essential. However, targeting 
proteins of interest with antibodies necessitates fixation and permeabilization of cells 
to guarantee access of immunoreagents to all cellular compartments. lmmunolabeling 
procedures, which usually follow standard protocols, can well determine the 
experimental outcome. A strong fixation ensures protein immobilization and 
ultrastructure preservation, but interferes with epitope recognition and penetration 
of antibodies as shown by imaging enhanced GFP (EGFP) transiently expressed in the 
cytoplasm of 293T cells using either live-cell imaging of EGFP or immunostaining with 
an antibody to GFP (Fig. 1 a). The immunostaining pattern clearly does not reflect the 
protein distribution seen with live-cell imaging and thus precludes proper analysis of 
protein localization. The balance between fixation and permeabilization in reaching and 
recognizing targets is well-acknowledged in electron microscopy studies3A, but artifacts 
arising from immunofluorescence studies using light microscopy easily go unnoticed. 
In addition to immune-based technologies, proteins are now being studied in situ 
using fusions to genetically encoded fluorescent proteins2 •5•6 (Fig. 1 b). The versatile and 
fertile application of this technology has revolutionized developments in biology7•8. Even 
though limitations of using fluorescent proteins as fusions are apparent1 and will be 
discussed below, these fusions provide a powerful means of examining proteins in living 
cells. When we used fluorescent proteins in our studies, we were struck by the drastic 
effects that immunostaining procedures can have on protein localization compared to the 
distribution in living cells. Here we discuss the often under-recognized problem of balancing 
immunodetection with preservation of in situ protein localization. Specifically, we discuss 
the use of standard fixation and permeabilization procedures and their effects on protein 
detection and preservation as well as cell morphology in the published literature, and 
show illustrative example experiments. We conclude that for unambiguous and unbiased 
interpretation of microscopy data, parallel studies relying on both fluorescent protein 
technology and alternative immunostaining procedures are indispensable. 
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STANDARD IMM UNOFLUORESCENCE PROTOCOLS 
The major immunofluorescence protocols for cultured cells are based on fixation with 
aldehydes or organic solvents, but combined and alternative protocols have also been 
described. 
Organic solvents. Methanol, ethanol and acetone are the most common organic 
solvents used in immunostaining. They all simultaneously fix and permeabilize cells by 
precipitation of proteins and extraction of lipids. Fixation with methanol is commonly 
used for the study of cytoskeletal components9• 1 0  but is known to extract cytosolic and 
nuclear proteins 1 1  14 (Supplementary Figs. 1 and 2) .  Furthermore, fixation with organic 
solvents can cause cell shrinkage and disruption of organelles 1 0· 1 3 . 
Aldehydes and permeabilization. Formaldehyde (from paraformaldehyde (PFA) or 
formalin; see Supplementary Methods) effectively preserves the cellular structure by cross­
linking proteins via methylene bridges. The number of bridges depends on the formaldehyde 
concentration, pH, temperature and fixation time1 5. A disadvantage is that fixation with 
formaldehyde requires subsequent permeabilization of cellular membranes to allow antibody 
access to all cellular compartments for ubiquitous detection of the proteins of interest. The 
most commonly used permeabilizing reagents are saponins (for example, saponin and 
digitonin) and nonionic detergents (for example, Triton X- 1 00, Nonidet P-40, Tween 20 
and Brij 35) 1 0· 1 6 . Saponin and digitonin are mild detergents that preserve the ultrastructural 
integrity and permeabilize membranes by selective removal of cholesterol. Whereas the use 
of saponins is sufficient for the detection of cytoplasmic antigens, saponins are not effective 
for permeabilization of cholesterol-poor membranes such as the inner mitochondrial 
membrane and the nuclear envelope3• 1 0• 1 6-18, which hampers examination of proteins in 
these organelles. To permeabilize the nuclear compartment, the use of a nonionic detergent, 
such as Triton X- 1 00, is preferred. Nonionic detergents permeabilize membranes by 
solubilizing and extracting lipids in a nonselective manner, resulting in possible co-extraction 
of hydrophobic integral membrane proteins1 0• 1 6 . In general, chemical cross-linking results in 
good preservation of proteins and cellular structure. However, aldehyde-induced changes of 
the 'in vivo' state of cells and organelles are unavoidable. Not only conformational changes 
of proteins may occur, but changes of organelles and lack of membrane fixation can be 
observed (reviewed by Neuhaus and co-workers 1 9) .  
Combined protocols. To access all cellular compartments with the immunoreagents, 
scientists have combined formaldehyde fixation with organic solvents replacing the 
detergent 1 0,20-23 . Sequential fixation has been incorporated in microscopy studies after 
its first use in flow cytometry assays23•24 , in which commonly cellular content, but not 
subcellular localization of target molecules, is analyzed. Formaldehyde fixation followed 
by methanol fixation leads to simultaneous preservation of cellular DNA content, cell­
surface proteins and intracellular proteins as assayed by immunofluorescence23 ·24 . 
In immuno-electron microscopy studies a combination of formaldehyde and 
glutaraldehyde is commonly used to provide optimal ultrastructural preservation. 
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Glutaraldehyde contains two aldehyde groups that engage in methylene-bridge 
formation, thereby cross-linking proteins efficiently and irreversibly10• Although 
glutaraldehyde aids in protein preservation and ultrastructural integrity3•2 1 •25•26, it hampers 
cellular penetration (Fig. 1 a), lowers protein antigenicity for many targets and can lead 
to high background autofluorescence when reactive aldehyde groups are not blocked10• 
Alternative protocols. Besides the most commonly used fixatives and permeabilization 
agents discussed here, other chemicals have been explored to balance epitope 
recognition and protein stabilization. Organic solvents combined with rapid freezing 
have been described to study proteins with both light microscopy and electron 
microscopy, but the general applicability of this specialized method warrants further 
investigation 1 9 . Moreover, cationic permeabilizing detergents may be applied to preserve 
specific structures27. A comprehensive list of chemicals used for immunofluorescence 
studies has been reviewed10; bench protocols for preparation and use of fixatives 
and permeabilization reagents have been described1 5• 1 6 • In addition to an appropriate 
fixation, examination of proteins by immunolabeling requires immunoreagents of high 
quality and specificity. Antibody specificity controls and immunostaining procedures are 
















EGFP anti-GFP merge DIC 
CLDN7-EGFP anti-CLDN7 merge 
Figure 1 I Fixation and permeabilization can affect epitope accessibil ity. (a) Fluorescence 
images of 293T cells expressing EGFP fixed with 2 % PFA and 0.05% glutaraldehyde for 30 min at 
room temperature (18-22 °C) and permeabilized with 0.05% Triton X-100 for 30 min with subsequent 
immunostaining with an antibody to GFP (anti-GFP) and mounting in Mowiol. Also shown are merged 
and differential interference contrast (DIC) images. Scale bar, 20 µm. (b) Images of 293T cells expressing 
tight junction protein Claudin-7- EGFP (CLDN7-EGFP) immunostained with an antibody to Claudin-7 
(anti-CLDN7) after fixation with 4% PFA (30 min) and permeabilized with either methanol (MeOH; 
-20 °C) for 1 min or 0. 1 % Triton X-100 (Triton) for 15 min at room temperature. Scale bar, 10 µm. 
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COM M ON PRACTICE: EXTRACTION AND REDISTRIB UTION OF 
PROTEINS 
Soluble proteins. The results of protein-localization experiments in cells and tissues 
can differ drastically depending on how fixation and permeabilization are performed 
and even on the cell type1 3 • 1 7•2 1 •25•26•30 •3 1  (Fig. 2a). A way to avoid these procedures is to 
examine protein localization in living cells. In 1992, only a few years before fluorescent 
protein technology became a common tool in research laboratories, Melan and Sluder25 
used small fluorescent dye-conjugated proteins as a live-cell reference for protein 
localization . Using formaldehyde for fixation and Triton X-100 as permeabilizing agent, 
the authors demonstrated that soluble proteins of various charge and size differentially 
extract from the cytoplasm. Proteins with a higher molecular weight (>50 kDa) 
seemingly redistributed to the nucleus during the immunostaining procedure. Such 
a ' specific' fluorescent signal can be caused not only by relocalization but also by 
differential extraction. Soluble proteins that are partially lost from the cytoplasm during 
fixation and permeabilization can appear to be preferentially located either bound to 
certain structures, or in compartments from which they are less easily extracted25 • As 
an example, the localization of soluble EGFP in formaldehyde-fixed human embryonic 
kidney 293T cells resembles that in living cells, whereas treatment with Triton X-100 
causes extraction of cytoplasmic, but not nuclear, EGFP (Fig. 2a,b and Supplementary 
Fig. 1 ). The decrease in EGFP signal in the cytoplasm relative to the nucleus gives the 
false impression of protein redistribution . Extraction can be avoided by using stronger 
fixatives or milder reagents, but that limits antibody access to the antigens1 6 . 
Notably, the same fixation and permeabilization protocol may have different effects 
depending on the cell type25 (Fig. 2b and Supplementary Figs. 1 and 2). In 293T cells, 
in situ localization of EGFP in nonpermeabilized formaldehyde-fixed cells resembles the 
localization in living cells, whereas permeabilization with the lowest effective Triton 
X-100 concentration (0 .05% for 15 min)1 8  or methanol extracts EGFP from the cytoplasm 
(Fig. 2a,b). In contrast, in Madin-Darby canine kidney (MOCK) cells, formaldehyde 
fixation with 4% PFA by itself results in relocalization or extraction of EGFP from the 
cytoplasm, whereas subsequent permeabilization with Triton X-100 or methanol does 
not induce an additional change in apparent localization (Fig. 2a,b). In both cell lines, 
a higher concentration of PFA (4%)  leads to better protein preservation compared 
to lower concentrations (2% )  or methanol alone (Supplementary Figs. 1 and 2) but 
interferes with permeabilization of the nucleus. Therefore, increasing fixation strength 
does not show the decreased relative amount of EGFP in the cytoplasm that is clearly 
evident when imaging EGFP fluorescence in the fixed and permeabilized cells (Fig. 2b). 
Thus, inadequate permeabilization can also lead to differential staining that does not 
reflect the true distribution of an antigen. 
Lack of nuclear immunostaining can be caused not only by insufficient 
permeabilization but, perhaps counterintuitively, also by high expression levels of 
the nuclear protein of interest. In 293T cells expressing histone H2B-EGFP32, the 
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Figure 2 1  Effects of standard fixation and permeabil ization protocol s  on protein localization 
and epitope accessibil ity in different cel l l ines. (a) Images of 293T and MDCK cells transfected 
with EGFP-encoding plasmids and imaged l ive or after fixation with 4% PFA. (b) Images of 293T and 
MDCK cel l s  after fixation as in a and permeabi l iz ion with 0 .05% Triton X- 1 00 (Triton; 1 5  min) or  
methanol (MeOH; 1 min -20 °C) and immunostaining with an  antibody to GFP (anti-GFP). (c) Images 
of 293T cells transfected with plasmids encoding EGFP fusion proteins that loca l ize in in id icated 
compartments. ER, endoplasmic ret iculum. 'Tubu l in ' , MDCK cel ls stably express ing EYFP-a-tubu l in .  
Cel ls were recorded l ive, after fixation with 4% PFA or after fixation and permeabi l ization with Triton 
X- 1 00 or MeOH and immunosta ining with anti-GFP. *Increased concentration of antibodies and 
Triton X- 1 00.  Whereas laser intensity and pinhole were the same in each experiment, ga in and offset 
settings were chosen for each cond it ion. See supp lementary data for fixation detai ls and complete 
image datasets . Al l sca le bars, 20  µm. 
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(Fig. 2 c  and Supplementary Fig. 3) and using higher concentrations of antibodies and 
Triton X-100 does not alleviate the poor staining (Fig. 2c, Supplementary Fig. 3 and 
data not shown). This lack of antibody penetration might be due to steric hindrance 
caused by protein cross-linking during fixation1 0 . In addition, epitopes might become 
cross-linked, leading to a loss of antigenicity. 
Proteins associated with membranes, structures or organelles. Whereas soluble 
proteins may be prone to relocalization or extraction after cell permeabilization, proteins 
located in organelles, associated with membranes or present in macromolecular 
complexes, such as structural components, are better preserved13  (Fig. 2c). Indeed, the 
distribution of proteins located in various organelles (peroxisomes, Golgi apparatus, 
nuclei and endoplasmic reticulum) and in the plasma membrane seems to be similar after 
formaldehyde fixation and subsequent permeabilization compared to their localization 
in living cells (Fig. 2c and Supplementary Figs. 3-9). In contrast, using microscopy and 
biochemical assays, Hannah and co-workers1 7 demonstrated that membrane proteins 
may be partially extracted with Triton X-100 after fixation with formaldehyde. However, 
the biochemical analysis used to reach this conclusion differs from the immunostaining 
procedure and is therefore not representative for extracted proteins. Another special 
subgroup of proteins comprises the diverse elements of the cytoskeleton. The outcome 
of immunostaining, which has been optimized by researchers in several labs33-36, is 
usual ly focused on proteins incorporated in cytoskeletal structures, such as intermediate 
filaments36, f-actin and microtubules . Here it may be advantageous not to detect the 
non-incorporated monomers or dimers. In fact, extraction of these proteins may be 
used to specifical ly highlight the cytoskeleton. Detailed comparisons of procedures to 
immunostain and/or extract cytoskeletal proteins are available34•3 5 . 
Specific protocols may be beneficial to target certain proteins or structures; however, 
a generally applicable fixation and permeabilization protocol would be favorable for 
immunostaining-based high-throughput studies. In search of a universal protocol for 
proteome-wide localization studies, Stadler and colleagues1 3 compared several cross­
linking- and dehydration-fixation protocols using 18 proteins located in different 
subcellular compartments. In comparison to fixation by dehydration, the combination of 
formaldehyde and Triton X-100 provided the best protein preservation and accessibility. 
However, because they did not present an analysis of protein localization in living cells 
in that study, the apparent protein localization after treatment with formaldehyde and 
Triton X-1 00 might have been affected by the inherent l imitations and resulting artifacts 
of the procedure. The assumption that the applied fixation method truthfully preserves 
the 'in vivo' protein distribution represents the major concern of immunolabeling 
techniques: How does one know whether the protein localization is preserved without a 
live-cell reference? Fluorescent protein technology is a useful control to define whether 
protein localization in immunostained cells reflects the in vivo distribution. 
An early study by Brock and colleagues found EGFP-tagged proteins at distinct sites in 
live versus fixed cel ls and determined that the EGFP-tagged receptor redistributed after 
fixation with formaldehyde followed by mounting in the antifading reagent Mowiol22. 
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Remarkably, protein cross-linking with formaldehyde followed by precipitation with 
methanol prevented this redistribution. In addition, this fixation also preserved soluble 
EGFP and its fluorescence that was lost after fixation with methanol alone22 . Therefore, 
Brock and co-workers22 recommend the combination of PFA and methanol as universally 
suitable for fixation of transmembrane and soluble proteins. Whether the complete 
protein or only its fluorescent properties were lost in methanol-fixed cells in this study 
was not clarified. In MDCK cells stably expressing epithelial cell adhesion molecule 
(EpCAM)-EGFP, we found that the EGFP fluorescence was transiently quenched during 
fixation with methanol but recovered after rehydration (Fig. 3a), showing that methanol 
can be used for fixation if followed by rehydration. More recently, glutaraldehyde in 
addition to PFA has been included in fixation procedures to avoid relocalization of 
lipid raft-associated proteins after fixation37. In this case, cell-surface proteins were 
studied, so antibody-permeabilization problems owing to glutaraldehyde-cross-linking 
(Fig. 1 a) were not relevant to the performance. In general, provided that epitopes are 
recognized, it might be beneficial to implement glutaraldehyde-based fixation in studies 
examining the extracellular epitopes of cell-surface proteins. To study intracellular 
epitopes, permeabilization of membranes is needed. 
Variation in permeab il ization. We compared Triton X-100 versus methanol for 
permeabilization after formaldehyde cross-linking and found no major differences 
regarding protein preservation and accessibility (Figs. 2 and 3 and Supplementary 
Figs. 1-9). We also examined the effects of the reagents on fluorescence during real-time 
experiments. We found that the EGFP fluorescence was reduced during fixation with 
both 2% and 4% PFA, but partially recovered after washing. After permeabilization 
with Triton X-1 00 or methanol, extraction of EGFP was apparent in the cells fixed 
with 2% PFA (Fig. 3). It is important to note that immunostaining methods should 
be optimized for each protein of interest and each cell type. For example, in the case 
of EGFP-tagged Claudin-7, a four transmembrane-spanning tight junction protein, we 
observed drastic differences in the epitope accessibility when comparing Triton X- 1 00 
permeabilization to the use of methanol after formaldehyde (Fig. 1 b). Visualization 
of EGFP showed that Claudin-7 was located at cell-cell contacts, presumably tight 
junctions. After permeabilization with methanol (Fig. 1 b), the immunodetection 
signal of Claudin-7 overlapped with the EGFP signal as expected. However, when we 
permeabilized the cells with Triton X-100, we could not detect the antibody signal, 
indicating that immunostaining after fixation with 4% PFA and subsequent Triton X-100 
treatment did not result in a reliable analysis of Claudin-7 protein localization. Although 
this problem might have been detected through the testing of alternate fixation and 
permeabilization methods as we recommend above, the use of an EGFP control provides 
a more straightforward means of detecting this problem and avoiding false conclusions. 
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F igure 3 I Effects of standa rd immunosta ining methods on p rotein ext ract ion a nd EGFP 
fluorescence. (a) Images of MDCK cells stably expressing EpCAM-EGFP and fixed with methanol 
in real time (imaged every 2 min). The initial methanol (first time MeOH) was replaced (second time 
MeOH) and cells were washed 3x with PBS. Note that EGFP fluorescence is lost during dehydration 
but recovers after rehydration. (b, c) Real-time imaging of MDC K cells stably expressing EGFP, fixed 
with 2 %  or 4% PFA and permeabilized with 0.1 % Triton X-1 00 (Triton; 1 5  min) or methanol (MeOH; 
1 min at -20 °C when added to the dish). After permeabilization, cells were washed 6x with PBS 
to mimic the washing steps during the immunostaining procedure. EGFP fluorescence was recorded 
every 3 min using the same microscope settings for each condition. Scale bars, 20 µm. (c) Normalized 
average fluorescence of cells in five different microscope fields. AU, arbitrary units. Error bars, s.d. 
(n = 5 different fields). 
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WHAT ARE WE DOING TO OUR CELLS? A FINE ANALYSIS 
In general, the disadvantage of fluorescence imaging after fixation and immunostaining 
is that the quality of the cellular ultrastructure is not apparent. As we mentioned 
before38, exaggeratedly stated, with fluorescence microscopy you see nothing, that is, 
only your fluorescent signal(s); with electron microscopy you see everything, that is, 
organelles, macromolecules and membranes. Electron microscopy reveals not only the 
fine ultrastructure of cells but also how cells are damaged during sample preparation. 
Using reflection contrast microscopy and electron microscopy techniques, Hoetelmans 
and col leagues1 2  studied the effects of formaldehyde, methanol and organic solvents 
on cellular integrity. Whereas methanol and acetone drastically affected (sub)cel lular 
structure, fixation with formaldehyde before organic solvents improved the protein and 
ultrastructural preservation. Although the use of nonionic detergents for permeabilization 
as an alternative for methanol has been suggested to be less damaging for the integrity 
of cytoplasmic organelles, these methods had not been tested1 2 . 
We compared several standard immunostaining protocols by electron microscopy 
(Fig. 4) and found that all methods induced changes in the cellular ultrastructure. 
Although nonpermeabilized formaldehyde-fixed cells (Fig. 4a,b) were relatively well 
preserved when compared to the positive control (2 % glutaraldehyde; Fig. 4h), damage 
and disruption of mitochondria was visible. This effect was even more pronounced 
when we fixed cells with 4% PFA, probably owing to the higher osmolarity of the 
fixative1 0  (Supplementary Methods). Permeabilization with Triton X-100 or methanol 
(Fig. 4c-f) after formaldehyde treatment induced a decreased cytoplasmic density and 
apparent loss of organelles. In contrast to Triton X-100 treatment, methanol treatment 
resulted in holes in the cytoplasm that might represent ' empty' mitochondria. Fixation 
with methanol alone resulted in severe extraction of cytoplasmic and nuclear protein as 
well as damaged organelles (Fig. 4g). This illustrates how fixation-induced changes are 
directly apparent using electron microscopy, whereas fluorescence microscopy studies, 
which only show highly selected details, cannot provide this information. Although 
we fully agree that proper immunobased techniques should be implemented in 
(microscopic) research as mentioned by Smith-Clerc and Hinz35 ( "  a poor picture [ . . .  ] can 
be worse than saying nothing at all"), we emphasize that also a 'pretty' picture might 
disguise important information about the real-life situation. 
STUDYING LIFE LIVE: IMM UNOLABELING AND FLUORESCENT 
PROTEINS 
lmmunolabeling is an invaluable tool to investigate proteins, but current techniques 
necessitate fixation and permeabilization of cells, possibly leading to artifacts. There is 
no generic protocol for immunofluorescence staining; each protein requires a certain 
fixation and permeabilization method to be reliably conserved and recognized1 2• 1 3 • 1 7•25•3 1 • 
Furthermore, immunostaining depends on the quality and specificity of the antibodies28 




























2% PFA 4% PFA 
Methanol 2% glutaraldehyde 
Figure 4 I U ltrastructural changes after fixation and permeabilization.  (a-g) Electron 
micrographs of MDCK cells fixed with 2 %  or 4% PFA (a-f), methanol (g) or glutaraldehyde (h). To 
mimic the immunostaining procedure, PFA-fixed cells were permeabilized with 0.05% Triton X- 100 
( 15  min; c,d) or MeOH (1  min at -20 °C; e,f). All samples were washed (6x PBS), then fixed with 2 %  
glutaraldehyde for 10 min and processed for electron microscopy. Scale bars, 2 µm. 
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differences to chemical exposure are well known from other studies, for example, cell 
type-specific transfection efficiency40 . We argue that the additional use of fluorescently 
tagged proteins in living cells is a powerful method to detect fixation-induced effects 
on protein distribution and epitope accessibility 14 ·22•3 1 . In contrast to immunoreagents, 
the easy construction and accessibility of cDNA chimeras make fluorescent proteins 
an excellent tool for standard implementation of protein investigation by microscopy. 
Besides providing the possibility to study protein dynamics in living cells, genetic tagging 
ensures optimal specificity of protein identification and thus allows for high-throughput 
screens4 1 A2 , which are especially useful to define the organelle localization of proteins. 
To combine the benefits of high-affinity recognition of epitopes by fluorophores and 
genetic delivery, fluorescent nanobodies are now being developed, which are genetically 
encoded single-chain antibodies fused to fluorescent proteins43 , holding great promise 
for protein identification. Of course, researchers must also consider the limitations of 
any fluorescent protein fusions and potential problems caused by ectopic expression 1 . As 
proteins are usually expressed using generic promotors, cells should be selected, either 
before or during imaging, that have protein expression comparable to endogenous 
amounts. Intrinsic to protein fusion is that the target protein is modified and this may 
affect protein behavior. Therefore, tagging is usually performed at multiple sites, and 
protein function and localization is compared with other techniques. Moreover, the 
well-documented different behavior of the diverse fluorescent proteins5•7 needs to be 
considered, including tendency to dimerize, bleach or change spectral properties, for 
example, depending on pH. But many easily accessible and well-characterized fusion 
proteins already exist and more are continuously being developed. These tools are an 
important resource that should not be ignored when examining protein localization. 
When feasible, endogenous proteins should also be examined using parallel techniques. 
CONCLUDING REMARKS 
Being aware of limitations and artifacts arising from routinely used standard fluorescence 
protocols is crucial for correct data interpretation. We highly recommend that investigators 
first optimize the immunostaining procedure for each protein of interest and for each cell 
line, using different immunofluorescent staining methods in parallel. Here we suggest 
that both methanol and Triton X-100 for permeabilization after formaldehyde fixation 
should be included, allowing an unbiased analysis. If only restricted subcellular areas are 
investigated, milder detergents or glutaraldehyde may be used, for example, for cell­
surface proteins. Furthermore, we argue that when scrutinizing protein localization in 
situ, immunostaining experiments in dead, permeabilized cells should be complemented 
with live-cell imaging such that implementation of fluorescent protein-tagged chimeras 
becomes a standard routine. 
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S U PPLE M E NTARY I N FO R MATION 
Supplementary Methods 
Cell culture and transfection - Human embryonic kidney cells (293T; ATCC, USA) 
and Madin-Darby Canine Kidney cells (MDCK; ATCC, USA) were cultured in DMEM 
supplemented with 5% FCS and penicilline (100 U/ml)/ streptomycine (1 mg/ml). Cells 
were cultured at 37°C in a humidified incubator in the presence of 5% COr Media 
and supplementation were obtained from PAA (Austria). 293T cells were transfected 
with FuGENE 6 according to the manufacturer's protocol (Roche Diagnostics, The 
Netherlands). MDCK cells were transfected using the NEON transfection system 
according to the manufacturer's protocol (lnvitrogen, The Netherlands) or retrovirally 
transduced (see Gaietta et al.45 for retroviral techniques); stable cell lines were generated 
by selection with 0.8 mg/ml geneticin (lnvitrogen, The Netherlands). 
Plasmids - Optimized GFP- or YFP-fusion constructs were used for transient or 
stable transfection. All constructs have been described before, or were made and 
verified by standard cloning procedures resulting in a small linker sequence between 
the fluorescent protein and the target protein. pBOS-H2B-EGFP32 , ER-superluc-EGFP 
(calnexin pre-sequence)44, Per-superluc-EGFP (peroxisomal targeting sequence)44 , 
pcDNA3. 1 -claudinl-EGFP, pcDNA3. 1 -EGFP; pCLNCX-EYFP-a-tubulin, pCLNCX-EYFP-{3-
actin, pcDNA3. 1 -Mannll-EGFP-4C45, pcDNA3. 1 -EpCAM-EGFP. 
Formaldehyde terminology - Formaldehyde can be purchased in solution (formalin) 
or as a powder (paraformaldehyde; PFA). The term formalin describes a solution 
of formaldehyde gas dissolved in water (100% formalin = 37% w/v or 40% v/v 
formaldehyde in solution, respectively). To circumvent polymerization during storage, 
10-15% methanol is added to 100% formalin. Thus, 10% formalin will contain 1-1 .5% 
MeOH. PFA is  the polymeric form of formaldehyde which can be obtained as a powder. 
When heated, PFA depolymerizes back to formaldehyde. In solution, this formaldehyde 
gas immediately dissolves, resulting in a formalin solution. The formaldehyde content 
of 3.7 %  PFA is therefore equivalent to 10% formalin. We used PFA in all experiments 
presented. In addition, all experiments performed with formalin yielded similar results 
to what we find with PFA (data not shown). 
Fixation - Cells were grown to subconfluency and fixed according to the following 
protocols: 
(A) 2% PFA: 2% PFA (Merck B.V. ,  The Netherlands) in 0.1 M phoshate buffer pH 7 .4  
for 30  min at room temperature (RT); 805 mOsm/L; 
(B) 4% PFA: 4% PFA in 0.1 M phoshate buffer pH 7.4 for 30 min at RT; 
137 4 mOsm/L; 
(C) PFA and MeOH :  2 % or 4% PFA for 5 min on ice and 10 min at RT22 • Cells were 
washed 3x with PBS and incubated in 100% methanol (MeOH; Biosolve B.V. ,  
The Netherlands) for 1 min at -20 °C; 
(D) MeOH :  6 min 100% MeOH at -20 °C; 
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( E )  2 %  GA:  2% glutaraldehyde (GA; Polysciences Europe GmbH, Germany) in 
0.1 M phoshate buffer pH 7.4 for 30 min on ice; 472 mOsm/L; 
(F) PFA and GA: 2% PFA and 0.05% in 0.1 M phoshate buffer pH 7.4 for 30 min 
at RT. 
After fixation, cells were washed 3 x with PBS (RT). Permeabilization (Protocols A and B) 
was done with Triton X-100 (0.05%-0.1 %;  Merck B.V, The Netherlands) in PBS with 
1 % normal goat serum (NGS; Vector Laboratories, USA) and 1 % BSA (Sanquin, The 
Netherlands) for 15 min at RT. The pH of all the buffered fixatives was adjusted to pH 7.4. 
lmmunofluorescent staining - Cells were fixed and permeabilized as described above 
and incubated with the primary antibody followed by an Alexa Fluor 568-conjugated 
secondary antibody, both in 1 %NGS and 1 % BSA in PBS for one hour at RT. After 
each antibody incubation, samples were washed 3 x with PBS. The polyclonal antibody 
rabbit-anti-Claudin-7 (1 µg/ml; 34-9100) and secondary antibodies were purchased 
from lnvitrogen (The Netherlands), polyclonal rabbit-anti-GFP from Rockland (2 µg/ml; 
600-401-215; USA). All samples were mounted in Mowiol 4-88 (Hoechst, Germany). 
Representative experiments are shown in the Figures. 
Transmission Electron Microscopy (TEM) - Cells were fixed and permeabilized as 
described (Fig.4). For EM-analysis all samples were post-fixed in 2% GA in 0.1 M cacodylate 
buffer (pH 7 .4) for 10 min, washed 3 x with 0.1 M cacodylate buffer and subsequently fixed 
in 1 % Os04 and 1.5% K/e(CN)6 (EMS, PA, USA) in 0.1 M cacodylate buffer (pH 7.4) for 30 
min. After rinsing with water (Milli-Q, Millipore B.V., The Netherlands) and dehydration in a 
graded alcohol series, samples were embedded in Epon 812 (Serva Electrophoresis GmbH, 
Germany). Ultrathin sections were stained following routine procedures and examined using 
a FEI CM100 electron microscope operating at 80 kV 
SU PPLE M E NTARY MATER IAL  
Experimental details Supplementary Figures 1 -9 - 293T or MOCK cells expressing 
EGFP- or EYFP-tagged proteins located in different compartments and organelles: 
cytoplasm and nucleus (EGFP; 1 ,  2), nucleus (histone H2B-EGFP; 3), Golgi apparatus 
(Mannosidase-EGFP; 4), peroxisomes (Peroxisome-EGFP; 5), endoplasmic reticulum 
(ER-EGFP; 6), plasma membrane (EpCAM-EGFP, transmembrane type I; 7), cytoskeleton 
(EYFP-Tubulin, 8; EYFP-Actin, 9). In each experiment, cells were imaged live or after 
fixation with 2% PFA (a, c, e), 4% PFA (b, d, f) , or methanol (g). For immunostaining, 
PFA-fixed cells were permeabilized using Triton X-100 (c, d) or methanol (MeOH; e, f). 
All permeabilized cells were immunostained with a polyclonal anti-GFP and an Alexa 
Fluor 568-conjugated secondary antibody. Samples were mounted in Mowiol (except 
for living cells) and imaged with a Leica SP2 AOBS Confocal microscope. Whereas laser 
intensity and pinhole were the same within each experiment, optimal gain and offset 
settings were chosen for each individual condition. 























IMMUNOLABELING ARTIFACTS AND THE NEED FOR LIVE-C ELL IMAGING 
293T EGFP 
DIC EGFP anti-GFP merge 
Supplementary Figure 1 I Effects of standard immunostaining protocols on EGFP localization 
in 293T cel l s .  293T cel l s  transfected with EGFP (l ive) were fixed with 2 %  PFA (a, c, e), 4% PFA (b, d, 
f), or methanol a lone (MeOH;  g). PFA-fixed cel l s  were either permeabi l ized with 0 .05% Triton X- 1 00 
(c, d) or with MeOH (e, f). All permeabi l ized cel ls were sta ined for GFP. Bar :  20 µm. 
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DIC EGFP anti-GFP merge 
Supplementary Fig u re 2 I Effects of standard imm unosta i n i ng p rotocols on EGFP local ization 
in M DCK cells . MDC K  cells stably expressing EGFP (live) were fixed with 2% PFA (a, c, e) ,  4% PFA 
(b, d, f), or methanol alone (MeOH; g). PFA-fixed cells were either permeabilized with 0 .05% Triton 
















IMMUNOLABELING ARTIFACTS AND THE NEED FOR LIVE-CELL IMAGING 
293T Nucleus 
DIC EGFP anti-GFP merge 
Supplementary Figure 3 I Effects of standard immunostaining protocol s  on H2B-EGFP 
localization in 293T cells .  293T cel ls transfected with histone H2B-EGFP (l ive) were fixed with 2 %  PFA 
(a, c, e), 4% PFA (b, d, f), or methanol a lone (MeOH; g). PFA-fixed cel l s  were e ither permeabi l ized with 
Triton X-1 00 (c: 0 .05%, d: 0 . 1  %) or with MeOH (e, f). All permeabi l ized cells were sta ined for GFP. In 
panel d the concentration of both primary and secondary antibody was i ncreased 5-fold. Bar: 20 µm. 
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293T Golgi apparatus 
DIC EGFP anti-GFP merge 
Supplementary Figure 4 I Effects of standard immunostaining protocols on Mannosidase­
EGFP loca l ization in 293T cells. 293T cel ls transfected with Mannosidase-EGFP (live) were fixed 
with 2% PFA (a, c, e), 4% PFA (b, d, f), or methanol a lone (MeOH; g). PFA-fixed cel ls were either 
permeabi l i zed with 0 .05% Triton X- 1 00 (c, d) or with MeOH (e, f). All permeabi l ized ce l l s  were 




























Supplementary Figure 5 I Effects of standard immunostain ing protocols on Peroxisome-EGFP 
localization i n  293T cells. 293T cel l s  transfected with Peroxisome-EGFP (live) were fixed with 2% 
PFA (a, c, e) ,  4% PFA (b, d, f) ,  or methanol a lone (MeOH; g). PFA-fixed ce l l s  were either permeabilized 
with 0 .05% Triton X- 1 00 (c, d) or with MeOH (e, f). Al l permeabilized cel ls were stained for GFP. 
Bars: 20 µm .  
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293T Endoplasmic reticulum 
DIC eGFP anti-GFP merge 
Supplementary F igure 6 I Effects of standard i m munostaining protocol s  on ER-EGFP 
localization in 293T cel l s .  293T cel l s  transfected with ER-EGFP (l ive) were fixed with 2 % PFA (a, 
c, e), 4% PFA (b, d, f), or methanol a lone (MeOH; g) .  PFA-fixed cel l s  were either permeab i l ized 
with 0 .05% Triton X-1 00 (c, d) or with MeOH (e, f). All permeabi l ized cel l s  were sta ined for GFP. 
Bar : 20 µm. 
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DIC 
293T Plasma membrane 
EGFP anti-GFP merge 
Supplementary Figure 7 I Effects of standard immunostaining protocols on EpCAM-EGFP 
localization in 293T cells. 293T cel l s  transfected with EpCAM-EGFP (l ive) were fixed with 2% PFA 
(a, c, e), 4% PFA (b, d, f), or methanol a lone (MeOH; g). PFA-fixed cells were either permeabi l ized 
with 0 .05% Triton X- 1 00 (c, d) or with MeOH (e, f). Al l permeabi l ized cel ls were sta ined for GFP. 
Bar :  20 µm.  
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DIC EYFP anti-GFP merge 
Supplementary Figure 8 I Effects of standard imm unostaining protocols on EYFP-Tubulin 
local ization in M DCK cel ls .  MDCK cel l s  stably expressing  EYFP-Tubu l in (l ive) were fixed with 2% PFA 
(a, c, e), 4% PFA (b, d, f), or methanol a lone (MeOH; g). PFA-fixed cel ls were either permeabi l ized 
with 0 . 1  % Triton X- 1 00 (c, d) or with MeOH (e, f). Al l permeabi l ized ce l l s  were sta ined with an  






















IMMUNOLABELING ARTIFACTS AND THE NEED FOR LIVE-CELL IMAGING 
MDCK Actln 
DIC EYFP anti-GFP merge 
Supplementary Figure 9 I Effects of standard immunostaining protocols on EYFP-Actin 
localization in M DCK cel l s .  MDC K cel ls stably express ing EYFP-Acti n (l ive) were fixed with 2 % PFA 
(a, c, e), 4% PFA (b, d, f), or methanol  a lone (MeOH; D). PFA-fixed cel l s  were either permeabil ized 
with 0 . 1  % Triton X- 1 00 (c, d) or with MeOH (e, f) . All permeabi l ized cel l s  were sta i ned with an 
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CORRELATED LIGHT MICROSCOPY AND ELECTRON MICROSCOPY 
AB BREVIATIONS 
CLEM correlated light and electron microscopy 
DAB diaminobenzidine 
EM electron microscopy 
FLM fluorescence LM 
FP fluorescent protein 
FRAP fluorescent recovery after photobleaching 
GFP green FP 
LM light microscopy 
ROI region of interest 
SEM scanning EM 
STED stimulated emission depletion 
TEM transmission EM 
PALM photoactivated localization microscopy 
ABSTRACT 
Understanding where, when, and how biomolecules (inter)act is crucial to uncover 
fundamental mechanisms in cell biology. Recent developments in fluorescence light 
microscopy (FLM) allow protein imaging in living cells and at the near molecular level. 
However, fluorescence microscopy only reveals selected biomolecules or organelles but 
not the (ultra)structural context, as can be examined by electron microscopy (EM). LM and 
EM of the same cells, so-called correlative (or correlated) light and electron microscopy 
(CLEM), allow examining rare or dynamic events first by LM, and subsequently by EM. 
Here, we review progress in CLEM, with focus on matching the areas between different 
microscopic modalities. Moreover, we introduce a method that includes a virtual overlay 
and automated large-scale imaging, allowing to switch between most microscopes. 
Ongoing developments will revolutionize and standardize CLEM in the near future, 
which thus holds great promise to become a routine technique in cell biology. 
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I. INTRODUCTION 
Fundamental to understanding how biomolecules regulate li fe is the abil ity to study 
them at the near-molecular level. M icroscopic techniques are highly valuable to 
determine protein location in space and time. Ongoing development of genetically 
encoded fluorescent proteins (FPs), such as the green fluorescent protein (GFP), 
allows imaging in living cells. In parallel, fluorescent microscopic techniques are being 
developed that allow near-molecular imaging of biomolecules (-10-50 nm resolution). 
Although these developments have revolutionized light m icroscopy, it can sti l l  not 
provide information about the (ultrastructural) cellular context, as can be determined 
with electron microscopy (EM). However, protein identification with EM can only be 
performed in fixed dead cells, and techniques that are used for 3D-protein determination 
usually depend on destructive procedures. Can experiments be designed that give both 
spatiotemporal information in living cells using (fluorescence) light microscopy (LM), 
and subsequently reveal the ultrastructural details and cellular context using EM? In 
general, the combination of multiple experimental approaches is a basic ingredient 
in scientif ic explorations. An excellent example is microscopy: When either LM or EM 
reaches lim i tations, the other modality is being used in paral lel. While these side-by-side 
approaches usually are straightforward, there is an additional option to use LM and EM 
techniques in a combined approach on the same sample, which may be challenging, 
but can have added benefits. 
II. CORRELATED LIGHT AND ELECTRON MICROSCOPY: USING THE 
BEST OF TWO WORLDS 
A. Conventional Use with Transmission LM 
Transmission LM is routinely used to identify specific cells and/or regions in tissues to be 
processed for EM. Usually, cells or tissue samples are subjected to a color stain, which 
allows recognit ion of tissue structures, certain cell types, or macromolecules. Once the 
selection has been made, samples are further processed and examined with EM. An 
overlay of the data of the two modalit ies is typically not made, since LM is only used as 
guidance for the region of interest (ROI) for EM. 
B .  Fluorescence LM and CLEM : Exploration and Exploitation 
Fluorescence microscopy combined with EM is more troublesome and will be the focus of 
this chapter. Importantly, these combinatorial approaches should only be implemented 
when there is an added benefit over using a single modali ty, since correlated light 
and electron microscopy (CLEM) procedures have limitations, including compromising 
optimal sample preparation for both LM and EM. Severe ultrastructural changes occur 
during standard (immuno)fluorescence sample preparation as shown by EM (reviewed 
in Schnel l, Di jk, Sjollema, & Giepmans, 2012). Furthermore, sample preparation for 
EM requires fixation, cutting of the sample, or even permeabili zation of cells or tissue, 
which may ruin the 3D-ultrastructural context. 
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A prerequisite to correlate FLM and EM images in CLEM is to find back the area 
imaged with LM, at cm (lateral) and µm (axial) scale, with EM, typically at lateral mm 
scale during sample preparation and µm - nm scale for acquisition. Several research 
groups encountered problems in correlating CLEM images. Since the 1980s (Maranto, 
1982; Roth, Bendayan, & Orci, 1980), CLEM has been explored and exploited (reviewed 
in Cortese, Diaspro, & Tacchetti, 2009; Giepmans, 2008; Kolotuev, Schwab, & Labouesse, 
2009; McDonald, 2009; Sosinsky, Giepmans, Deerinck, Gaietta, & Ellisman, 2007; van 
Oriel, Valentijn, Valentijn, Koning, & Koster, 2009; van Weering et al. ,  2008). A number 
of inventive procedures and probes have now been developed to match LM and EM 
data, especially to examine organelles or molecules. In this chapter, the most recent 
developments in CLEM and the available methods of correlating the areas are presented, 
including the introduction of a widely applicable technique we use in our laboratory. 
Most methods result from the revolution of FPs, which play a central role in advanced 
FLM techniques, such as super resolution microscopy and dynamic imaging of molecules. 
1. High Resolution LM Markers - Biomolecules can be studied with fluorescence 
microscopy down to the near-molecular level with 10 - 50 nm precision, so-called "super 
resolution microscopy" (see for reviews Leung & Chou, 2011; Patterson, Davidson, 
Manley, & Lippincott- Schwartz, 201 0; Schermelleh, Heintzmann, & Leonhardt, 201 0; 
Walter, Huang, Manzo, & Sobhy, 2008). CLEM provides the unique possibility to correlate 
super resolution FLM data with the ultrastructural EM information, thereby showing 
single molecules in the context of macromolecules, membranes, organelles, cells and 
tissue. The importance of CLEM in combination with super resolution techniques was 
shown using photo-activated localization microscopy (PALM), locating the fluorescent 
signal of a mitochondrial protein within the mitochondria following cryosectioning 
(Betzig et al. ,  2006). More recently, both PALM and stimulated emission depletion (STED) 
have been used in combination with EM, where fluorescent super resolution data could 
be localized to mitochondria and nuclei (Watanabe et al. ,  2011 ). In the latter study, EM 
procedures have been optimized to allow super resolution FLM in fixed and sliced sections 
for EM (see below). Although these developments hold promise for broader application, 
super resolution CLEM applications are in a pioneering stage and therefore still limited. 
2. CLEM of Sparse Events and Dynamic Processes - Changes in levels, interactions, 
activity and subcellular localization of molecules determine cell behavior. Key to 
understanding cellular processes is to know when and where molecules are present with 
high accuracy. FP-techniques allow spatiotemporal imaging of proteins during short­
lived events, such as cell division, and detection of rare cells or events in large samples. 
Using FLM markers and subsequent EM, different states of cells or organelles, e.g. , 
the state of mitochondria during apoptosis, can be complemented with ultrastructural 
examination (Sun et al. , 2007). Moreover, CLEM allows matching ultrastructure where 
dynamic information has been acquired with live-cell FRAP-imaging, followed by 
photoconversion of newly formed signals (Darcy, Staras, Collinson, & Goda, 2006). 
These new possibilities of studying protein dynamics in the u ltrastructural context of 
cells can uncover details that would have remained ' in the dark' using FLM only. 
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3.  Combinatorial Probes - Development of  probes suitable for LM and EM started 
in 1 980 with affinity labeling using protA labeled with both FITC and immunogold 
(Roth et al. , 1 980; reviewed in Robinson & Takizawa, 2009) . In this chapter, we focus on 
recognition of proteins. However, also markers for complete cells or membranes, e.g. , 
DAPI, Lucifer yellow (LY; Maranto, 1 982), or labeled lipids (Dantuma, Pijnenburg, Diederen, 
& Van der Horst, 1 998) have been shown great tools for CLEM. Besides affinity-based 
targeting, genetically encoded proteins or combinatorial probes, e.g. , FluoroNanogold 
or Quantum dots, are available that exhibit fluorescence and simultaneously can be 
visualized by EM due to electron-dense precipitates or particles (see Cortese et al. , 2009; 
Sims et al. , 2006; Sosinsky et al. , 2007). Such probes ensure specific targeting of the 
protein of interest and can be broadly applied to study protein activity and localization 
(reviewed in Giepmans, 2008; Giepmans, Adams, Ellisman, & Tsien, 2006). Recently, a 
genetically encoded protein has been developed that does not need additional labeling 
(mini-SOG). Because of its high singlet-oxygen quantum yield, it forms a great target for 
photoconversion (Shu et al. , 20 1 1 ) .  Although combinatorial probes for CLEM hold great 
promise, some approaches using the super resolution techniques m ight make a subset 
of probes that deposit an EM mark obsolete (see Watanabe et al. , 201 1 ) .  
While the sample preparation using either affinity-based or genetically encoded 
probes might seem straightforward, it is not easy to overlay the FLM data with EM. 
Currently, the bottleneck in most CLEM-approaches that include live-cell imaging is to 
find back your ROI imaged by LM for EM. Below we review the current " search-&- find 
protocols " ,  some of which rely on LM imaging of EM-prepared samples, others that 
require a new type of microscope that integrates LM and EM. As an important step 
toward routine CLEM, we present a more generic method that allows combining data 
from almost any LM with SEM or TEM. 
Ill . ROIS: SEARCH & FIND TOOLS 
A. La rge-Sca le  LM and EM 
Traditionally, large-scale, high resolution imaging has been performed by  manual 
acquisition followed by gluing pictures together. Automation and computer capacity to 
handle GB datasets have been the basis of the development of automated imaging of 
large areas at high magnification, which is a recent development (Chow et al. , 2006). 
Currently, this large volume imaging is a standard feature on most advanced fluorescence 
microscopes. Similar progress has been made on electron microscopes, allowing 
acquisition of high resolution datasets of large areas (typically > 1 GB) .  The orientation 
between LM and EM datasets is relatively easy: hallmarks in the sample (especially in 
tissue) or the borders of the culture dish or slide can be used for guidance. In principle, 
LM or EM datasets are reformatted and rotated until they match,  and the CLEM is done 
entirely post image acquisition, since all ROls are present in both datasets. 
Major benefits of large-scale imaging include the chance of capturing rare spatial 
events and the ability of high-throughput analysis, allowing quantitative studies. 
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However, acquisition of a single point in time during imaging of the mosaic is relatively 
time consuming, which limits the possibilities for temporal imaging. The resulting large 
datasets contain a wealth of information, which should preferably be analyzed in an 
automated manner. This usually requires dedicated software and compilation of macros 
or plugins for image analysis programs such as lmageJ. While automated LM acquisition 
and stitching have been standardized, automated acquisition and reconstitution of EM 
data is still in a pioneering phase, although very promising (Anderson et al. , 2009; 
Briggman, Helmstaedter, & Denk, 2011; Cardona et al. , 201 O; Kaynig, Fischer, Muller, 
& Buhmann, 201 O; Sims & Hardin, 2007). 
B. Marks 
Essential for CLEM is to find back the ROI selected by LM (cm scale) during EM sample 
preparation (mm scale) and acquisition (µm - nm scale). Grids or marks included in cell 
culture dishes are of great help for orientation. To aid in relocating ROls, glass coverslips 
with etched grids can be used, which are reproduced on the resin block after embedding 
(Perkins, Sun, & Frey, 2009). Another way of highlighting an area of interest is to use a 
diamond pen to induce a scratch, which will also be visible in the resin. The marked area 
can then be selected either by eye or by hand, or for instance by using an objective holder 
with a diamond (or other marker) instead of a lens to encircle the area of interest, which 
is further processed for EM (Merdes & De Mey, 2011 ). Gridded coverslips with positional 
markers are also used to combine live-cell imaging and immunolabeling (Hanson, Reilly, 
Lee, Janssen, & Phillips, 2010; van Rijnsoever, Oorschot, & Klumperman, 2008). Because 
the grid is not visible during imaging at high magnification, a separate image at lower 
magnification is needed to see the grid pattern and coordinates. Another disadvantage 
of growing cells on a finder grid is that the sample may be partially obscured (Sartori 
et al. , 2007). Alternatively, cells can be grown on Formvar that is coated with a finder 
mask of a fine layer of gold or carbon. During the coating, a "masking device" can be 
used that prevents gold deposition on the Formvar in certain positions, thereby creating 
a "negative" grid pattern (Auinger & Small, 2008). 
A seemingly straightforward way of pinpointing areas of interest is to extract the ROI 
during sample preparation, which is routinely performed when selecting certain areas 
of tissues for further analysis. This method can also be applied when (pre-)selecting 
cells of interest in a culture dish. Using a pipet tip, the cells surrounding the ROI can be 
carefully removed. 
C. Photoconversion and CLEM 
Several methods for correlated microscopy depend on polymerization of osmiophilic 
diaminobenzidine(DAB; Meisslitzer-Ruppitsch, Rohr!, Neu muller, Pavelka, & Ellinger, 2009; 
Sosinsky et al. , 2007). When fluorophores are used to generate singlet oxygen to 
polymerize DAB by intense illumination using an objective, the illuminated area will be 
darker than its surrounding, and is thereby intrinsically labeled. This straightforward 
method to define ROls imaged at LM level has been used by several researchers 
(pioneered by Deerinck et al. , 1994; Maranto, 1982). A highly informative cartoon with 
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the steps of this procedure was recently presented (Meisslitzer-Ruppitsch e t  al. , 2009), 
and several examples of CLEM using photoconversion of genetically encoded probes 
are shown by Shu and coworkers (2011 ). While photoconversion provides a fast, 
straightforward orientation at the mm scale, obviously, the match has to be made at 
the cellular scale as well. 
D. l mmuno labe l i ng and Combi natoria l  Probes a nd CLEM 
The most developed way of CLEM is labeling thin sections with immunoreagents that 
can be detected at both LM and EM levels. This is a generic way of labeling, which is 
being explored for CLEM since the 1980s, prior to the GFP revolution. The Tokayasu(-like) 
labeling (Bos et al. , 2011; Tokuyasu, 1973) of ultrathin sections no longer only includes 
immunogold, but combinatorial probes combining gold and fluorescent dyes. Following 
labeling, the sections are first analyzed by LM and subsequently by EM . Special finder grids 
for FluoroNanogold labeling of thin sections have been explored by Takizawa (Robinson, 
Takizawa, Pombo, & Cook, 2001; Takizawa, Suzuki, & Robinson, 1998). Combinatorial 
probes have been applied as markers not only to identify proteins or structures, but 
also to orient the sample at the multi-nm scale: Protein A-gold in combination with 
fluorophores can be used as fiducial markers to overlay LM and EM data (Vicidomini et 
al. , 2008, 2010). Obviously, this approach is highly suitable for serial sections followed 
by 3D reconstruction. To detect numerous antigens with high resolution, a procedure has 
been developed to repeat immunolabeling and imaging several times, applying different 
antibodies. Implementing this on many thin sections and reconstructing the image is 
presented as "Array Tomography," which also can be followed by EM analysis of the 
specimen (Micheva & Smith, 2007). An added bonus of this technique is the improved 
axial resolution by using thin sections at the FLM level. The axial resolution is the physical 
section thickness, typically -60 - 80 nm. As opposed to many other CLEM setups, the use 
of combinatorial probes is true-correlated CLEM at the molecular scale: the same antigen 
is detected at both modalities. This might even be further optimized using intrinsic 
properties of the probe, e.g., quantum dots for postembedding EM (Nisman, Dellaire, 
Ren, Li, & Bazett-Jones, 2004), for both LM and EM. The Tokayasu approach focuses on 
immunolabeling. In addition, for affinity dyes, such as nuclear stains or phalloidin, the 
procedure also has been nicely illustrated by Jahn et al. (2009). 
E. Live-Ce l l  Imag ing and CLEM 
A disadvantage of immunolabeling is the common incapability of live-cell studies. 
One straightforward solution is the use of FPs for live-cell imaging followed by 
cryoimmunogold labeling for EM (van Rijnsoever et al. ,  2008). Here, a mark on the 
coverslip or gridded coverslips is usually needed for orientation. For vitrified samples, 
the approach of whole-grid imaging may also be used, including imaging of living cells 
using certain probes. LM imaging of the grid requires a special cryoholder as described 
by Sartori. Also here, finder grids will aid in relocating the region of interest (Briegel et 
al. , 2010; Sartori et al., 2007). Additionally, the use of software-directed guidance to 
find back coordinates of cells grown on EM grids may be useful (Sartori et al. , 2007). A 
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recent report described fabrication of special holders for cryo-LM imaging of samples 
at low costs (Carlson & Evans, 201 1  ). Nowadays, genetically encoded proteins can also 
directly be detected in thin sections that have a well-preserved ultrastructure: multicolor 
live-cell imaging can be more easily combined with tomography when the EM samples 
also still have their fluorescence using cryopreparations, as well demonstrated by 
Briggs and coworkers (Kukulski et al. ,  201 1 ;  see Watanabe et al. , 201 1  for chemical 
fixation). This can be even extended to intravital CLEM, shown already for zebrafish 
embryos (Nixon et al. , 2009). Besides cryo-EM, CLEM is also compatible with high­
pressure freezing (HPF). In this approach, cells are typically grown on special sapphire 
discs or aclar (Jimenez et al. ,  201 0). As for grid-labeling, the area of the discs restricts 
the area of interest at the (live) FLM level. Thus, the HPF method is suitable for high 
resolution EM analysis, but not for large-scale CLEM (Lucic et al. ,  2007). To facilitate a 
fast transition from the FLM imaging toward the vitrified state, a rapid transfer system 
has been developed that allows to process living cells, in which dynamics have been 
analyzed with fluorescent probes, within 5 s for EM-analysis (Verkade, 2008). 
F. Super Resolution Microscopy and CLEM 
The most recent development in correlating both the FLM signal and the ultrastructure 
in thin sections is with the aid of super resolution microscopy. While this has been 
performed on cryomaterial in the PALM-studies mentioned earlier (Betzig et al. ,  2006), 
here the ultrastructural preservation was hampered. Recently, CLEM for genetically 
encoded probes has been optimized. Crucial ingredient to balancing ultrastructural and 
fluorescence preservation was a cocktail of 0. 1 % potassium permanganate combined 
with 0.001 % osmium tetroxide. To retain the fluorescence capability, samples were 
embedded in glycol methacrylate. This protocol led to sufficient fluorescence to 
perform PALM and STED imaging on semithin sections, and simultaneously allowed 
good preservation of the ultrastructure (Watanabe et al. , 2011 ). 3D reconstitution of 
large volumes using LM markers has been pioneered by Smith, using array-tomography 
(Micheva & Smith, 2007) as mentioned earlier. 
G .  Correlation of LM and EM Using LM Image of Block Face 
Alternative to imaging ultrathin sections, imaging of the complete block face might 
be an option. This allows relative easy orientation of the sample, and all LM lateral 
information will correspond to the EM sample, since both images can be overlaid 
completely. We showed an example previously, where chemically fixed samples had been 
labeled preembedding using quantum dots. Postembedding, excluding Osmium to avoid 
loss of fluorescence, the block face was imaged first with FLM, followed by ultrathin­
sectioning and TEM analysis (Giepmans, Deerinck, Smarr, Jones, & Ellisman, 2005). While 
this procedure leads to x I y CLEM, the axial information taken with the LM will extend 
several ultrathin-sections. Alternative to serial sectioning EM as described earlier (see 
also Anderson et al. ,  2009; Cardona et al. ,  201 0), the whole sample can be embedded 
after LM and imaged as a block in a SEM using the backscatter detector. While no 
selection of the area is needed, the disadvantage of this method is the lower resolution. 
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H .  Stage Holders for CLEM and Integrated M icroscopes 
Custom stage holders or rapid transfer systems have been built to facilitate live-cell 
imaging followed by cryo-EM analysis as described earlier. Currently, devices are 
constructed that are designed to find back the area of interest. A commercially available 
device is "Shuttle & Find" from Zeiss. This system is based on positioning a mark on the 
holder, and with software intervention it allows to automatically allocate the position 
which is imaged with a dedicated inverted LM on a dedicated SEM. Currently, this 
device is not suitable for TEM because it is incompatible with ultrathin sectioning of 
the samples. Further developments are needed to make such a system more versatile. 
When samples are prepared for LM and EM analysis, using fluorescence imaging 
integrated in an electron microscope is a straightforward way to identify ROls. Some 
systems have now been developed that allow FLM in the EM, suited to study rare 
events/features in tissue but incompatible with live-cell imaging. Systems are built by 
several manufacturers, including a TEM-based system with an integrated LM objective 
by FEI (Agronskaia et al. , 2008), as well as a system that has the optical and electron 
detecting devices at the opposite sides of the sample (JEOL Clairscope; Nishiyama et 
al. , 2010), and an LM positioned in situ in the SEM underneath the sample (Delmic 
Secom; J. Hoogenboom personal communication). The latter integrated microscope 
may benefit from improving wet EM, i.e . ,  imaging specimens with both LM and EM 
in liquid, pioneering the work being undertaken by de Jonge and coworkers (Dukes, 
Peckys, & de Jonge, 2010; de Jonge & Ross, 2011). 
Depending on the experimental question, a certain microscopy modality is selected 
for CLEM. All methods mentioned earlier have advantages, but also restrictions, such as 
lack of freedom of switching between any LM and/or EM of choice. 
IV. OUR APPROACH: VIRTUAL REALITY OVERLAY DURIN G 
PREPARATION 
While mosaic microscopy was still challenging a decade ago, it is nowadays available 
on many microscopes. U tilizing automated large-scale imaging, our method allows a 
relative straightforward correlation of LM and EM images taken on almost any system 
and of almost any type of sample (both cultured cells and tissue). Subsequent analysis of 
the underlying ultrastructure with EM does not need expensive equipment. Orientation 
and correlation of LM and EM images is facilitated by an intrinsic hallmark (tissue, dust, 
etc.) or an induced mark (e.g. , scratch) in the sample. 
A. Aim - Facilitate finding back objects imaged in any LM and EM. 
B. Requirements (See also Fig. 1) 
0 Fluorescence microscope, preferably capable of making automated mosaics 
0 A binocular equipped with a drawing tube 
0 Computer and monitor 
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0 Image analysis software (we use Adobe Photoshop, lmageJ , T issueFaxs viewer from 
T issueGnostics and ICE from M icrosoft) 
0 Standard embedding and sectioning facility 
0 Electron microscope, preferably capable of making automated mosaics 
C. Principle - In our approach, a complete LM mosaic is being overlaid with the 
embedded sample using a drawing tube (virtual overlay). ROls can be marked in the 
image as well as on the embedded sample, enabling processing exactly the same area 
for EM analysis. 
D. Workflow (See also Figs. 2 and 3) 
1 .  Grow cells on a glass bottom Petri dish or chamber slide. Preferably, glass should 
contain a mark like a finder grid or diamond pen scratch. Later orientation is easier 
in a chamber than in a Petri dish. 
F ig u re 1 I Setup for search ing and f ind ing areas of interest. Microscope setup to faci litate 
tracking RO ls: a Zeiss Stemi SV11 binocular equipped with continuous zoom and a drawing tube. The 
drawing tube is pointed toward a computer monitor, which is rotated by 90° to match the computer 












9 .  
Preferably use a nonconfluent layer of cells providing hallmarks. 
If needed, follow cells of interest with live-cell imaging or fix cells. 
Make a mosaic image of a large area of the chamber at sufficient magnification 
(fluorescent channels and bright field/DIC), preferably including one or more corners 
of the chamber . 
Fix and stain the cel ls according to a TEM protocol (cel ls have to be visible in a light 
microscope; therefore, include Osmium or another clearly visible dye). 
Repeat imaging as in step 4 if necessary. 
Dehydrate and embed the cells in a suitable resin such as Epon (careful ly, there 
should not be any disruption of the cell layer). 
Polymerize the resin. 
Remove the glass bottom of the dish, e.g. , with hydrofluoric acid (>4 h). 
10. Make mosaic reconstructions of the images acquired in step 4, fluorescence and 
bright field separated on aligned layers in one Photoshop file. 
11. If necessary, improve the quality of the bright field reconstruction by contrast 
enhancement (e.g., by using the shadow function of lmageJ) and background 
subtraction to remove the halo. 
12. Match the improved bright field mosaic image with the embedded cells in the chamber 
(bottom-up) using the binocular and drawing tube. The tube is pointed forward toward 
the computer monitor, which, in our case, is rotated by 90° to match the view in the 
microscope. The mosaic image has to be flipped horizontally. The magnification of the 
microscope has to match the size of the image on the monitor. A zoom function on the 
microscope is obligate. If Photoshop is used, the image can easily be zoomed in or out 
and can be panned on the monitor (keep all layers linked). 
1 3. When positions of the cells in resin and on the monitor match, switch to the fluorescent 
layer in Photoshop. The fluorescent signal is now projected on the embedded cells. 
14. Locate ROls and mark them with some scratches in the resin. Looking through the 
drawing tube, mark exactly the same areas in the Photoshop document. 
15. Use a jigsaw to isolate small blocks (<25 mm2) that contain the selected areas. 
16. Insert the block in a microtome sample holder and place it back in the drawing tube 
microscope. 
17. Overlay the areas of interest and match it with the cel ls visible in the block face. 
18. Mark the area with a razorblade to facilitate the location and trimming of the area 
of interest . 
19. Make a pyramid to be able to section the area of interest in an ultramicrotome. 
Draw the exact outline of the pyramid in the Photoshop document. 
20. Make ultrathin sections of the block face, and place them on large mesh grids, 
preferably single hole. Stain them if necessary. 
21. Acquire a low magnification TEM image or a mosaic so that the complete section is 
in one image. Overlay and correlate this image with the Photoshop image as a new 
layer in the Photoshop document. 
22. Locate the area of interest in the TEM and acquire high magnification images. 
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Figure 2 I CLEM using a v irtual overlay. Example of tracking down cells of interest from low 
magnification FLM to high magnification EM. (A) Stitched mosaic (1 2 x 29 images; TissueFaxs) of 
living cel ls grown on a chamber slide; merge of bright field and red (mCherry) and green (GFP) 
fluorescence images. This overview will be projected on the embedded cells. Yellow and green 
rectangles: silhouettes of two eventually trimmed pyramids prior to ultrathin sectioning. (B) 1 µm 
thick, toluene blue stained section of the upper yellow pyramid indicated in (A). Arrows indicate 
landmarks also visible in the ultrathin section (C) of the same pyramid. (D) Higher magnification of 
(A) (see inset), which is overlaid with the low magnification TEM image (E) to facilitate the localization 
of cel ls of interest on TEM scale. (F) Overlay of (D) with a higher magnification of the T EM overview 
(G), enabling the tracking of cells of interest in the TEM for high magnification imaging. The arrow 
indicates a green fluorescent cel l that is selected for higher magnification imaging. (H) Enlarged 
fluorescent image of the cell of interest as indicated in (F), which can be overlaid with a mosaic 
reconstruction of ten TEM images of the same region (I, J). The rectangle indicates the final high 
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Figure 3 1  Schematic flow chart of mosaic based CLEM back track. ( 1 )  A chamber slide on which 
cells are grown, only one cell is fluorescent (green) .  Aim is to select this particular cell for TEM . A 
mark in the chamber, e .g. ,  a scratch in the glass (diamond pen), facilitates later matching of the fixed 
cells with the fluorescent images. The ind icated grid in the chamber represents positions on which LM 
images are made a t  20x  or  40x  magnification (bright field/DIC and  fluorescence), using an automated 
stage . Typically, a hundred or a few hundred images are needed . (2) Cells are fixed, dehydrated, 
stai ned, and embedded in  Epon .  After polymerization,  the glass bottom of the chamber is removed. 
(3) Images taken in step 1 are stitched i nto one large image (T issueFaxs Viewer), with fluorescence 
and bright field as separate files . Images are converted to separate layers in one Photoshop file, 
facilitating easy switching between bright field, fluorescence and the merged image. I n  this large­
scale image, ROls can be marked by drawing a circle in a new layer. (4) Viewing the embedded sample 
from step 2 in a binocular (bottom-up), the sample is overlaid with the image constructed in step 3 ,  
using a drawing tube  which i s  pointing toward a computer monitor. Marks i n  chamber and  image 
can be used for positioning of the sample . Note that orientation and magnification of sample and 
Photoshop image have to match (see Fig. 1 ). (5) Areas of i nterest selected i n  step 3 are marked with 
scratches using a razorblade, which are also drawn i nto the Photoshop image . (6) Areas of interest 
are sawed out and trimmed for ultrath in section i ng. The drawing tube and Photoshop image are used 
to control the exact position . (7) Low magnification TEM image or mosaic of the complete section 
is acquired and overlaid with the Photoshop image as a new layer. (8) High magnification images of 
relocated area of interest can be acqu ired . 
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V. DISCUSSION AND CONCLUSION 
Correlative microscopy is being explored since the 1980s and has been revolutionized 
since the introduction of FPs. Still, no routine method is available, and procedures, 
probes, microscopes, and add-ons are under full development. The lack of a standard 
procedure is partially caused by (1) compromising sample preparation or imaging when 
needing to use both the modalities and (2) the difficulty of finding back areas of interest 
as discussed here. The latter problem has been approached by several laboratories and 
researchers, resulting in custom-made solutions, which have their specific benefits, but 
also are of limited usability. 
Considerations when using CLEM are first and foremost what kind of data is needed 
to solve the research question. For example, we advocate automated mosaic imaging, 
but the acquisition of 1000 images of a large area is much more time consuming than 
imaging a single area. This precludes high temporal imaging of the individual areas 
which might be needed for studying fast processes in living cells. Tokayasu-like labeling 
on ultrathin sections is well developed, but may be incompatible with live-cell imaging 
when solely immunoreagents are used. Alternatively, GFP can be immunolabeled on 
ultrathin sections following live-cell imaging. Another limitation of Tokayasu-like labeling 
is the restriction on ultrathin sections, precluding 3D analysis, which can be solved by 
array tomography. At the molecular level, labeling ultrathin sections gives a genuine, 
molecular correlation, which is typically not seen when combining preembedding (live) 
images with EM because of the limited resolution at LM level. 
A recurrent theme of this chapter is the problem of correlating images from different 
microscopes. This is not easy when selecting a - 25 mm2 area of interest, but even 
more difficult when making the selection at the cellular or macromolecular scale. In 
most approaches, including ours, marks in the sample are important to match images. 
These marks can either be intrinsic (stained nuclei, cell shapes, or groups of cells) or 
introduced (finder grids, scratches, etc.). 
Regarding the choice of microscopes, commercial systems are available for CLEM, 
which are, however, quite costly. Preferably, microscopes are used that are easily 
accessible and most helpful to solve the particular research question. When limited 
to certain instruments, several options are available to correlate LM and EM data. Our 
approach has the advantages that it can be done at low costs, and that it provides a 
high degree of freedom regarding the choice of microscopes. Given all the different 
approaches being undertaken to allow a more routine CLEM, what would these 
developments bring us next? 
VI. F UTURE PERSPECTIVE 
A recent prediction of the direction of CLEM was the increase of super resolution LM and 
EM and software assistance in overlaying the LM and EM images (Cortese et al., 2009). 
Indeed, recent studies discussed here have shown that these predictions were right. 
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further development of  integrated LM/EM microscopes and (2 )  large-scale LM and 
EM imaging of large areas of interest at high magnification. We predict that these 
developments will help to establish CLEM as a routine technique available at institutional 
and academic microscopy centers within the next 5 years . 
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Mutations in the epithel ia l  cel l  ad hesion molecu le (EpCAM) gene are ca usa l  for 
Congenital Tufting Enteropathy (CTE), characterized by i ntesti na l  abnorma l ities that 
lead to letha l  d iarrhea . Why the d ifferent mutations al l lead to the same d isease is 
not clear. Here, we report that most mutations, i ncl ud ing a novel i ntron ic va ria nt, 
wi l l  result in  lack of EpCAM's transmembrane domain ,  whereas two mutations a l low 
tra nsmembrane local ization .  We fi nd that these mutants are not routed to the plasma 
membrane, and that truncated mutants are secreted or degraded . Thus, a l l  epcam 
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Figure 1 I (A) epcam mutations l inked to CTE. Nucleotide and amino acid (aa) coordinates are g iven (A 
of the start codon is 1 ). a: donor spl ice site; b: acceptor spl ice site; *coord inates deviate from reference; 
* *predicted with Alamut Software . (B) Schematic representation of EpCAM. Grey: signal peptide; 
green: EpCAM motif- 1 ; purple: Thyroglobul in Type 1 A-l i ke repeat; black: transmembrane doma in .  (C) 
EpCAM mutant proteins in CTE. Colors as in (B); red: CTE-mutations; *Swiss-Prat: P 1 6422 .2 .  
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CTE is a rare form of neonatal intractable diarrhea1 . The disease is characterized by 
morphological abnormalities in the intestinal epithelium, including subtotal villous 
atrophy with crypt hyperplasia and focal crowding of surface enterocytes2 . 
Mutations in epcam have been discovered as the genetic basis of CTE (Fig. 1 A)3-7. 
EpCAM is a transmembrane cell surface protein (Fig. 1 B) that regulates morphology8• 1 0 • 
In the intestinal epithelium, EpCAM is localized at the basolateral membrane of 
cells8. EpCAM has proposed functions in cell-cell adhesion8, as well as in receptor-like 
mediated control of cell proliferation1 1 . While it remains to be explored how these 
EpCAM functions are separated or connected, EpCAM's function at the cell surface is 
not debated8• 1 1 • Here, we set out to uncover why the different epcam mutations lead 
to the same disease. 
All identified CTE mutations have been found to be homozygous or compound 
heterozygous (Fig. 1 A), consistent with autosomal recessive inheritance3 •6 . Notably, 
C66Y had been found as the only heterozygous mutation3 • Here we report that 
further genetic screening of this patient identified an additional intronic variation 
(c.556- 1 4A>G), which predictably leads to a frameshift and premature truncation 
within EpCAM's ectodomain (p.Y 1 86FfsX6; Fig. 1 ;  Suppl. Fig. 1 ). 
While most of the EpCAM mutations found in CTE lead to premature STOP codons 
resulting in the loss of the transmembrane domain, two mutations (W1 43_ T1 64del and 
C66Y) result in other structural changes, retaining the transmembrane domain (Fig. 1 C). 
To identify the molecular basis of CTE, all mutants were mimicked at the cDNA level and 
expressed in HEK293T cells followed by analysis of subcellular localization (Fig. 2A-C). 
Whereas wtEpCAM is predominantly localized at the plasma membrane, both the deletion­
mutant (W1 43_ T1 64del) and the point-mutant (C66Y) are retained in the endoplasmic 
reticulum (ER). In cells expressing these two mutant proteins, the level of EpCAM multimers 
is increased (Fig. 2D). All EpCAM mutants with premature STOP codons are minimally 
detectable (Fig. 2A). Only in a subset of cells, the mutant proteins are present in the ER 
(Fig. 2A). FACS analysis shows that none of the mutants is present at the cell surface 
(Fig. 2B, Suppl. Table 1 ). Western blot analysis of cell lysates and concentrated cell-free 
medium reveals that all mutant proteins are expressed (Fig. 2C), and that mutants R 1 38X 
and K1 06X are secreted. Note that a weak band shows that also Y 1 86FfsX6 is secreted 
to a lesser extent. Inhibition of protein transport with Nocodazole increases the levels of 
truncated mutants in cell lysates (Fig. 2C, middle panel). Notably, both wtEpCAM and its 
cleaved ectodomain are present in cell-free medium due to presence of the protein on 
microvesicles and ectodomain shedding (Fig. 2C, bottom). 
Al though the CTE-mutations in epcam lead to different gene-products, all mutations 
cause loss of cell surface EpCAM, thus explaining the similar phenotype. ER retention 
of the deletion-mutant and C66Y might be caused by misfolding, resulting in 
increased multimerization and aggregation. Loss of the cys66, which is normally 
engaged in a disulphide bond 1 2 , leads to free cys99, possibly resulting in intermolecular 
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Figure 2 I (A) Mutants are absent from the plasma membrane. 293T cells expressing an EGFP-ER 
marker and wt or mutant EpCAM, immunostained with an antibody recognizing EpCAM motif- 1 
followed by an Alexa647-conjugated secondary antibody. Bar: 20 µm. (B )  Living 293T cells transfected 
and immunostained as in (A) analyzed by FACS. For percentages of gated cells per quadrant see 
Suppl. Table 1 .  ER-EGFP was used to identify transfected cells. (C) Truncated mutants are secreted or 
degraded. Western blot analysis of lysates and concentrated medium of 293T cells, expressing wt 
or mutant EpCAM as indicated. Middle blot: Cells were treated with 10 uM Nocodazole for 24 h 
to inhibit vesicle transport. MW indication of proteins includes N-glycosylation. (D) EpCAM mutants 
multimerize. Western blot analysis of 293T cells, expressing wtEpCAM (wt), C66Y, W1 43_ T 1 64del 
(Del), or empty vector (---). *monomers; * *dimers; * * *oligomers. 
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dimerization. A similar model of i ntermolecular aggregation has been suggested 
to occur in gelatinous drop-like corneal dystrophy, involving a C 119Y mutation in 
EpCAM's homologue TROP-2 1 3. 
EpCAM mutants that lack the transmembrane domain are either secreted or seem 
to be degraded. Notably, only the mutants with unchanged sequence prior to the 
STOP codon are secreted (K106X and R138X), whereas mutants with frame shifts, 
resulting in regions of novel amino acids, are not detectable in the medium and hardly 
detectable in cell lysate. These mutants may be recognized as targets for endoplasmic­
reticulum-associated protein degradation (ERAD), leading to ubiquitination and fast 
degradation by the proteasome 1 4. M utant Y186FfsX6, which only has six novel amino 
acids added, is secreted at very low levels in comparison to the other secreted mutants. 
Thus, the relatively long regions of novel amino acids in CTE mutants Q167PfsX21 and 
A 165MfsX24 might play a role in the substrate recognition for ERAD. 
In conclusion, we show that CTE is a truly autosomal recessive disease, characterized 
by mutations in epcam. All mutations identified lead to absence of EpCAM from the 
cell surface, impairing normal development of the intestinal epithelium. Revealing the 
effects of epcam mutations might help in the development of CTE therapies, i.e. the 
prevention of protein aggregation to reroute EpCAM to the cell surface. In addition, 
these mutations may be instrumental to understand EpCAM's normal role in regulating 
cell signaling and/ or adhesion. 
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S UPPLEMENTARY MATERIAL & METHODS 
Genotyping - Informed consent of the subjects/parents was obtained according to the 
local institutional review board guidelines. Available unaffected subjects (parents) were 
also recruited, and, after informed consent, blood samples were collected, and genomic 
DNA was extracted and sequenced as previously described 1 • 
Cell culture and transfection - Human embryonic kidney cells (293T; ATCC, USA) were 
cultured in DMEM (1 g/I G lucose) supplemented with 5% FCS and penicilline (100 U/ml)/ 
streptomycine (1 mg/ml). Cells were cultured at 37°( in a humidified incubator in the 
presence of 5% CO2 " Media and supplementation were obtained from PAA (Austria). 
293T cells were transfected with Polyethylenimine2 (linear, MW 25,000; Polysciences Inc. , 
USA). Briefly, 0.5-1 ug DNA and Polyethylenimine (ratio 1 :5) were incubated in serum­
free medium for 30 to 60 min at room temperature and added to the cells during plating 
(6-well plate). Cells were used for experiments at least 24 hours after transfection. 
Plasmids - For this study, human EpCAM cDNA3 (kind gift of V. Cirulli) subcloned 
into pcDNA3.1 was used. Using this as template, the C66Y mutation was introduced 
(G>A substitution as in Fig.1 A, no. 4) by Quick Change Mutagenesis (Stratagene, The 
Netherlands). Also mutants K 106X (A> T substitution; Fig. 1 A, no. 8), R 138X (C> T 
substitution; Fig. 1A, no. 5), and Q167PfsX21 (insertion C; Fig. 1A, no. 6) were generated 
using Quick Change Mutagenesis. The W143_ T164del mutation (Fig. 1 A, no. 1 and 2) 
was introduced by combining N-terminal and (-terminal PCR fragments, ligated together 
following a BsiWI cut, resulting in the TY-AL amino acid sequence of the predicted mutant 
(Fig. 1 C, W143_ T164del). Mutation A 165MfsX24 (Fig. 1 A, no. 9) was predicted to result 
from skipping of Exon 5 and a subsequent frameshift. The mutant was generated similarly 
to the deletion mutant W143_ T164del, ligating N- and (-terminal PCR fragments via an 
introduced BsiWI restriction site. Predicted mutation Y186FfsX6 was created by using 
standard cloning techniques. Plasmids were verified by sequencing. The ER-marker ER­
superluc-EGFP (calnexin pre-sequence) 4 and pcDNA3.1-EGFP5 have been described. 
Flow Cytometry - Transfected 293T cells were trypsinized and kept in ice-cold PBS 
containing 1 % BSA and 0.1 % NaN3 (also used for antibody dilutions; all incubations on 
ice). For immunostaining, the living, non-permeabilized cells were incubated for 15 min 
with monoclonal antibody MOC316, which is directed against the first motif in EpCAM's 
extracellular domain (wtEpCAM as wel l as mutants are recognized). After washing, cel ls 
were incubated for 15 min with an Alexa Fluor 647-conjugated secondary antibody 
(lnvitrogen, The Netherlands) and used for FACS analysis (FACSCalibur flow cytometer, 
BO Biosciences, USA). 
Confocal microscopy & lmmunofluorescent staining - Fluorescent images were 
acquired using a Zeiss LSM 780 microscope (Zeiss, Germany). For immunostaining, 
transfected 293T cells were fixed using 10% formalin for 30 minutes (Sigma-Aldrich ,  
The Netherlands), washed (PBS) and permeabilized with 0.1 % Triton X-100 (Merck, The 
90 
ABSENCE OF CELL SURFACE EpCAM IN CONGENITAL TUFTING ENTEROPATHY 
Netherlands) in PBS (15 min). After blocking with 1 % BSA in PBS for 15 min, cells were 
incubated with first and secondary antibodies (60 min each, diluted in 1 % BSA/PBS) as 
described for FACS. Nuclei were counterstained using Hoechst33258 (Sigma-Aldrich, 
The Netherlands). All immunostaining steps were executed at room temperature. 
Western Blotting - SDS polyacrylamide gel electrophoresis (SDS-PAGE) and Western 
Blotting procedures were conducted according to standard protocols (equipment from 
BioRad, USA; Millipore, USA). Transfected 293T cells were lysed using either reducing or 
non-reducing Laemmli Sample Buffer and denatured at 95°( for 5-10 min. For detection 
of secreted proteins, 293T cells, transfected for 24 hours, were incubated with medium 
containing 0.1 % serum for additional 24 hours. Centrifuged and filtered medium 
(0.2 µm; Whatman, Germany) was concentrated using Amicon Ultra-4 centrifugal 
concentration filter tubes with a molecular weight cut-off of 3 kDa (Millipore, U SA). 
The final concentrate was diluted with 5x Laemmli sample buffer (non-reducing), and 
denatured at 95°C for 5-1 0 min. To block microtubule polymerization and thereby 
vesicle transport, cells were incubated with 1 0µM Nocodazole for 24 hours prior to lysis. 
For EpCAM immunostaining, antibody MOC31 (Fig. 2C) or polyclonal antibody P6052 
(Fig. 2D), raised against the intracellular domain, were used (designed in our laboratory, 
generated by BioGenes, Germany). Following incubation with an HRP-conjugated 
secondary antibody, proteins were detected by enhanced chemiluminescence (antibody, 
ECL detection kit, film: GE Healthcare, UK). 
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Supplementary Table 1 I Mutants are absent from the plasma membrane. 293T cells expressing 
EG FP-ER and wt or mutant EpCAM, immunostained with antibody MOC31 recognizing EpCAM 
motif- 1  followed by an Alexa647-conjugated secondary antibody, analyzed by FACS. *NC= 
negative control without primary antibody. 
Transfect ion 
Empty vector 
Empty vector NC* 
wtEpCAM 
C66Y 
W143_ T 1  64del 
R138X 
K 106X 
Q 1 67PfsX21 
Y1 86FfsX6 
A 1 65MfsX24 
c. 1 97G>A 
Total  no.  




4, 1 45 
4,3 2 1  
4 , 302 




Cel l s  per quadrant (%) 
B -/- B+/- B+/+ 
(non-transfected} (GFP-positive) ( GFPIMOC3 1 -positive) 
5 2 . 8  47 .2  
52 .2  47.7 
64.5 4.8 
63 .1  36.7 
46. 9  53.0 
47.7 52 .3  
50.0 50.0 
47.3 52.6 
55 .6 44.3 
49.9 50.0 
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c. 556-1 4A>G 
Supplementary Fig ure 1 I Pedigree of patient with 2 heterozygous mutations: c. 1 97G>A and 
c.556-14 A>G with predicted amino acid changes and sequence chromatograms. Unaffected mother 
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The epithelial cell adhesion molecule (EpCAM) is highly expressed on epithelium-derived 
tumors and can play a role in cell proliferation. Recently, regulated intramembrane 
proteolysis (RIP) has been implicated as the trigger for EpCAM-mediated proliferative 
signaling. However, RIP does not explain all EpCAM-derived protein fragments. To shed 
light on how proteolytic cleavage is involved in EpCAM signaling, we characterized the 
protein biochemically using antibodies binding to three different EpCAM domains. Using 
a newly generated anti-EpCAM antibody, we find that EpCAM can be cleaved at multiple 
positions within its ectodomain in addition to described peptides, revealing that EpCAM 
is processed via distinct proteolytic pathways. Here, we report on the new peptides, 
but also discuss the previously described cleavage products to provide a comprehensive 
picture of EpCAM cleavage at multiple positions. The complex regulation of EpCAM 
might not only lead to absence of full-length EpCAM, but the newly formed EpCAM­
derived proteins may have their own signaling properties. 
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INTRODUCTION 
The epithelial cell adhesion molecule (EpCAM, CD326; Fig. 1) is a transmembrane 
glycoprotein that plays a role in the balance between cell proliferation and 
differentiation. In healthy tissue, high EpCAM levels are associated with proliferation 
during morphogenesis1 , tissue regeneration2•3 and the maintenance of the proliferative 
state of embryonic stem cells4. In epithelial cancer, high EpCAM expression has been 
found to promote tumor progression and often corresponds to a poor prognosis2 •5-7 • 
In contrast to high EpCAM levels, absence of EpCAM due to gene mutations results in 
congenital tufting enteropathy (CTE), a rare disease causing severe diarrhea in newborns 
due to abnormal development of the intestinal epithelium8. Because of its tumor-specific 
overexpression, EpCAM has been explored as a prognostiddiagnostic marker and anti­
cancer target since the 1970's5 • However, how EpCAM is functionally involved in tumor 
biology is not completely understood. Notably, parts of the protein might be absent 
during diagnosis, since EpCAM is subject to limited proteolysis by a variety of enzymes. 
During synthesis, EpCAM's signal peptide for proper endoplasmic reticulum (ER)­
targeting is removed9-1 1  (Fig. 1, arrow 1 ). Furthermore, EpCAM can be cleaved between 
two arginines within its ectodomain1 0• 1 2• 1 3  (Fig. 1, arrow 2). Although this cleavage site 
was detected soon after EpCAM 's discovery, the functional consequence remains to be 
established. More recently, EpCAM-mediated proliferative signaling has been proposed 
to be activated by regulated intramembrane proteolysis (RIP)14, an evolutionarily 
conserved mechanism combining regulated ectodomain shedding with the consecutive 
release of the intracellular domain (ICD) from transmembrane proteins1 5 . Generally, RIP 
can (i) activate signaling events triggered by the shed ectodomain (e.g. as soluble growth 
factors) and/or the ICD (e.g. as cytosolic signaling molecules or nuclear transcription 
cofactors); and (ii) lead to degradation, thus functional inactivation, of transmembrane 
proteins (Lichtenthaler et al. 2011 1 6  and references therein). The best-studied substrates 
for RIP include Notch, epidermal growth factor (EGF), tumor necrosis factor ex (TNF-cx), 
and the amyloid precursor protein (APP) (reviewed in ref. 17)1 7 . In addition, several cell 
adhesion molecules (CAMs), both classical and non-classical, have been identified as 
substrates for RIP, e.g. epithelial E-Cadherin, neuronal N-Cadherin, CD44 and L 1-CAM 
(reviewed in ref. 18)1 8 • ADAM 17 (A Disintegrin And Metal/oprotease 1 7; also known 
as TACE: TNF-a converting enzyme) is the metalloprotease which initiates EpCAM 
cleavage at the extracellular site, resulting in shedding of EpCAM's ectodomain (EpEX). 
Subsequently, an additional cleavage by a y-secretase with presenilin-2 (PS-2) as active 
subunit causes the release of EpCAM's intracellular domain (EplCD). EplCD may interact 
with (co)transcription factors in the nucleus, altering gene transcription1 4 • 
Here, we address where and when EpCAM is proteolytically cleaved, and discuss how 
the different proteolytic steps may be implicated in EpCAM's function. Due to EpCAM's 
discovery in a screen for tumor-specific cell surface proteins, the majority of available 
antibodies is directed against EpCAM's N-terminal extracellular domain. To distinguish 
between this domain and the short cytoplasmic tail, we first made an antibody directed 
against EpCAM's (-terminal domain. While characterizing EpCAM biochemically using 
97 
CHAPTER 4 
M 1  
: 1� 
P O V L A F G  L L L A A A T A T F A A A Q E  
MOC31 
E C V � E N Y K L A V N f F � 10 20 
•::... 
: o N  




: •:... R 
M V L Q K A  A L  K S  r;_· 1 V T  N Q A  G V S  T .C, Q .C, Q 
--·--��--�: 80 . . . . . 
A L O  N N D  G L Y D P  D � D E S  G L F K A K  Q Q 
E R A  K H  K L  E l  
100 
• • • • •  • • • • • •k 
• • • • • • • • • • •
• • •• • • • • •  V 
I W Y T R V R E S .C_if l E T D K D T R R V G A T N 




O S K  S L R 
160 
T A L Q K E  I T T R Y Q L D P K F I T S  I L Y  E N N V I  T l  D L V Q 
170 180 1ll0 










Q G P D L D L O E G N V T L D M K  K S H F L S E G K V  D K  E F Y Y A  V D A  I 
D 
T 240 230 220 210 
V
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Figure 1 I EpCAM amino acid sequence and posttranslational modification. Arrow 1 :  Signal peptide 
cleavage site; arrow 2 :  N-terminal cleavage site between R80/R8 1 . EpCAM motif 1 (green): Six-cysteine motif 
with a unique disulfide linkage pattern1 1 ; Thyroglobulin type-1 repeat (motif 2, purple): second cysteine-rich 
domain, displaying sequence homology to a Thyroglobulin type-1 A repeat, a domain exhibiting protease 
inhibitor activity. Approximate regions of the epitopes recognized by monoclonal antibodies MOC3 1 and 
31 1-1 K2 and the polyclonal rabbit antibody P6052, which binds EpCAM's ICD, are indicated. See Table 2 
in the Material and Methods section for defined epitope location. 
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three different antibodies recognizing distinct domains, we found four novel (-terminal 
proteolytic fragments. We conclude that EpCAM is proteolytically processed by an 
additional pathway, thus highlighting the importance of proteolysis in the regulation of 
EpCAM signaling. Whether the novel cleavage sites only lead to functional downregulation 
of EpCAM or may serve additional functions remains to be established. 
RES U LTS 
Here, we provide an overview of all EpCAM fragments we detected, starting with 
N-terminal fragments (NTFs) that have been reported previously. We did not detect 
EpCAM with the signal peptide (cleavage at aa 23), which is removed during EpCAM 
translation by a signal peptidase in de ER lumen1 9, and thus will not be part of full­
length EpCAM in other cellular compartments. 
N-terminal cleavage. Another previously identified cleavage site at the N-terminus of 
EpCAM is between R80/R81. Following cleavage, the domains predictably will stay bound 
together by the disulphide bridge in EpCAM's thyroglobulin-like motif (Figs. 1 and 2), 
which will be broken under reducing conditions. When EpCAM is analyzed under 
reduced conditions, R80/R81 cleavage is detected using antibody 311- 1  K2 in 293T cells 
expressing EpCAM (Fig. 2A). Similarly, the cleavage occurs in numerous cancer cell 
lines endogenously expressing EpCAM (Fig. 28). The cleaved N-terminal fragment has 
A 293T 







25- 38 kD 38 kD 32 + 6 kD 
B HT29 CaCo2 A431 HaCaT HepG2 
NR R NR R NR R NR R NR R 
43-
34-
F igure 2 I EpCAM is cleaved in the N-term i n al reg ion.  Lysates of 293T cells transfected with 
EpCAM (A) and various cancer cell lines expressing EpCAM endogenously (B) were analyzed by 
Western blot using an antibody binding to EpCAM's ectodomain (cysteine-free region ;  3 1 1 -1 K2). 
R80/R81 cleavage (red arrow) is apparent under reducing (R) but not under non-reducing conditions 
(NR). Lysate of non-transfected 293T cells serves as antibody-specificity control. 
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a predicted molecular weight (MW) of 6 kDa (non-glycosylated). Based on the size 
difference between non-cleaved EpCAM and the remaining 32 kDa part on Western 
Blots, the glycosylated cleaved fragment has a size of 10 kDa (Table 1 ). Notably, only a 
fraction of total EpCAM is cleaved, and the the ratio of cleaved to non-cleaved protein 
varies between cell lines (Fig. 2) as well as between experiments (data not shown). 
EpCAM ectodomain shedding .  To determine whether EpCAM undergoes RIP, resulting 
in shedding of its ectodomain (EpEX) and subsequent release of a cytoplasmic peptide 
(EplCD)14, we analyzed cell lysates and cell-free medium. Using antibodies directed 
against EpCAM's extracellular domain (ECD; antibody 311-1 K2) or intracellular domain 
(ICD; antibody P6052), the full-length protein is detected in cell lysates of the colon 
carcinoma cell line HT29 (Fig. 3A, LYS). In concentrated cell-free medium, only the 
antibody binding EpCAM's ECD but not the one directed against the ICD, detects 
cleaved EpEX (Fig. 3A, MED), demonstrating that the ICD is absent. Based on analysis 
of Western Blots, EpEX has a MW of 35 kDa (Table 1,). Notably, full-length EpCAM is 
detectable in the cell-free medium, possibly as part of microvesicles, which are secreted 
by cells and only will be pelleted after ultracentrifugation20 (Fig. 3B). The levels of EpCAM 
on microvesicles or the amount of vesicles, respectively, as well as the amount of EpEX 
in the medium depends on the cell line (Fig. 3C). Whereas all cell lines release EpCAM­
containing microvesicles, the level of EpEX is near the detection limit in most cell lines. 
EplCD cleavage. Following ectodomain shedding, EpCAM may be cleaved within the 
transmembrane domain, releasing a soluble cytoplasmic peptide (EplCD). The detection 
of EplCD is impeded by its predicted size of only 2-3 kDa. To visualize EplCD, we used 
an EpCAM-EGFP fusion protein to increase the MW by 26 kDa. Indeed, in 293T cells 
expressing EpCAM-GFP, several protein fragments are recognized by the antibody binding 
EpCAM's ICD (P6052; Fig. 3D). The lowest three bands with sizes between 27 and 29 kDa 
correspond to EplCD-EGFP and the band at 32 kDa to the intermediate cleavage product, 
consisting of EpCAM's transmembrane domain and ICD only. To address which protease 
is responsible for the intramembranous cleavage, cells were treated with y-secretase 
inhibitor DAPT. Treatment resulted in an increase of the intermediate cleavage product 
and decrease of the 29 kDa EplCD-EGFP band (Fig. 3D, DAPT vs. DMSO), pointing to 
y-secretase involvement in the second cleavage step of RI P. 
Novel proteolytic peptides. Our new antibody directed against EpCAM's ICD detected 
several novel proteolytic fragments: (i) a 20 kDa fragment (CTF20: C-terminal fragment 
of 20 kDa; Fig. 4A), and (ii) fragments ranging from 12 to 15 kDa (CTFs12-15: C-terminal 
fragments of 12 to 1 5  kDa; Fig. 4A and Table 1; see Suppl. Fig. 1 for more cell lines). 
These CTFs are not recognized by the antibody against EpCAM's ECD (311-1 K2; Fig. 4A, 
anti-ECD), but can also be detected with anti-lCD antibody E144 (commercially available; 
data not shown).To rule out that the CTFs arise due to trypsinization, we detached cells 
using EDTA for several weeks, showing that the CTFs are not a result of trypsinization (Fig. 
4B). As the MW differs from the fragments discussed before, the CTFs are distinct from 
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Figure 3 I EpCAM undergoes regul ated intramembrane p roteolysis. (A-D): Size determination 
of EpCAM by Western blot. (A) Lysates (LYS) and concentrated medium (MED) from HT29 cells were 
analyzed with antibodies against EpCAM's extracel lu lar domain (ECD) or intracel l u lar domain (ICD) 
as indicated . EpEX = cleaved ectodomain .  (B) HT29 lysate, concentrated medium before and after 
ultracentrifugation ( 1 00,000xg for 1 h), and the pel leted fraction resu lt ing from u ltracentrifugation were 
immunoblotted against EpCAM's ectodomain (3 1 1 - 1  K2). (C) Distinct ratios of EpEX and EpCAM on 
microvesicles in different cel l l ines as indicated. (D) 293T cells expressing EpCAM-GFP were incubated 
with DMSO (0 . 1  %) or 1 0  µM DAPT for 24h, lysed, and immunoblotted aga inst EpCAM's ICD (P6052). 
those generated by RIP (Table 1, page 108). The low levels of CTF20 in comparison to 
CTFs12-15 in all cell lines might indicate that the two cleavage events occur sequentially 
(Fig. 4D). Incubation of cells with DAPT leads to increased CTFs12-15 levels (Fig .  4D), 
suggesting that these fragments might be further processed by a y-secretase (Fig. 4D). 
The trigger of proteolysis remains unclear for most of the fragments. For activation 
of EpCAM signaling by RI P, cell-cell contact or binding of EpEX as a ligand has been 
suggested to be the initial trigger2 1 • We addressed whether the CTFs arise upon cell-cell 
contact formation during cell growth (Fig. SA). The first day after plating, single cells or 
small cell clusters were present, whereas at day 5 cells were grown to confluency (Fig. 5B). 
In all cell lines tested, the levels of CTFs did not change in a cell-density dependent 
manner (Fig. SA). To test whether EpCAM needs to be present at the cell-surface to allow 
CTF-generation, we used an EpCAM point mutant (Cys66Tyr) that causes congenital 
tufting enteropathy (CTE8; see chapter 3). EpCAM-C66Y does not reach the cell surface 
because it is retained in the ER (Fig. SC; see chapter 3). Interestingly, ER retention leads 
to a reduction, but not a complete absence of CTFs (Fig. SD), indicating that cleavage of 
the new CTFs occurs during synthesis in the Golgi apparatus or in the ER lumen. 
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Figure 4 I EpCAM is processed v ia  a n  a lternat ive proteolytic pathway. Blots were probed against 
EpCAM's cytoplasmic domain (ICD; antibody P6052), unless noted otherwise; CTF = (-terminal 
fragment .  (A) Lysates of HT29 cells or 293T cells transfected with empty vector (EV) or EpCAM. Note 
that the protein fragments are not recognized by the antibody against the ECD (first lane, MOC3 1 ). 
(B) HT29 cells, passaged with trypsin versus EDTA for several weeks and analyzed under reducing 
conditions. (C) 293T cel ls transfected as indicated and HT29 cells treated with DMSO (0. 1  %) or 1 0  
µM DAPT for 24hrs. Lysate of non-transfected 293T cells serves as antibody-specificity control (lane 
was spiked with MW marker). (D) Schematic representation of EpCAM's cleavage. Orange arrow= 
EplCD cleavage. Antibody binding sites are indicated . 
The exact cleavage positions would help to reveal responsible proteases and the 
functional consequences of EpCAM proteolysis. However, mass spectrometry did not 
reveal conclusive results because the purity of the isolated protein was below the 
required threshold (data not shown). An alternative approach to narrow down the 
estimated cleavage sites giving rise to CTFs was performed by deglycosylation (Fig. SE) . 
Since EpCAM contains three N-glycosylation sites (Fig. 1 ), PNGase F treatment resulted 
in a shift of the full-length EpCAM from 39 kDa to 35 kDa (Fig. SE, upper arrow; 
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Table 1. Moreover, a shift of CTF20 down to 18 kDa is visible (Fig. SE, lower arrow). 
Deglycosylation did not affect any of the CTFs12-15 bands. Thus, CTFs12-15 are 
generated (-terminal ly of EpCAM's third glycosylation site at aa 1 98 (Figs. 1 and 68). 
Table 1 I S izes of EpCAM-derived fragments . Molecu lar weights (MW) of EpCAM and its fragments 
deduced from Western B lots (using lmageJ) or predicted with and without N-G lycosylation (2 kDa 
per g lycosylation site) . *without signal peptide; * *calcu lated by the difference between fu l l­
length EpCAM and EpCAMb.6kD .  a) comp lete extrace l lu la r  domain ;  b) if cleaved after aa 1 52 ;  
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Original ly discovered as a protein overexpressed in epithelial cancers, and therefore 
used as a cel l surface tumor marker, we show that EpCAM can have different faces at 
the extracel lular site. The different cleavage events in EpCAM's ectodomain may lead 
to loss of its detection in EpCAM-based diagnostic tests. EpCAM's diverse (-terminal 
fragments, which may have their own signaling properties, may therefore often remain 
undetected. Below, we discuss how proteolysis of EpCAM, including the newly identified 
cleavage sites presented in this study, might affect EpCAM's function. 
N-termina l cleavage at position R80/R8 1 . Soon after EpCAM's discovery as an epithelial 
cancer-specific cel l  surface marker, the cleavage at position R80/R81 was identified1 0• 1 2• 1 3 . 
In al l cel l-lines tested we find that this cleavage partial ly occurs, resulting in a 6 kDa 
NTF that remains bound to the protein backbone by the first disulfide bond within the 
thyroglobulin-like domain. Most likely, the cleavage wil l lead to structural changes in the 
ectodomain, which may influence the homophilic binding properties or recognition of 
EpCAM by other proteins, e.g. proteases. Alternatively, EpCAM might be synthesized 
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Figu re 5 I Alternative cleavage is independent from s ubcellu la r  l ocali zation. (A) HT29,  HaCaT, 
and CaCo2 cells were lysed after 1 ,  3 or 5 days of culture and analyzed by Western Blot, using 
P6052 antibody against EpCAM's ICD. n-fold values represent intensities of the 12 kDa EpCAM band 
normalized against tubulin (Tub). (B) Brightfield images of cells used in A. (C) 293T cells co-transfected 
with ER-EGFP and wtEpCAM or EpCAM-C66Y immunostained with MOC3 1 and fluorescently­
conjugated secondary antibody. Confocal images are shown. (D) Cells expressing wtEpCAM or 
EpCAM-C66Y analyzed by Western blotting using P6052. (E) Cell lysates treated with a deglycosylase 
(5 units of PNGase F for 1 8hrs), and immunoblotted with P6052 .  
proteolytic action 12•1 3 . Notably, only a certain percentage of EpCAM undergoes cleavage, 
which could be due to the subcellular localization of responsible proteases. The presence 
of predominantly non-cleaved EpCAM in al l cel l  l ines tested might reflect that EpCAM 
needs to be exposed at the cell surface to be available for proteases. 
Both serine and cysteine proteases are able to conduct the R80/R81 cleavage 1 3 • It 
has been suggested that EpCAM might be able to affect certain cysteine proteases, 
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F igure 6 1  EpCAM is  cleaved i n  multi ple  d ist i n ct ways. (A) Cleavage by regulated intramembrane 
proteolysis comprises ectodomain  shedding (1 st step, red arrow) and intra membranous cleavage (2nd 
step, orange arrow). (B) Alternative proteolysis presented here includes cleavage within EpCAM's 
ectodomain (blue arrows), followed by intramembrane cleavage (3 rd step, orange arrow). I n  both 
(A) and (B), intramembrane cleavage involves a y-secretase. Additionally, EpCAM may be cleaved at 
position R80/R81 in both pathways (grey dotted arrows). 
the cathepsins, via its conserved thyroglobulin (TY)-domain5. TY type-1 A domains have 
been shown to inhibit certain cathepsins, which can be localized in lysosomes and in 
the extracel lular space23 , by binding their active site cleft24 . Cathepsins can promote 
migration and invasion of tumor cells by enhancing extracellular matrix degradation23•25 • 
It has been proposed that EpCAM might function as a membrane-bound protease 
inhibitor, possibly protecting tumor cells from their own secreted cathepsins during 
tumor progression5. In that case, cells could benefit from EpCAM overexpression either 
because of enhanced inhibition of cathepsins, but also because EpCAM may serve as a 
"decoy" substrate for cathepsins. Notably, cleavage within EpCAM's ectodomain by RIP 
or the newly identified proteolysis events results in truncation of the TY-domain, which 
would impair a protective role of EpCAM. Whether non-cleaved EpCAM is able to bind 
or inhibit cathepsins or serves as a substrate remains to be established. 
EpCAM is subject to regulated intramembrane proteolysis. RIP of EpCAM has been 
shown to induce downstream signaling14• Since we find EpCAM's ectodomain EpEX 
derived from various cancer cell lines, RIP seemingly is a general phenomenon in vitro. By 
measuring the size, we predict that the cleavage site generating EpEX is close to the plasma 
membrane. Our results are concordant with the findings of Maetzel and colleagues1 4and 
confirm that a y-secretase is involved in the second step of EpCAM RIP. Notably, in our 
Western blot experiments we detect multiple !CD-peptides generated by intramembrane 
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cleavage. y-secretases are able to cleave the same substrate at multiple sites26; however, only 
the 29 kDa fragment decreased in response to inhibition with DAPT (Fig. 4D), suggesting 
that other intramembranously cleaving proteases26 might be involved. 
Ex vivo, EpEX has been reported to be present i n  serum of cancer patients27-29; however, the 
detection methods did not distinguish between full-length EpCAM and cleaved EpEX. Since 
EpCAM is present on microvesicles, conclusions about the in vivo occurrence and relevance 
of EpEX shedding cannot be made. As yet, only a few studies have used antibodies against 
EpCAM's ICD in cancer tissue, showing that nuclear or cytoplasmic staining is exclusively 
detectable in tumors but not in normal tissue14 •30•31 • In thyroid cancer, abundant nuclear 
and cytoplasmic staining using an antibody against EpCAM's ICD has been presented as a 
prognostic marker for poor prognosis and tumor aggressiveness30 . However, based on our 
own immunostaining data, we cannot exclude artifacts due to lack of antibody specificity in 
cancer tissues (data not shown). Using fluorescent proteins and immunostaining in vitro, we 
could not detect EpCAM's ICD in the nuclei of cancer cell lines32 . 
EpCAM is cleaved via an additional pathway. We generated an antibody directed 
against EpCAM's cytoplasmic tail that, for the first time, identified novel CTFs in multiple 
cell lines. In the majority of studies characterizing EpCAM, only antibodies recognizing 
EpCAM's ectodomain were used, including to visualize EpCAM fragments1 2 • 1 3 • Hence, CTFs 
lacking extracellu lar epitopes due to cleavage would have been missed. The corresponding 
NTFs, which should be recognized by antibody MOC31, cannot be detected in cell lysates, 
indicating that these fragments are either degraded or secreted into the medium. 
The processing of EpCAM by RIP seems to occur exclusively at the plasma membrane. 
Homophilic binding, either due to cell-cell contact or EpEX as a ligand for non-cleaved 
EpCAM, has been shown to be the initial trigger for RIP14•2 1 • In contrast, cleavage of 
the new CTFs seems to be independent from cell-cell contact and to occur both at 
the plasma membrane and during protein synthesis: Retention of EpCAM in the ER 
decreases cleavage, but does not prevent it. Moreover, treatment with DAPT led to 
an i ncrease of CTFs 12- 1 5, i ndicati ng that these fragments are i ntermediate cleavage 
products that are further processed by intramembrane proteolysis. Therefore, we 
hypothesize that EpCAM can be processed in two distinct ways (see Fig. 6): (1) RIP, 
resu l ting in shedding of EpEX and the release of EplCD (in agreement with ref 14); 
and (2) consecutive cleavage at two sites within the cysteine-poor motif in EpCAM's 
ectodomain ,  followed by intramembrane proteolysis, releasing EplCD. 
Crosstalk between the two proteolytic pathways. EpCAM-induced proliferation 
has been shown to be dependent on the cleaved intracellular domain EplCD, which 
may translocate to the nucleus, inducing target genes14 . Our experiments show that 
the alternative proteolytic pathway is sensitive to inhibition of y-secretases, pointing 
to the generation of EplCD. However, in contrast to the alternative (CTF) cleavage, 
RIP also generates EpEX, which might function as a ligand for non-cleaved EpCAM 14 • 
This homophilic binding may induce RIP and thereby a positive feedback-loop, 
contributing to loss of proliferation control. In contrast, the CTF proteolytic pathway 
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seems to be constitutive, ligand-independent. Since R IP only has been found to occur 
in tumor tissue1 4•30•3 1 , in which ADAM metalloproteases are upregulated, the alternative 
proteolysis could be involved in the regulation of EpCAM signaling in healthy tissue, 
i.e. during development and maintenance. Notably, although generating distinct 
extracellular fragments, both pathways will lead to loss of EpCAM-mediated cell-cell 
adhesion. Ectodomain shedding of CAMs may represent an important regulatory 
mechanism for cell adhesion . 
Is EpCAM proteolysis regu lated by its loca l ization? The best studied protein 
processed via two competing RIP pathways is the amyloid precursor protein (APP) 1 6 . 
Processing of APP by a 13-secretase and y-secretase generates the Alzheimer's disease 
causing amyloid 13 peptide (Ai:,), whereas cleavage by a-secretase ADAM 10 prevents 
its generation 1 6•3 3 . Interestingly, processing of APP via the 13-secretase occurs in lipid 
rafts34, whereas ADAM10 cleaves APP in non-raft regions35·36 . In addition to ADAM17, 
ADAM10 represents a candidate for EpCAM cleavage 14 . Notably, both EpCAM and 
ADAM 10 have been found in tetraspanin-enriched microdomains (TE Ms), membrane 
microdomains distinct from lipid rafts37•38, which have been implicated in the regulation of 
ADAMs39-42 . Hence, localization of EpCAM and relevant proteases in distinct membrane 
compartments may play a role in the regulation of different cleavage pathways. 
Additionally, tetraspanins have been identified as the major components of exosomes, 
microvesicles released by cells into the extracellular environment that can be taken 
up by other cells via different mechanisms43 . Exosomes can function as intercellular 
communicators by transfering mRNA and microRNA43 , and might influence the tumor 
microenvironment, promoting tumor progression and metastasis20.43A4 _ Non-cleaved 
EpCAM on microvesicles, likely exosomes, is present in the medium of all cancer cell lines 
tested. In ovarian carcinoma patients, EpCAM has been found on exosomes derived from 
malignant ascites20 . Interestingly, shedding of EpCAM44 as well as L 1-CAM and CD44 has 
been shown to occur on exosomes, conducted by ADAM10 in the latter cases45 . Hence, 
exosomes may enable long distance transport of non-cleaved proteins which can further 
be cleaved or act as ligands, thereby inducing downstream signaling events or interfering 
with cell-cell adhesion 1 8. The role of EpCAM on exosomes requires further investigation . 
In general, EpCAM's spatiotemporal localization within cells, on the cell surface or on 
exosomes may may be decisive for the distinct proteolytic cleavage events. 
Concluding remarks. EpCAM-mediated proliferative signaling has been linked to 
proteolytic cleavage. In this study, we uncovered novel EpCAM-derived polypeptides, 
and provide a confirmation of previously reported EpCAM fragments. EpCAM 
proteolysis might be crucial in the regulation of EpCAM's multiple functions, including 
cell-cell adhesion and cell proliferation. Additionally, cleavage of EpCAM via two 
distinct pathways may account for the loss of proliferation control in cancer in contrast 
to normal tissue. Unraveling the identity of responsible proteases and how the different 
cleavage events and derived peptides are involved in EpCAM signaling will aid in the 




MATERIAL AND M ETHODS 
Cell culture and transfection - Human embryonic kidney cells (293T; ATCC, USA) 
were cultured in DMEM (1 g/I Glucose) supplemented with 5% FCS and penicilline 
(100 U/ml)/streptomycine (1 mg/ml). Human epithelial colon carcinoma cell lines HT29 (ATCC; 
kindly provided by J.W. Kok, University Medical Center Groningen/UMCG), CaCo2 and 
HCT116 (both ATCC, USA), human keratinocyte cell line HaCaT and epidermoid carcinoma 
cell line A431 (Dept. of Dermatology, UMCG), human hepatoma cell line HepG2 (kindly 
provided by S. van IJzendoorn, UMCG), human breast cancer cell line MCF7 (ATCC, USA), 
human ovarian cancer cell line OVCAR-3 (ATCC, USA), and head and neck carcinoma cell lines 
FaDu, SCC23, and SCC32 (kind gift from E. Schuuring, UMCG) were cultured in DMEM (4.5 
g/I Glucose) supplemented with 10% FCS, 1 x MEM Non-Essential Amino Acids (lnvitrogen, 
The Netherlands) and penicilline (100 U/ml)/streptomycine (1 mg/ml). Cells were cultured 
at 37°( in a humidified incubator in the presence of 5% CO2 " Media and supplementation 
were obtained from PAA (Austria). 293T cells were transfected with Polyethylenimine (linear, 
MW 25,000; Polysciences Inc. , USA)46 or FuGene6 (Roche, The Netherlands). 
Antibodies and reagents - For detection of EpCAM, we used mouse monoclonal 
antibodies MOC31, binding EpCAM motif 1, and 311-1 K2, binding within the cysteine­
free motif (hybridomas kindly provided by L.F.M.H. de Leij, UMCG)47. EpCAM CTE-mutant 
W143_ T164del8 is not recognized by antibody 311-1 K2, revealing its binding site (see 
Table 2 below). Furthermore, rabbit polyclonal antibody P6052, raised against EpCAM's 
intracellular domain (immunizing peptide: CEIKEMGEMHRELNA) was designed in our 
laboratory and generated by BioGenes, Germany). Beta-Tubulin antibody (B512), DAPT 
and PNGase F were obtained from Sigma-Aldrich (The Netherlands). 
Table 2 I Recognition of EpCAM domains by antibod ies used in this study. 
Anti body Domain/motif  R egio n  of b i nd ing  (amino acids) 
MOC 3 1  Extrace l lu la r  domain/ EpCAM motif 1 27-5948 
3 1 1 - 1 K2 Extrace l lu l a r  domain/ Cystei ne-free reg ion 1 43- 1 64 
P6052 I ntrace l lu lar  doma in  30 1 -3 1 4  
Plasmids - Human EpCAM cDNA (kind gift from V. Cirulli, University of Washington)49 
was subcloned into pcDNA3.1. Plasmids were verified by sequencing. Either the non­
tagged versions were used, or the (-terminal EGFP-tagged versions with the linker 
"RSAAAT" . The ER-marker ER-superluc-EGFP5° (calnexin pre-sequence) and the C66Y 
EpCAM mutation have been described before (see chapter 3). 
Western blot - SOS polyacrylamide gel electrophoresis (SOS-PAGE) and Western blot 
procedures were conducted according to standard protocols (equipment from BioRad, 
USA; Millipore, USA), using 10% or 15% gels. Cells were plated in 6-well plates and 
108 
EpCAM PROTEOLYSIS: NEW FRAGMENTS WITH D ISTINCT FUNCTIONS? 
grown until confluency. If indicated, cells were incubated with DMSO (0.1 %) or 10 µM 
DAPT for 24hrs. Cells were lysed using either reducing (1 % beta-mercaptoethanol) 
or non-reducing Laemmli Sample Buffer (62.5 mmol/L Tris-HCI; 20 g/L SDS; 100 
mUL glycerol; bromophenol blue; pH 6.8). Following incubation with the primary 
and an HRP-conjugated secondary antibody, proteins were detected by enhanced 
chemiluminescence (antibody, ECL detection kit, film: GE Healthcare, UK). 
Medium concentration - Confluent cells were incubated for 24 hrs in medium with 
reduced FCS (0.1 %) to enable Western blot analysis after concentration. First, medium was 
centrifuged at 4500 g for 15 min to pellet dead cells and cell debris. Filtered medium (0.2 
µm; Whatman, Germany) was concentrated using Amicon Ultra-4 centrifugal concentration 
filter tubes (Millipore, USA) with a 10 kDa MW cut-off. The final concentrate was diluted with 
5x Laemmli sample buffer (non-reducing), denatured at 95°C for 5-10 min, and analyzed 
by Western blot. To separate microvesicles and soluble proteins, medium was cleared by 
centrifugation and filtering and subjected to ultracentrifugation at 100,000 g for 1 h at 
4°C. The resulting pellet was dissolved in 1.2x non-reducing Laemmli sample buffer and the 
supernatant was concentrated as described above. 
lmmunofluorescent staining - 293T cells, co-transfected with ER-GFP and either 
wtEpCAM or EpCAM-C66Y for at least 24hrs, were fixed with 10% formalin (equals 4% 
formaldehyde; Sigma-Aldrich, The Netherlands) for 30 min and permeabilized with 0.1 % 
Triton X-100 (Merck, The Netherlands)/1 % BSA/PBS for 15 min. Following blocking with 1 % 
BSA/PBS for 15 min, primary antibody MOC31 and Alexa Fluor 568-conjugated secondary 
antibody (lnvitrogen, The Netherlands), diluted in 1 % BSA/PBS, were applied for 1 h each 
and cells were mounted with Vectashield (Vector, USA). All steps of the immunostaining 
procedure were conducted at room temperature. Fluorescent images were acquired using a 
Leica SP2 AOBS Confocal microscope (Leica Microsystems, Germany). 
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Supplementary Figure 1 I Novel (-terminal EpCAM fragments can be detected in various cel l  
lines. Lysates of different cancer cel l  l ines a s  ind icated were immunoblotted with anti body P6052 
against EpCAM's ICD. CTFs are present i n  a l l  cel l l i nes that express EpCAM . 
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CHAPTER 5 
ABSTRACT 
The epithelial cell adhesion molecule EpCAM, discovered as a tumor marker, has been 
implicated in cell-cell adhesion and cell proliferation. Different mechanisms of EpCAM­
mediated signaling have been proposed, involving activation of EpCAM by proteolysis 
and association with binding partners within tetraspanin-enriched microdomains 
(TEMs). How EpCAM's functions are interconnected is still poorly understood. To shed 
light on the role of EpCAM as a cell-cell adhesion molecule, we compared EpCAM with 
classical cell-cell contact (associated) proteins. Additionally, we addressed EpCAM's role 
as a proliferation-inducing signaling protein, by elucidating its interplay with tetraspanin 
CD9 and the metalloprotease ADAM 1 0 . We find that EpCAM is not restricted to cell-cell 
contacts and displays a high mobility at the plasma membrane. Furthermore, our results 
reveal involvement of ADAM 1 0  in EpCAM proteolysis, which may occur in TE Ms. We 
conclude that EpCAM has hallmarks that are incompatible with stabilizing cell-cell 
contacts, and that it predominantly functions as a signaling molecule. 
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INTRODUCTION 
The epithelial cell adhesion molecule EpCAM (CD326) is highly expressed on epithelium­
derived tumors1 -5 _ Since its discovery in the late 1970's, EpCAM has been reported 
to be functionally involved in a multitude of disease-related processes, ranging from 
cell-cell adhesion to metastasis6 • Early functional studies have shown that EpCAM can 
promote Ca2+-independent homophilic cell-cell adhesion in cells lacking other adhesive 
properties7 • However, when co-expressed with classical cadherins, EpCAM has been 
shown to weaken cell-cell adhesion, leading to the concept that EpCAM can act 
as a functional antagonist of E-Cadherin8 . Furthermore, EpCAM plays a role in cell 
proliferation. High levels of EpCAM expression correlate with increased proliferation 
in epithelial cancer cells5, but also during morphogenesis6·9, tissue regeneration6• 1 0 and 
embryonic stem cell maintenance1 1 • 1 2 . In vitro, EpCAM-mediated proliferation has been 
shown to be induced by upregulation of cell-cycle related genes1 3 • 1 4 . 
Recently, two models of EpCAM-mediated proliferative signaling have been 
proposed1 5• 1 6• The first is based on the activation of EpCAM signaling by regulated 
intramembrane proteolysis (RIP): Shedding of EpCAM's ectodomain (EpEX) by 
metalloprotease ADAM17 ('A disintegrin and metal/oprotease'  17, or TACE) is followed 
by the release of EpCAM's intracellular domain, which associates with (co)transcription 
factors inside the nucleus, thus inducing target genes1 5 . The second model proposes 
that EpCAM signaling depends on the localization within tetraspanin-enriched 
microdomains (TEMs), upon association of EpCAM and Claudin7 1 6, a protein originally 
identified as a tight junction component. 
TEMs are constituted by tetraspanins that associate with one another and a variety 
of proteins and lipids, thereby creating signaling platforms1 7 with an organization 
distinct from conventional lipid rafts. Tetraspanins are also a major component of 
extracellular microvesicles called exosomes, which are abundantly secreted by normal 
cells and tumor cells and involved in intercellular signaling and tumor progression18 . 
In cancer, different tetraspanins can have seemingly opposing effects1 9 . Whereas high 
levels of tetraspanin CD9 have been found to suppress tumor progression by promoting 
adhesion and counteracting motility, other tetraspanins can promote metastasis1 9 . 
CD9 has been shown to interact with EpCAM in the "tetraspanin-web", as well as 
with metalloprotease ADAM1020. Since ADAM10 and ADAM17 often share the 
same substrates2 1 •22 , EpCAM could potentially be cleaved by ADAM10. Importantly, 
tetraspanins are involved in the regulation of the proteolytic activity of ADAMs. 
Incubation with antibodies against several tetraspanins, including CD9, can specifically 
induce ADAM 10-mediated cleavage of tumor necrosis factor (TNF}-a and epidermal 
growth factor (EGF)23 . However, whether ADAM 10 and CD9 are functionally connected 
with EpCAM-mediated proliferation is unknown. 
Due to EpCAM's multiple functions and complex signaling properties, the current 
state of knowledge concerning EpCAM's role in cell adhesion and cell proliferation is still 
strewn with contradictory findings. Here, we set out to characterize EpCAM's cell-cell 
adhesion properties as well as to investigate the influence of EpCAM's localization in 
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TE Ms on proliferative signaling via RIP. We hypothesize that (i) ADAM 10 is involved in 
the cleavage of EpCAM, and (ii) that CD9 plays a role in the regulation of ADAM 10-
mediated EpCAM proteolysis. Analyzing protein localization and dynamics, we find that 
EpCAM is not restricted to cell-cell contacts and highly mobile, contrasting with the low 
motility characteristics of junction-associated CAMs E-Cadherin and ZO-1. In addition, 
knock-down of ADAM 10 shows a decrease in cleaved EpCAM, revealing a role for 
ADAM 10 in EpCAM signaling. Co-clustering experiments using antibodies point to 
an interaction between these proteins in TEMs. In conclusion, our results highlight 
EpCAM's predominant role as a signaling molecule. 
RES U LTS 
EpCAM is not a classical CAM . Although EpCAM is named after its ability to promote 
homophilic cell-cell adhesion, its role as a CAM is not well understood. Assessment of 
EpCAM's localization indicates that EpCAM and cadherins are mainly present at cell-cell 
contacts and partially in vesicles, likely involved in transport or degradation. Strikingly, 
EpCAM is also detectable in regions of the plasma membrane that are not in contact with 
neighboring cells, as well as in filopodia (Fig. 1 A), revealing that EpCAM is not restricted 
to cel l-cell contacts as seen for classical CAMs (Fig. 1 A). High-resolution analysis of cells 
transduced with EpCAM by electron microscopy confirms that EpCAM is localized at the 
surface of filopodia and in non-cell-cell contact regions (Fig. 1 B, upper picture). Notably, 
EpCAM is present in between cells, but regions of "tight" cell-cell contacts, which might 
represent adherens junctions, lack EpCAM staining (Fig. 1 B, lower picture). 
Given that EpCAM is not only present in cell-cell contacts, we asked if the protein 
would have more atypical characteristics . Usually, classical CAMs show a low rate of lateral 
diffusion because of their homotypic interactions in the extracellular space and anchorage 
to the cytoskeleton24. Using FRAP (Fluorescence recovery after photobleaching) assays to 
determine protein diffusion (Fig. 1 C), we find that the fluorescence of EpCAM-GFP in the 
Figure 1 (on the next page) I EpCAM is not a typical cell-cell adhesion molecule. (A) Head and 
neck carcinoma cell lines SCC23, SCC32 and FaDU were immunostained for Cadherins (green) and 
EpCAM (red). Note the presence of EpCAM in the plasma membrane outside cell-cell contacts and in 
filopodia. (B) Localization of EpCAM in transduced PANC-1 cells using immunoelectron microscopy. 
Black arrows: EpCAM staining outside cell-cell contacts; blue arrows: filopodia; red arrows: absence 
of EpCAM staining in tight cell-cell contacts. Bars: 2 µm. (C) A region in the plasma membrane of 
living 293T cells, expressing EpCAM-EGFP, EGFP-E-Cadherin, or EGFP-ZO-1 was bleached by intense 
illumination (arrow) and fluorescence recovery after photobleaching (FRAP) was quantified. (D) 
Schematic representation of antibody-induced EpCAM clustering. (E) Living Min6 cells, expressing 
EpCAM-EGFP, were incubated with an antibody against EpCAM's ectodomain for 1 5  min, followed 
by a fluorescent secondary antibody. Live-cell imaging (1 frame/3 sec) was started before adding the 
secondary, clustering antibody (Cy5-conjugated; 0 min). (F) EpCAM clusters do not colocalize with early 
endosomes or clathrin-coated pits/vesicles. Left panel: HeLa cells after endogenous EpCAM-clustering 
with ck-anti-EpCAM and a conjugated secondary antibody (red), immunostained for early endosome 
marker EEA 1 (g reen). Right panel: Living HeLa cells, expressing Clathrin-EGFP, after clustering EpCAM 
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EpCAM-EGFP ADAMlO Merge X • 
Figure 2 1  EpCAM colocalizes with metal loprotease ADAM 1 0  and tetraspanin CD9. (A) MCF7, CaCo2 and HaCaT cel l s  were immunolabeled for EpCAM, 
ADAM 1 0 or CD9 .  (B) HT29 cel ls , expressing EpCAM-EGFP, immunolabeled for ADAM 1 0  or CD9 (Alexa 594; red) . Single confoca l p lanes and s ide views of a 
stack are shown . White arrows point to the apical s ide of the cel l  layer in s ide view. All bars :  20 µm. 
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bleached plasma membrane region (cell-cell contact) is restored faster and more efficiently 
than that of the adherens junction protein E-Cadherin and tight junction-associated ZO-1, 
indicating that EpCAM has a higher mobility (Fig. 1 C). In addition, antibody-mediated 
crosslinking induces translocation of EpCAM into spot-like clusters (Fig. 1 D,E), which do 
not co-localize with a marker for early endosomes (EEA 1) or with clathrin-EGFP (Fig. 1 F), 
indicating that these clusters represent cross-linked proteins on the cell surface. 
EpCAM, CD9 and ADAM 1 0  co-local ize at the plasma membrane. In addition to adhesion, 
EpCAM has been reported to promote cell proliferation, initiated by RIP15 . To address a 
functional relationship between EpCAM, metalloprotease ADAM10 and tetraspanin CD9, 
we first determined their expression in different cell types (Fig. 2). A variety of cancer cell 
A 
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non-target ADAMlO CD9 
slRNA 
F igure 3 I Effect of ADAM10 a nd CD9 s ilenci n g  o n  EpCAM and  E-Cadherin ectodoma in  shed d in g. 
(A) Cell-free medium from HT29 and HaCaT cells was concentrated (MED) and cells were lysed (LYS). 
Non-cleaved proteins and shed ectodomains of EpCAM and E-Cadherin were detected by Western 
blot using antibodies against the ECDs of EpCAM or E-Cadherin. (B) HaCaT cells were transfected with 
siRNA against GFP (non-target), ADAM 1 0  or CD9 (target). Cell lysates were analyzed as indicated. (C) 
Concentrated medium from HaCaT cells treated as in B was immunoblotted for shed E-Cadherin and 
EpCAM. (D) Quantification of shed E-Cadherin and EpEX in medium from HaCaT cells as in C (lmageJ). 
Averages of mean band intensities ± s.d .  (n=3) are shown. **= p<0.0 1  (Student's t-test). 
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lines express all three proteins, predominantly localized in the plasma membrane (Fig. 2A,B). 
In EpCAM-EGFP expressing HT29 cells (Fig. 2B), ADAM10 and EpCAM are both present in 
the (baso)lateral and apical membrane, whereas CD9 is predominantly localized at the upper 
lateral and apical side of the cells (Fig. 2B, see side views). 
Involvement of ADAM 1 0  and CD9 in E pCAM ectodomain shedding . ADAM 17 
and ADAM 10 are frequently involved in the process of RIP, and tetraspanins have been 
implicated in the regulation of ADAM activity23 • To determine whether ADAM10 and 
CD9 play a role in EpCAM ectodomain shedding, we silenced these proteins in human 
immortalized keratinocytes (HaCaT). In this cell line, ADAM 10 has been shown to be 
able to shed the ectodomain of E-Cadherin25, indicating that the p rotein machinery for 
RI P is functional. Both EpEX and the soluble shed ectodomain of E-Cadherin can be 
detected in the medium of several cell lines (Fig. 3A, MED;  see Fig. 3C in chapter 4). 
Cell lysates only contain the non-cleaved proteins (Fig. 3A, LYS). Notably, full-length 
EpCAM is also present in cell-free medium, due to its presence on exosomes (Fig. 3A, 
MED;  see Fig. 3B in chapter 4), whereas full-length E-Cadherin cannot be detected in 
the medium. ADAM 10 silencing (Fig. 3B) decreases both shed E-Cadherin and EpEX 
levels in the medium when compared to the non-target control (siRNA against GFP, 
Fig. 3C,D). In contrast, downregulation of CD9 (Fig. 38) has no influence on either 
EpCAM or E-Cadherin cleavage (Fig. 3C,D). 
Antibody-induced clustering of EpCAM co-clusters tetraspanin CD9. To unravel 
whether EpCAM and CD9 are present in the same microdomain, the localization of 
CD9 was determined after antibody-induced EpCAM clustering26. Visualization of CD9, 
either by co-transfection using CD9-EGFP (Fig. 4A) or by immunostaining (Fig. 48), 
demonstrates that CD9 co-localizes with EpCAM in the plasma membrane in non­
treated cells (Fig. 4B upper panels and as seen in Fig. 2). Upon antibody-induced EpCAM 
clustering, CD9 co-localizes with EpCAM clusters (lower panels). Reciprocal ly, clustering 
of CD9 leads to partial co-clustering of EpCAM (Fig. 4C). 
EpCAM c lustering co-clusters ADAM 1 0. We found that downregulation of ADAM 10 
led to decreased levels of EpEX in the medium of HaCaT cells (see above, Fig. 3). To 
substantiate a functional link between ADAM 10 and EpCAM in TE Ms, we tested 
whether the localization of ADAM10 would be affected by antibody-induced EpCAM 
clustering in OVCAR-3 and HT29 cells (Fig. 5). Similar to CD9, ADAM10 co-localizes 
with EpCAM in the plasma membrane (upper panels) and partially co-clusters upon 
EpCAM-crosslinking (Fig. 5, lower panels), showing that the two p roteins are somehow 
associated and present in the same microdomain. 
DISCUSSION 
EpCAM has been implicated in a variety of cellular processes, including cell-cell adhesion, 
cell proliferation, migration and metastasis6 • Although different models of EpCAM-induced 
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Figure 4 I Antibody-induced clustering of EpCAM induces co-clustering of tetraspanin CD9. 
(A) 293T cel ls, transfected with CD9-EGFP and EpCAM-mCherry, were fixed and imaged without 
treatment (upper panel) or after c l ustering EpCAM (lower panel) . (B) PANC- 1 cel ls ,  expressing EpCAM­
EGFP, were imaged after fixation and immunosta in ing for CD9 (upper panel) or after antibody- induced 
EpCAM clustering prior to immunosta in ing (lower panel) . (C) PANC- 1 cel ls ,  expressing EpCAM-EGFP, 

































EpCAM ADAMlO Merge 
Figure 5 I Antibody-induced clustering of EpCAM leads to co-clustering of CD9 and 
metalloprotease ADAM 1 0. (A, B )  OVCAR3 or HT29 cells were fixed and immunolabeled for EpCAM 
(green) and CD9 (red) (upper panel), or fixed and immunolabeled for CD9 after EpCAM clustering 
(lower panel). (C, D) OVCAR3 or HT29 cells were fixed and immunolabeled for EpCAM (green) and 
ADAM 10 (red) (upper panel), or fixed and immunolabeled for ADAM 10 after EpCAM clustering 
(lower panel). Bars: 20 µm. The EpCAM signal in nuclei and cytoplasm in A-D is due to non-specific 
binding of the primary antibody (ck-anti-EpCAM). 
proliferation have recently been proposed, its precise role in these processes and how 
EpCAM's multiple functions are interconnected and regulated remains poorly understood. 
Does the epithel ia l  cell adhesion molecu le live up  to its name? EpCAM was given 
its name due to the ability to promote cell-cell adhesion when ectopically expressed in 
cells lacking other CAMs7 • However, EpCAM is structurally different from any of the 
four major CAM families. lmmunostaining assays indicate the absence of EpCAM from 
cell-cell junctions8•2 7 • Interestingly, EpCAM seems to be anti-adhesive when co-expressed 
with classical cadherins8 • Aggregation assays have shown that cells that lack EpCAM, 
but endogenously express cadherins, are t ightly interconnected, whereas induction of 
EpCAM expression results in cell aggregates with only loosely connected cells8 . In a 
more physiological setup, we find that EpCAM is predominantly localized in cell-cell 
contacts, together with classical cadherins (Fig. 1 ). However, unlike cadherins, EpCAM 
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can be found in filopodia and in regions of the plasma membrane that are not engaged 
in contact with neighboring cells. In fact, EpCAM is not detected in regions of " tight" 
cell-cell contact, which likely represent cadherin-mediated adherens junctions (Fig. 1 ). 
Considering EpCAM's ability to destabilize E-Cadherin-mediated adhesion, EpCAM 
might be an important regulator of cell-cell adhesion plasticity, which is crucial during 
morphogenesis and tissue regeneration. Here, the expression levels of EpCAM will be 
tightly controlled. In contrast, uncontrolled overexpression of EpCAM observed in many 
cancers might play a major role in influencing cell motility and migration by depleting 
cadherin-mediated cell-cell adhesion. 
EpCAM's homophilic properties may facilitate cell proliferation. Notably, high or de 
nova expression of EpCAM correlates with proliferation in cancer but also in normal tissues28• 
Epithelia display a high abundance of adherens junctions, and E-Cadherin is important for the 
maintenance of cell polarity and contact inhibition29- 3 1 . In adults, the highest levels of EpCAM 
can be found in the stem cell compartment32 of colonic epithelium28, a highly regenerative 
tissue type. EpCAM might contribute to cell proliferation not only by signaling and induction 
of cell-cycle related genes 1 5, but also by loosening cell-cell adhesion. Clustering experiments 
and FRAP assays show that EpCAM is very dynamic and displays a higher mobility in the 
plasma membrane than E-Cadherin (Fig. 1 ); hence, during cell division, EpCAM may provide 
sufficient adhesion and simultaneously enough room/plasticity for cells to divide. In patients 
suffering from congenital tufting enteropathy (CTE)33, the absence of EpCAM from the cell 
surface (chapter 3) might lead to reduced tissue plasticity and cell proliferation, thereby 
impeding the normal development of the intestinal epithelium. 
EpCAM-mediated proliferation has been shown to be induced by RIP, resulting in 
shedding of its ectodomain1 5 . However, homophilic adhesion can only occur when 
EpCAM is in its non-cleaved form34·3 5 (see also chapter 4). In addition to being involved 
in the regulation of cell-cell adhesion, homophilic interaction of EpCAM may be required 
as the first step in EpCAM's proliferative signaling cascade. Cell-to-cell contact as well 
as binding of EpCAM 's shed ectodomain as a homophilic ligand has been shown to 
trigger RIP and thereby proliferative signaling 1 5·36 . 
Resembling EpCAM, RIP of E-Cadherin and N-Cadherin has been shown to enhance 
Wnt signaling via the cleaved ICD and/or the release of p-catenin3 1 •3 7•38 • We find the shed 
ectodomain of E-Cadherin in the medium of different cancer cell lines (Fig. 3). Proteolysis 
of CAMs in cancer may promote proliferation while abrogating cell-cell adhesion39 . 
Does EpCAM signal in tetraspanin-enriched microdomains? Another possibility of 
EpCAM displaying multiple functions simultaneously is the spatiotemporal separation of 
the different cellular processes. EpCAM signaling induced by RIP or other cleavage events 
(chapter 4) might occur in specific membrane compartments. Protein-protein interactions 
in certain microdomains can be revealed based on co-patching behavior upon antibody­
induced protein crosslinking26 . We show that antibody-induced clustering of EpCAM 
induces movement of tetraspanin CD9 into EpCAM-positive patches (Fig. 4), indicating 
that the proteins are both part of the same membrane microdomain. Localization of 
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EpCAM in TEMs, in association with tight junction protein Claudin7, has been shown to 
prohibit EpCAM-mediated adhesion while promoting tumor growth and progression 1 6 . 
This indicates that EpCAM function may be dictated by its localization. 
Both EpCAM and metalloprotease ADAM 1 0  have been found to be associated 
with CD920 and therefore as part of TEMs. ADAM1 0, closest homologue of ADAM1 7, 
is frequently involved in ectodomain shedding processes22 and represents a possible 
candidate for EpCAM cleavage. Because tetraspanins play a role in the regulation of 
ADAM activity, we asked whether ADAM1 0  and CD9 are involved in EpCAM cleavage. 
Downregulation of ADAM1 0 resulted in a significant decrease in ectodomain shedding 
of EpCAM and E-Cadherin, indicating that ADAM 1 0  does not only cleave E-Cadherin25 , 
but also EpCAM (Fig. 3 ) . Moreover, partial co-clustering of ADAM1 0  upon EpCAM 
crosslinking suggests an association between the two proteins, supporting that ADAM 1 0  
is involved in RIP of EpCAM (Fig. 5) .  The fact that ADAM 1 0  silencing only leads to a 
partial reduction of both EpCAM and E-Cadherin cleavage suggests that additional or 
compatible proteases are involved in shedding. As yet, only ADAM 1 7  had been shown to 
cleave EpCAM's ectodomain 1 5, while E-Cadherin is known to be processed by a multitude 
of proteases, including several matrix metalloproteases and serine proteases40 . 
Further, we asked if CD9, known as a tumor suppressor 1 9, regulates ADAM 1 0-
mediated EpCAM shedding. Decreased tumor growth and cell motility/migration could 
be a resu lt of CD9-mediated inhibition of the shedding of substrates such as EpCAM, 
E-Cadherin and EGF4 1 , thereby preventing proliferative signaling and maintaining 
cell-cell adhesion .  We find that silencing of CD9 had no effect on the levels of shed 
E-Cadherin and EpEX (Fig. 3), indicating that CD9 does not play a role in the regulation 
of ADAM 1 0  activity towards these substrates. Considering that the efficiency of CD9 
knockdown was not ideal (approximately half), further studies are needed to unravel 
whether EpCAM signaling is affected by tetraspanins. 
TEMs may serve as a platform for EpCAM proteolysis not only in the plasma 
membrane of cells, but also on exosomes, microvesicles secreted by cells and enriched in 
tetraspanins 1 8• 1 9 . Tumor-derived exosomes play a role in intercellular communication and 
modulation of the tumor microenvironment. While EpCAM is present on microvesicles 
in cancer cell-derived medium (also see Fig. 3 in chapter 4), full-length E-Cadherin was 
not detected, indicating that E-Cadherin is not localized in TE Ms . Notably, ADAM 1 0  has 
been shown to cleave CD44 and L 1 -CAM on exosomes42•43 ; hence, these microvesicles 
may serve the transport of full-length proteins to distant sites44 , where they can be 
cleaved and induce signaling via homophilic interactions. The presence of EpCAM in 
TEMs and exosomes represents another distinct feature from classical CAMs such as 
E-Cadherin, emphasizing EpCAM's pivotal role as a signaling molecule rather than as a 
cell-cell adhesion molecule. 
Concluding remarks. EpCAM has been reported to play a role in multiple cellular 
processes, including cell-cell adhesion and cell proliferation . Despite the fact that 
these two functions of EpCAM seem to be opposing, they might be linked. Although 
proliferative signaling involves shedding of EpCAM's ectodomain, which abrogates cell 
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adhesion, homophilic interactions due to cell-cell contact or ligand binding might be 
crucial for the induction of RIP-induced EpCAM signaling. Moreover, EpCAM's ability 
to affect the strength of Cadherin-mediated adhesion and thereby the tissue plasticity 
may benefit cell proliferation. We find that ADAM 10 is involved in EpCAM proteolysis; 
however, whether EpCAM's localization in TE Ms is important for ADAM 10-induced 
signaling requires further investigation. Overall, we conclude that the name "epithelial 
cell adhesion molecule" is misleading: EpCAM does not display typical CAM features, 
but may instead act as a modulator of cell-cell adhesion as part of its predominant 
function as a proliferation-inducing signaling protein. 
MATERIAL AND METHODS 
Cell culture and transfection - Human embryonic kidney cells (293T; ATCC, USA) and 
Hela cells (ATCC, USA) were cultured in DMEM (1 g/I Glucose) supplemented with 5% 
or 10% FCS, respectively. Human epithelial colon carcinoma cell lines HT29 (ATCC; kindly 
provided by J.W. Kok, UMCG) and CaCo2 (ATCC, USA), human keratinocyte cell line 
HaCaT (Dept. of Dermatology, UMCG), human breast cancer cell line MCF7 (ATCC, USA), 
human ovarian cancer cell line OVCAR-3 (ATCC, USA), and head and neck carcinoma cell 
lines FaDu, SCC23, and SCC32 (kind gift from E. Schuuring) were cultured in DMEM (4.5 
g/I Glucose) supplemented with 10% FCS, 1 x MEM Non-Essential Amino Acids (lnvitrogen, 
The Netherlands). Human pancreatic duct cell line PANC-1 and mouse insulinoma cell 
line Min6 (kind gift from V. Cirulli) were grown in RPMI (lnvitrogen, The Netherlands), 
supplemented with 5% FCS. All media contained penicilline (100 U/ml)/streptomycine 
(1 mg/ml) and cells were cultured at 37°C in a humidified incubator in the presence of 
5% CO2. Media and supplementation were obtained from PAA (Austria). 293T cells 
were transfected with FuGene6 (Roche, The Netherlands). Stable HT29 cells expressing 
EpCAM-EGFP were generated by transfection using the NEON transfection system 
according to the manufacturer's protocol (lnvitrogen, The Netherlands) and subsequent 
selection with 1 mg/ml geneticin (lnvitrogen, The Netherlands). Individual clones were 
picked and tested for expression by fluorescence microscopy. 
siRNA transfection - HaCaT cells were transiently transfected with siRNA 
oligos (obtained from Biolegio, The Netherlands) targeting human ADAM 10 
(5 '-GACAUUUCAAC C UAC GAAU-3' ), human C D9 (5 ' -GAGCAUC UUC GAGCAAGAA-3 ' )  
o r  GFP as the non-target control (5' -CAAGCUGACCCUGA AGUUC-3'), using 
DharmaFECT4 transfection reagent (Thermo Scientific, USA) according to the 
manufacturer's instructions (final concentration of 100 nM). Cells were used for 
experiments 72 to 96 hrs after transfection. 
Plasmids - Human EpCAM cDNA (kind gift from V. Cirulli)45 was subcloned into 
pcDNA3.1. Either the non-tagged version was used, or the (-terminal EGFP-tagged 
version with the linker " RSAAAT" .  Other plasmids used for transfection were 
pcDNA 1.1-EGFP-E-Cadherin (kind gift from W.J. Nelson), pEGFP-ZO-146, pcDNA3.1-
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CD9-EGFP (kindly provided by M. Ishi i ) ,  and pcDNA3 . 1 -Clathrin-EGFP (kindly provided 
by B. Marlin) .  Plasmids were verified by sequencing. 
Primary antibodies - For detection of EpCAM, we used mouse monoclonal antibodies 
MOC3 1 ( IF), 3 1 1 - 1 K2 (WB) (hybridomas kindly provided by L .F. M.H. de Leij)47 and KS 1 /4 (EM 
and clustering in Fig. 1 ), or chicken-anti-EpCAM (remaining clustering experiments; kind gift 
from V. Cirulli). Other antibodies used were obtained as follows: beta-Tubulin (85 1 2; Sigma­
Aldrich,  The Netherlands), anti-pan Cadherin (for I F; Sigma-Aldrich, USA), anti-E-Cadherin 
(for WB; H-1 08; Santa Cruz, USA), anti-ADAM 1 0  ( 1 1 G2; Abeam, UK), anti-CD9 (TS9 for WB 
and IF, MM2/57 for IF in Fig. 4; Abeam, UK), anti-EEA 1 ( 1 4; BD Biosciences, USA). 
EpCAM clustering & lmmunofluorescent staining - To induce clustering, living cells 
were incubated with antibodies directed against the ectodomain of EpCAM or CD9 
for 1 2- 1 5 min, followed by incubation with a secondary fluorescent antibody for the 
live-cell imaging time period or for 20 min before washing and fixation. Cells were fixed 
with 1 0% formalin (equals 4% formaldehyde; Sigma-Aldrich ,  The Netherlands) for 
30 min and permeabilized with 0 . 5-0 . 1 % Triton X- 1 00 (Merck, The Netherlands)/1 % 
BSA/PBS for 1 5 min. Following blocking with 1 % BSA/PBS for 1 5  min, primary and 
secondary antibodies (lnvitrogen, The Netherlands), diluted in 1 % BSA/PBS, were 
applied for 1 h each and cells were mounted with Vectashield (Vector, USA). All steps 
of the immunostaining procedure were conducted at room temperature .  Fluorescent 
images were acquired using a Leica SP2 AOBS Confocal microscope (Leica Microsystems, 
Germany) or a Zeiss LSM 780 microscope (Zeiss, Germany). 
Fluorescence recovery after photobleaching (FRAP) - 293T cells were transfected 
with EGFP-tagged EpCAM, E-Cadherin or ZO- 1 and imaged live ( 1  frame per 3 
seconds) . A region in the plasma membrane (cell-cell contact) was bleached by intense 
illumination after 30 seconds (0 s) . 
Transmission Electron Microscopy - Cells were fixed using 2 % paraformaldehyde with 
0. 1 % glutaraldehyde for 30 min on ice. EpCAM was labeled with antibody KS 1 /4 and a 
biotin-conjugated secondary antibody followed by visualization with 3,3' -Diaminobenzidine 
tetrahydrochloride (DAB). 0 .05% Triton X- 1 00 was present during the entire immunostaining 
procedure. Samples were post-fixed in 1 % GA in 0. 1 M cacodylate buffer (pH 7 .4) for 1 0  
min, washed 3 x with 0. 1 M cacodylate buffer and subsequently fixed in 1 % OsO4 and 
1 . 5% K/e(CN)6 (EMS, PA, USA) in 0 . 1  M cacodylate buffer (pH 7 .4) for 30 min. After rinsing 
with water (Milli-Q; Millipore B.V. , The Netherlands) and dehydration in a graded alcohol 
series, samples were embedded in Epon 8 1 2  (Serva Electrophoresis GmbH, Germany). 
Ultrathin sections were stained following routine procedures and examined using a FEI 
CM 1 00 electron microscope operating at 80 kV. 
Medium concentration & Western blot - SOS polyacrylamide gel electrophoresis 
(SOS-PAGE) and Western blot procedures were conducted according to standard protocols 
(equipment from BioRad, USA; Millipore, USA). Cells were lysed using non-reducing Laemmli 
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Sample Buffer. Following incubation with the primary and an HRP-conjugated secondary 
antibody, proteins were detected by enhanced chemiluminescence (antibody, ECL detection 
kit, film: GE Healthcare, UK). For analysis of ectodomain shedding, confluent cells were 
incubated in medium containing 0.1 % FCS for 24 hours. Medium was centrifuged at 
4500 rd for 15 min to pellet dead cells and cell debris. Filtered medium (0.2 µm; Whatman, 
Germany) was concentrated using Amicon Ultra-4 centrifugal concentration filter tubes 
(Millipore, USA) with a 10 kDa MW cut-off. The final concentrate was diluted with 5x 
Laemmli sample buffer (non-reducing), denatured at 95°C for 5-10 min, and analyzed by 
Western blot. Similar amounts of total protein per lane were applied after concentration 
determination using the NanoDrop (Thermo Scientific, USA). 
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The regulation of cell proliferation and differentiation plays a crucial role in the 
development and maintenance of tissues. An imbalance of these key processes is 
involved in multiple diseases, including cancer. The epithelial cell adhesion molecule 
EpCAM is expressed in most epithelia and plays a role in the balance between cell 
proliferation and differentiation: High levels of EpCAM have been found during 
morphogenesis, regenerative processes, as well as in stem and progenitor cells that 
need to maintain their self-renewal capacities1 •3 _ While EpCAM levels seem to be 
tightly regulated in healthy tissue, they are out of balance in disease: Absence of 
functional EpCAM causes severe diarrhea in newborns due to abnormal development 
of the intestinal epithelium4, whereas overexpression of EpCAM is frequently found in 
epithelium-derived tumors5·7. EpCAM's high expression in cancer cells initially led to its 
discovery in a screen for tumor-specific cell surface antigens in the 1970's. Due to the 
simultaneous identification by many research groups, EpCAM was given a multitude of 
names corresponding to antibodies or cDNA clones. Today, the name "Epithelial Cell 
Adhesion Molecule" is generally used, originating from studies showing that EpCAM 
can promote cell-cell adhesion via homophilic interaction8 . A comprehensive overview 
of the current knowledge on EpCAM's structure, its signaling properties and different 
reported functions is provided in Chapter 1 .  
In this thesis, the main focus has been on unraveling the mechanism of EpCAM 
signaling in health and disease. Conflicting data in literature, as well as inconsistencies 
with our own microscopy data regarding EpCAM's localization led us to the critical 
investigation of the effects of different immunostaining procedures (Chapter 2a9) .  
A major drawback of visualizing proteins using immunofluorescence is the need for 
fixation and permeabilization of cells, which can induce artifacts such as protein 
extraction and redistribution. To obtain reliable results, a compromise between the 
quality of preservation and the ability to penetrate the cells with immunoreagents must 
be made. Although fixation and permeabilization-induced artifacts have been reported 
earlier, laboratories often use traditional protocols, independent of the type of protein. 
To raise awareness about artifacts resulting from standard immunostaining procedures, 
we reviewed the existing literature and presented data comparing several methods 
and differentially localized proteins. In addition to fluorescence light microscopy (FLM), 
revealing the subcellular localization of proteins, we also used electron microscopy 
(EM) to analyze the general effects of immunostaining procedures on the cellular 
ultrastructure. Given the often dramatic effects, we emphasize that the use of 
fluorescent proteins in living cells as controls should be routinely applied when studying 
the localization of proteins. 
To combine live-cell imaging with uncompromised high resolution EM, an important 
and increasingly used microscopy technique can be used, so-termed correlated light 
and electron microscopy (CLEM, Chapter 2b 1 0) .  With this method, selected cells or 
proteins of interest are first visualized by FLM, followed by examination by EM. CLEM 
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thus allows it to study the dynamics of proteins in living cells and to merge the resulting 
functional findings with structural information of the same molecules or cells. One of 
the major challenges of CLEM is to find back the cell of interest imaged by FLM by 
EM. Here, we presented an approach that facilitates this matching by using mosaic 
microscopy, generating large area overviews, and a virtual overlay of the generated 
pictures during sample processing. In follow-up studies of Chapter 3 (see below), we 
will use CLEM to reveal whether EpCAM mutants that are retained in the endoplasmic 
reticulum (ER) may affect the ultrastructure of this organelle. 
In Chapter 3, the first chapter focusing on EpCAM function and signaling, we took 
advantage of EpCAM gene mutations identified as the basis for congenital tuft ing 
enteropathy (CTE)4 • This rare disease is manifested by severe and often fatal diarrhea 
in newborns as a result of abnormal development of the intestinal epithelium. 
Since the mutations found in patients affect both the structure and the function of 
EpCAM, studying them may aid in the understanding of EpCAM's function. Hence, we 
characterized the molecular consequences of the eight different mutations identi fied 
to date on the protein and its subcellular local ization. We found that all the mutations 
lead to absence of EpCAM from the cell surface, either due to secretion, degradation, 
or ER-retention, explaining why the different mutations generate the same disease. Our 
findings highl ight the importance of EpCAM's plasma membrane localization for proper 
functioning and for the normal morphogenesis of the human intestine. 
In contrast to its absence, high levels of EpCAM have been implicated in cell 
proliferation and tumor progression1 1 •7 . In 2009, two models of EpCAM signaling 
have been proposed. The first model is based on activation of EpCAM signaling by 
regulated intramembrane proteolysis (RIP; see chapter 1, F ig. 6)1 2 . Here, the cleavage 
of EpCAM, involving metalloprotease ADAM 1 7, eventually leads to translocation of 
the cytoplasmic domain to the nucleus, altering transcription of cell cycle-related 
target genes. The second model of EpCAM signaling suggests that EpCAM signaling 
is affected by co-recru i tment with tight junction protein Claudin7 into tetraspanin­
enriched microdomains (TEMs), which can function as signaling platforms (see chapter 
1, Fig. 8)1 3 .  It is possible that both models work independently, but it may also be that 
in fact the proposed mechanisms are combined (hypothesis of Chapter 5). 
Chapter 4 first addresses where and when EpCAM is proteolytically cleaved, and 
provides a biochemical characterization of all EpCAM-derived protein fragments. Due to 
EpCAM's discovery in a screen for tumor-specific cell surface proteins, the majority of available 
antibodies is directed against EpCAM's extracellular domain. To be able to distinguish 
between EpCAM's large extracellular domain and its short cytoplasmic tail, we first designed 
an antibody directed against the (-terminal domain. Besides the known peptides derived 
from RIP and an earlier identified cleavage in the N-terminal region, we identified several 
novel C-terminal fragments with the new antibody that had not been described before and 
may affect EpCAM's function. The determination of EpCAM's specific cleavage sites would 
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allow elucidating the function of the individual cleavage steps and proteolytic fragments, 
but could unfortunately not be completed in the scope of this thesis. However, our findings 
highlight that EpCAM proteolysis at distinct sites is important in the regulation of EpCAM 
signaling. The newly identified (-terminal fragments and their implication in EpCAM's 
function provide an interesting basis for follow-up studies. 
In Chapters 5, we asked whether EpCAM proteolysis is regulated by its localization 
in TEMs, combining the two models described above. Besides EpCAM, metalloprotease 
ADAM10, the closest relative of ADAM17, has been found in association with the 
tetraspanin CD9 and thus as part of TEMs (chapter 1, Fig. 8)1 4 • Our results revealed 
the involvement of ADAM 10 in EpCAM proteolysis, which likely takes place in TE Ms. 
The fact that EpCAM plays a role in TEMs raises the question whether EpCAM actually 
functions as a cell-cell adhesion molecule (CAM). While its name implies a prominent 
role in mediating cell adhesion in epithelia, EpCAM has been shown to destabilize 
E-Cadherin-mediated adherens junctions when co-expressed, thus acting in an anti­
adhesive manner 1 5. To address how EpCAM ranks among classical CAMs, we compared 
the localization and dynamics of EpCAM with junction-associated proteins. We found 
that EpCAM displays a higher mobility in the plasma membrane than classical cell-cell 
contact proteins and that it is not restricted to cell-cell contacts. In conclusion, EpCAM 
does not act like a typical CAM, but may predominantly function as a proliferation­
inducing/-regulating signaling protein. 
GENERAL CONCLUSION, DISCUSSION AND PERSPECTIVES 
EpCAM was discovered as a tumor marker more than three decades ago and has since 
been identified to play a role in several diseases and during normal tissue development 
and maintenance. However, the overall understanding of EpCAM's biological role is 
still incomplete. The findings presented in this thesis contribute to the knowledge on 
EpCAM's signaling properties and function. Most importantly, our results highlight 
the significance of EpCAM's localization at the cell surface for proper function and 
signaling, which may be induced and regulated by various proteolytic cleavage events 
and localization in special signaling platforms, i.e. TEMs. 
The original aim of this thesis was to unravel the mechanism of EpCAM-induced 
beta-cell proliferation, based on the finding that EpCAM plays a morphoregulatory role 
in the development of pancreatic islets of Langerhans1 . Strikingly, a 10-fold increase of 
beta-cell mass could be observed in pancreas sections from transgenic mice expressing 
EpCAM (unpublished results of V. Cirulli). These findings raised our interest in utilizing 
EpCAM for the generation of insulin-producing beta-cells, which are destroyed by an 
autoimmune reaction in Type I Diabetes. However, our studies showed that EpCAM 
is not a useful target for the manipulation of beta-cell proliferation, because of its 
absence in already differentiated cells. 
Nevertheless, it seems certain that high levels or overexpression of EpCAM promote 
cell proliferation. As a basic prerequisite, EpCAM needs to be localized at the cell surface, 
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where it may engage in homophilic adhesion and/or interact with other cell surface 
proteins. Post-translational modifications of EpCAM such as glycosylation and proteolytic 
cleavage at various sites, as well as association with binding partners and localization in 
TEMs seem to be important factors in the activation and regulation of EpCAM signaling. 
The devastating consequences of the absence of EpCAM, as seen in CTE patients as 
well as in knock-out mice, demonstrate that EpCAM is essential during embryogenesis 
and the normal development of tissues . However, when EpCAM levels exceed a certain 
limit, the balance between proliferation and differentiation is disturbed, as seen in 
epithelial cancer. What could be the initial trigger for the enhanced EpCAM expression in 
cancer? First of all, it has been shown that ablation/downregulation of tumor suppressor 
protein p53 is associated with an increase in EpCAM expression 1 6, possibly explaining 
EpCAM's frequent overexpression in tumors. In addition, EpCAM has been found as a 
target of Wnt signaling 1 7 . Since proteolytic cleavage of EpCAM's intracellu lar domain 
( ICD) has been shown to induce genes via Wnt, EpCAM itself may trigger a positive 
feedback loop, increasing its expression 1 2 . Moreover, differential expression levels of the 
various proteins interacting with EpCAM in malignant versus healthy tissue, for example 
ADAM metalloproteases, might aid in EpCAM being "out of control " in cancer. 
Future investigation of EpCAM signaling at the molecular level should include the 
identification of EpCAM's exact cleavage sites. Generating non-cleavable mutants and 
the precise fragments would allow unraveling the roles of the individual proteolytic 
events and their spatiotemporal localization in EpCAM signaling. In addition, EpCAM's 
three-dimensional structure would aid in the understanding of EpCAM signaling by 
providing information about possible binding and cleavage sites. Structural insight 
would also provide the possibility to use rational design approaches for the development 
of cancer therapeutics targeting EpCAM. 
Due to its frequent tumor-specific overexpression, EpCAM is not only of high 
interest for cancer therapy but also as a diagnostic marker. Since most antibodies 
bind to the ectodomain, proteolysis of EpCAM has to be taken into consideration. 
Absence of EpCAM staining might not reflect lack of protein expression, but could 
be due to the proteolytic removal of the ectodomain. To rule out epitope loss due to 
cleavage or possible artifacts when using antibodies against EpCAM's ICD in tissue 
material , it might be reasonable to include the assessment of mRNA levels . This would 
also allow validating the occurrence and relevance of EpCAM proteolysis during cancer 
progression in vivo . 
Since the knowledge on EpCAM signaling is mainly derived from in vitro studies, 
it will be crucial to elucidate EpCAM under more physiological conditions. EpCAM's 
multiple roles in different types of cancer suggest that the regulation of EpCAM 
signaling is affected by the microenvironment, which is difficu lt to mimic in in vitro 
models . The generation of conditional knock-out or transgenic mice would allow further 
determining EpCAM's function during normal development and the pathogenesis of 
diseases, including cancer and CTE . 
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Interesting aspects regarding EpCAM's role in health and disease include the 
presence of EpCAM in embryonic stem and progenitor cells, as well as in cancer 
initiating cells and on exosomes. Released and taken up by (tumor) cells, exosomes can 
alter the fate of their target cell by transferring proteins as well as mRNA and microRNA. 
Hence, exosomes display high potential as a delivery method for gene therapy1 8• 1 9 . 
EpCAM's expression on stem and progenitor cells may open new possibilities for tissue 
engineering and stem cell treatment. Regarding Type I Diabetes, the EpCAM-expressing 
pancreatic duct epithelium, possibly housing the endocrine progenitor cells, may be a 
promising target for beta-cell expansion. 
Finally, the understanding and manipulation of EpCAM function and signaling will 
aid in the development of treatments for multiple diseases in different areas, not only 
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Goed gereguleerde celproliferatie en differentiatie zijn cruciaal voor een normale 
ontwikkeling en het levenslange onderhoud van cellen en weefsels. Vele ziekten, 
waaronder kanker en aangeboren afwijkingen, zijn een direct gevolg van een verstoorde 
regulatie van de betrokken moleculaire mechanismen. In dit proefschrift ligt de nadruk 
op het ontrafelen van het mechanisme van groeicontrole door het eiwit EpCAM. 
Dit transmembraaneiwit is normaal gesproken aanwezig is op het oppervlak van 
epitheelcellen en speelt een rol in de regulatie van celproliferatie en differentiatie. Hoge 
EpCAM niveaus zijn gevonden gedurende morfogenese en regeneratieve processen, 
maar ook in stamcellen en voorlopercellen die het vermogen tot vernieuwing moeten 
behouden 1 -3 _ Aan- en afwezigheid van EpCAM is strikt gereguleerd in diverse celtypes 
in gezond weefsel, maar deze controle is verloren gegaan bij bepaalde ziekten : 
afwezigheid van functioneel EpCAM veroorzaakt ernstige diarree bij pasgeborenen als 
gevolg van abnormale ontwikkeling van het dunne darm (intestinale) epitheel4, terwijl 
overexpressie van EpCAM vaak gevonden wordt in epitheliale tumoren5 7. De hoge 
expressie van EpCAM in deze tumoren heeft zelfs geleid tot de ontdekking van het 
eiwit in een screen voor tumor-specifieke antigenen op het celoppervlak in de jaren ' 70. 
Door de gelijktijdige identificatie van EpCAM door diverse onderzoeksgroepen zijn er 
minstens 10 namen ge"fntroduceerd. Momenteel is de meest gangbare naam ".E.Qithelial 
.hell Adhesion Molecule", een naam die naar de expressie en functie van eel-eel interactie 
door binding van EpCAM-eiwitten van nabuurcellen verwijst8 • Een uitgebreid overzicht 
van de huidige kennis over de structuur/functie relatie van EpCAM, met nadruk op 
signaleringseigenschappen, staat beschreven in hoofdstuk 1 .  
Om de structuur/functie relatie te onderzoeken, is het niet alleen belangrijk om 
te weten of EpCAM aanwezig is, maar ook precies te weten waar in het weefsel en 
waar in de eel het voorkomt. Verder is het van belang te weten of het er continue 
aanwezig is of dat dit tijdsafhankelijk gereguleerd wordt. Plaatsbepaling met behulp 
van microscopie biedt hier uitkomst. Voor EpCAM lokalisatie zijn er echter tegenstrijdige 
gegevens in de literatuur beschreven, die soms ook afwijken van onze eigen resultaten. 
Daarom hebben we eerst kritische onderzoek gedaan naar de effecten van verschillende 
immunokleuring procedures en technieken (hoofdstuk 2a9) .  Een belangrijk nadeel 
bij visualisatie van eiwitten met behulp van immunofluorescentie is de noodzaak van 
fixatie en permeabiliseren van cellen. Deze procedure kan artefacten veroorzaken 
zoals eiwitextractie en herverdeling van moleculen in de eel. De uitkomst van deze 
experimenten weerspiegelt dan niet langer de lokalisatie zoals deze was in de levende 
eel. Om betrouwbare resultaten te krijgen, moet een compromis tussen de kwaliteit 
van het behoud van membraanstructuur en de mogelijkheid om immunoreagentia 
in de cellen te laten doordringen warden bereikt. Hoewel fixatie en permeabilisatie 
ge"fnduceerde artefacten eerder onder de aandacht zij n gebracht, warden vaak 
traditionele niet geoptimaliseerde protocollen gebruikt. Om de veelvoorkomende 
artefacten als gevolg van standaard immunokleuring procedures te benadrukken, 




de methoden geanalyseerd die worden gebruikt om de specifieke lokalisatie van 
eiwitten aan te tonen, met belangrijke controle fluorescerende eiwitten in levende 
cellen. Naast fluorescentiemicroscopie (FLM), waarmee de subcellulaire lokalisatie van 
eiwitten bepaald wordt, is glektronenmicroscopie (EM) gebruikt om de gevolgen van 
immunokleuringstechnieken op de cellulaire (ultra)structuur te analyseren. Gezien de 
vaak dramatische effecten van deze procedures, zou het gebruik van fluorescente 
eiwitten om ook in de levende eel de plaatsbepaling te kunnen doen tegenwoordig 
standaard moeten worden toegepast. 
Om "live-cell imaging" te combineren met hoge resolutie EM, dat onverenigbaar 
is met bestuderen van levende cellen, is ge�orreleerde licht- en glektronenmicroscopie 
ontwikkeld (CLEM, hoofdstuk 2b 10). CLEM selecteert eerst cellen of eiwitten met FLM, 
gevolgd door analyse van de onderliggende (ultra)structuur met EM. CLEM maakt het dus 
mogelijk om zowel de dynamiek van eiwitten in levende cellen te bestuderen, en vervolgens 
te combineren met structurele informatie van dezelfde moleculen en cellen. Een van de 
belangrijkste uitdagingen van de CLEM is het terugvinden in de EM van dezelfde plaats die is 
opgenomen met FLM. Wij presenteren een manier die deze matching vergemakkelijkt door 
het gebruik van moza·1ek microscopie. Deze vorm van microscopie wordt gecombineerd met 
het genereren van een virtueel beeld door het monster te prepareren voor EM met behulp van 
het FLM beeld. In een vervolgstudie gebaseerd op hoofdstuk 3 wordt door ans momenteel 
CLEM toegepast om te bepalen of EpCAM mutanten van patienten de ultrastructuur van het 
gndoplasmatisch reticulum (ER) be·1nvloeden. 
In hoofdstuk 3 bestuderen we de EpCAM structuur/functie relatie door gebruik 
te maken van EpCAM genmutaties ge"fdentificeerd op basis van een aangeboren 
darmafwijking (" .congenital tufting .e_nteropathy"; CTE)4. Deze zeldzame ziekte 
manifesteert zich door ernstige en dikwijls fatale diarree bij pasgeborenen als gevolg 
van abnormale ontwikkeling van het darmepitheel. Omdat door de mutaties zowel 
structuur en functie veranderd zijn, kan onderzoek bij deze patientenpopulatie wellicht 
helpen om de functie van EpCAM beter te begri jpen. Al ie  acht ge"fdentificeerd mutaties 
zijn getest. De verschillende mutaties leiden tot zeer diverse eiwitten, varierend van een 
puntmutatie, een kleine deletie tot truncaties van EpCAM. Functioneel hebben deze 
mutati es, naast het ziektebeeld, gemeenschappelijk dat mutant EpCAM afwezig is van 
het celoppervlak. Afhankelijk van de mutatie is dit het gevolg van secretie of afbraak 
(mutaties die leiden tot truncaties), of ER-retentie (puntmutant en deletiemutant). 
De afwezigheid van EpCAM op het celoppervlak verklaart waarom de verschillende 
mutaties leiden tot dezelfde ziekte. Onze bevindingen benadrukken het belang van 
EpCAM lokalisatie aan de plasmamembraan voor een goede werking en voor de 
normale morfogenese van de menselijke darm. 
Niet alleen afwezigheid, maar ook teveel EpCAM kan leiden tot ziektebeelden: veel 
EpCAM expressie wordt gezien bij snelle celproliferatie; een te veel aan EpCAM is 
geassocieerd met tumorprogressie7• 1 1 . Gedurende mijn promotieonderzoek zijn twee 
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modellen van EpCAM signalering onderzocht en getoetst die transcriptieprogramma's 
kunnen be·invloeden: Het eerste model is gebaseerd op de activering van EpCAM 
signalering door "gereguleerde intramembraan Qroteolyse" (RIP; hoofdstuk 1, figuur 6)1 2. 
Hier is de splitsing van EpCAM door het metalloprotease ADAM17 essentieel. Uiteindelijk 
leidt deze splitsing tot translocatie van het cytoplasmatische domein naar de kern, dat 
zorgt voor veranderde transcriptie van celcyclus-gerelateerde genen. Het tweede model 
suggereert dat EpCAM signalering wordt be"invloed doordat het eiwit samen met het tight 
junction eiwit Claudine7 in tetraspanin verrijkte microdomeinen (TEM) wordt gebracht, 
wat een signaleringsbolwerk is (hoofdstuk 1, figuur 8)1 3. Het is mogelijk dat beide 
modellen onafhankelijk van elkaar werken, maar het kan ook zijn dat in werkelijkheid de 
voorgestelde mechanismen gecombineerd zijn (hoofdstuk 5). 
In Hoofdstuk 4vragen weons in eerste instantieaf hoe en wanneer EpCAM in extracellulair 
en cytoplasmatische delen wordt geknipt, dat resulteert in diverse nieuwe polypeptiden. 
Cruciaal zijn hier goede reagentia: de meeste anti-EpCAM antilichamen zijn gericht 
tegen het extracellulaire domein, gevonden in screens voor tumorantigenen. Om verschil 
te kunnen maken in het grote extracellulaire domein en het cytoplasmatische domein, 
is eerst een antilichaam ontworpen tegen de carboxyterminale cytoplasmatische staart 
(circa 30 aminozuren lang). Hoewel er al knipplaatsen in EpCAM geTdentificeerd waren, 
bleek direct met het gebruik van dit nieuwe antilichaam dat er meer fragmenten van 
EpCAM bestaan dan eerder aangetoond. Alie fragmenten zijn systematisch biochemisch 
gekarakteriseerd. Naast de bekende peptiden afgeleid van RIP en een eerder vastgestelde 
splitsing in de aminoterminale regio vinden we verschillende nieuwe carboxyterminale 
fragmenten die niet eerder beschreven zijn, en die potentieel de functie van EpCAM 
kunnen be"invloeden. Geprobeerd is om de exacte knipplaats te bepalen, om ook deze 
artificieel na te maken zoals gedaan voor de mutaties beschreven in hoofdstuk 3. Hoewel 
we de fragmenten redelijk kunnen zuiveren, zal dit in de toekomst opgeschaald moeten 
worden om de exacte splitsingsplaats succesvol te kunnen bepalen. Onze bevindingen 
benadrukken dat EpCAM proteolyse op vele plaatsen van belang is bij de regulatie van 
EpCAM signalering. In het verlengde van hoofdstuk 3 lijkt het dat het aminoterminale 
deel van EpCAM voor de eel zelf geen functie meer heeft, het zal immers niet meer 
met het celoppervlak geassocieerd zijn. De nieuw-ontdekte carboxyterminale delen van 
EpCAM zijn belangrijke kandidaten om de andere functies dan celadhesie (hoofdstuk 5) 
te reguleren, een interessante basis voor vervolgstudies. 
De hypothese in hoofdstuk 5 combineert de twee modellen die hierboven zijn 
beschreven: wordt EpCAM proteolyse gereguleerd door de lokalisatie in TEMs? Een 
familielid van ADAM17, namelijk het metalloprotease ADAM10, is gevonden in 
associatie met de tetraspanine CD9, een ander eiwit dat met EpCAM in TEMs wordt 
gevonden (hoofdstuk 1, figuur 8)1 4. Onze resultaten tonen de betrokkenheid van 
ADAM 10 in EpCAM proteolyse aan, die waarschijnlijk plaatsvindt in TE Ms. Als EpCAM 
een rol speelt in TEMs, werpt dit direct de vraag op of het wel een celadhesie-eiwit is, 
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wat de naam " Epithelial Cell Adhesion Molecule " immers impl iceert. Echter, EpCAM 
kan E-cadherine-gemedieerde adherens junctions destabiliseren, waardoor celadhesie 
verzwakt wordt1 5 . Om er achter te komen of EpCAM een klassiek celadhesiemolecuul 
i s, hebben we de !oka ! i satie van EpCAM en de dynamiek verge!eken met zogenaamde 
adherens-, gap- en tight junction-geassocieerde eiwitten. We vinden dat EpCAM ook 
buiten eel-eel contacten aanwezig is, en dat het met een hogere mobiliteit door het 
plasmamembraan diffundeert dan de k!assieke eel-eel contact eiwitten. EpCAM is dus 
zeker niet een typische structureel eel-eel contact eiwit, en de belangrijkste functie 
is wellicht niet het positief be'fnvloeden van eel-eel adhesie, maar een pro! iferatie/ 
differentiatie sturend signaleringseiwit. 
ALG EM ENE CONCLUS IE  - EpCAM werd meer dan dertig jaar geleden ontdekt a !s  
een tumormarker. S indsdien is het duidel ijk geworden dat het eiwit ook een actieve 
rol speelt in diverse z iekten. Echter, hoe en waarom EpCAM in normaal weefsel 
functioneert en we!k  mechanisme er ten grondslag l igt aan de regulatie en het 
disfunctioneren was nog onbekend. Niet alleen bestaan er schijnbare tegenstell ingen 
over EpCAM's functie, maar z ijn er ook bevindingen controversieel. Dit proefschrift laat 
z ien dat er op grate schaal routine-technieken warden gebrui kt op gefixeerde cellen 
in de celbiologie, het bestuderen van de levende eel, die vaak leiden tot verkeerde 
beeldvorming. Door revolutionaire technieken is het meer en meer mogel ijk, en daarom 
essentieel, om eiwitlokal isatie en biologische/biochemische processen ook in de levende 
eel te bestuderen. De toepassing hiervan en de bevindingen in dit proefschrift dragen 
b ij aan de kennis over het s ignaal transductieeigenschappen van EpCAM. De resultaten 
benadrukken dat voor een normale functie tijdens de embryogenese de lokal isatie van 
transmembraan EpCAM aan het celoppervlak cruciaal is. Hoewel het paradoxaal lijkt, 
is het ook duidelijk dat signalering en functie geactiveerd warden door verscheidene 
proteolytische splitsingen. Andere onderzoeksgroepen hebben aangetoond dat 
dit fenomeen zich afspeelt onafhankel ijk van signaleringsplatforms zoals TEMs, dit 
proefschrift laat z ien dat de twee modellen wellicht samengaan. In de toekomst zal de 
kennis en het onderzoek naar de rol en de functie van EpCAM bij signaal transductie 
helpen b ij de ontwikkel ing van de behandel ing van verschillende typen z iekten, 
waaronder kanker en regeneratieve geneeskunde. 
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D E UTSCH E  ZUSAM M E N FASS U N G  
Die Regulation der Zellproliferation (Zellvermehrung) und der Zelldifferenzierung spielt 
eine entscheidende Rolle in der Entwicklung und Aufrechterhaltung von Geweben. Ein 
Ungleichgewicht dieser wichtigen Prozesse ist an der Entstehung vieler Krankheiten 
beteiligt, darunter auch Krebs. Das epitheliale ZelladhasionsmolekOI EpCAM kommt 
in den meisten epithelialen Geweben vor und beeinflusst die Balance zwischen 
Zellproliferation und Zelldifferenzierung: Hohe Expressionswerte von EpCAM korrelieren 
mit der Vermehrung von Zellen, zum Beispiel wahrend der Morphogenese, regenerativer 
Prozesse, sowie in Stamm- und Vorlauferzellen, die ihre Selbst-Erneuerungskapazitat 
aufrecht erhalten m0ssen1 3. Wahrend das Vorhandensein bzw. das N icht­
Vorhandensein von EpCAM in gesundem Gewebe streng reguliert ist, erscheint die 
Kontrolle dieses Gleichgewichts im Falle bestimmter Krankheiten verloren gegangen 
zu sein. So fOhrt das Fehlen von EpCAM zur Missbildung des Darmepithels, was fatale 
Durchfallerkrankungen bei Neugeborenen zur Folge hat4, wohingegen eine Oberhohte 
Expression von EpCAM haufig in epitheliaren Tumoren zu finden ist5 7. EpCAMs 
hohe Expression in Krebszellen fOhrte wahrend der Suche nach tumor-spezifischen 
Zelloberflachenproteinen in den 1970er Jahren zu dessen Entdeckung. Aufgrund der 
zeitgleichen ldentifizierung durch verschiedene Forschergruppen erhielt EpCAM eine 
Vielzahl von Bezeichnungen, von denen noch heute viele in der Literatur verwendet 
werden. Der heutzutage gelaufige Name " Epithelial Cell Adhesion Molecule" verweist 
auf den Ort der Expression des Proteins und dessen Fahigkeit, Zell-Zell-Adhasion durch 
homophile Bindung zu vermitteln8 . Kapitel 1 gibt einen umfassenden Oberblick Uber 
den aktuellen Wissensstand in Bezug auf die Struktur von EpCAM, dessen Eigenschaften 
als SignalmolekO I  sowie dessen bislang beschriebene unterschiedliche Funktionen. 
Zielsetzung dieser Arbeit war die EntschlOsselung des Mechanismus der von EpCAM 
vermittelten Signaltransduktion. Um die Beziehung zwischen Struktur und Wirkung 
genauer zu untersuchen, ist es nicht nur wichtig zu wissen, ob EpCAM vorhanden ist, 
sondern auch, wo genau EpCAM in Geweben und Zellen lokalisiert ist. Des Weiteren 
spielt eine wichtige Rolle, ob das Protein kontinuierlich oder zeitabhangig anwesend 
ist. Mikroskopie bietet die Moglichkeit, diese Fragen zu beantworten. WidersprOchliche 
Angaben in der Literatur, sowie Unstimmigkeiten mit unseren eigenen Oaten bezUglich 
EpCAMs Lokalisierung fOhrten uns zu der kritischen Untersuchung der Auswirkungen 
verschiedener lmmunfarbungsverfahren (Kapitel 2a9). Ziel dieser Methode ist es, Proteine 
mit Hilfe von Antikorpern in ihrer natOrlichen ,, in vivo" Lokalisierung sichtbar zu machen. 
Ein wesentlicher Nachteil bei diesem Verfahren ist die Notwendigkeit der Fixierung 
und Permeabilisierung von Zellen, da dies zu Artefakten wie Proteinextraktion oder 
Umverteilung fOhren kann. Um zuverlassige Ergebnisse zu erhalten, muss ein Kompromiss 
zwischen der Qualitat der Zellkonservierung (durch Fixierung) und der Fahigkeit, mit 
lmmunreagenzien in die Zellen eindringen zu konnen (durch Permeabilisierung), 
gefunden werden. Obwohl Artefakte bereits frUher erkannt und beschrieben wurden, 
benutzen Laboratorien haufig traditionelle, nicht optimierte Protokolle. Mit dem Ziel 
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das Bewusstsein Ober Artefakte durch Standard-lmmunfarbungsverfahren zu erhohen, 
OberprOften wir die vorhandene Literatur und prasentieren eigene Oaten aus dem 
Vergleich mehrerer Methoden und unterschiedlich lokalisierter Proteine. Unsere Studie 
betont, dass die Verwendung von fluoreszierenden Proteinen in lebenden Zellen eine 
essentielle Kontrolle fur lmmunfarbungsexperimente darstellt. 
Um fluoreszierende Proteine oder Proben im strukturellen Kontext der gesamten 
Zelle zu untersuchen, kann eine zunehmend genutzte Mikroskopie-Technik angewandt 
werden, bezeichnet als ,, korrelierte Licht- und Elektronenmikroskopie" (Correlated light 
and electron microscopy, CLEM; Kapitel 2b 1 0) .  Bei diesem Verfahren werden ausgewahlte 
Proteine erst durch Fluoreszenz visualisiert und im Anschluss die zugrunde liegende 
zellulare Ultrastruktur mit Hilfe hochauflosender Elektronenmikroskopie sichtbar gemacht. 
So ermoglicht CLEM es, die Dynamik von Proteinen in lebenden Zellen zu studieren 
und die sich ergebenden funktionellen Erkenntnisse mit strukturellen lnformationen 
zusammenzufuhren . Eine der gr6Bten Herausforderungen von CLEM ist es, den Bereich, 
der mit dem Lichtmikroskop abgebildet wurde, im Elektronenmikroskop wiederzufinden, 
sodass sich beide Bilder decken. Wir prasentieren eine Methode, die dieses Wiederfinden 
durch das Erstellen groBflachiger Obersichten (Mosaik-Mikroskopie) wahrend der 
Praparat-Verarbeitung erleichtert. In Folgestudien von Kapitel 3 (siehe unten) werden 
wir mit Hilfe von CLEM OberprOfen, ob EpCAM Mutanten, die im endoplasmatischen 
Reticulum (ER) zurOckgehalten werden, die Ultrastruktur dieses Organells beeinflussen . 
In Kapitel 3 ,  dem ersten Kapitel mit Schwerpu nkt auf EpCAM, untersuchten wir 
EpCAM Genmutationen, die als Grund fur die angeborene Tufting-Enteropathie 
(Congenital Tufting Enteropathy, CTE)4 identifiziert wurden .  Diese seltene Krankheit 
ist durch eine abnorme Entwicklung des Darmepithels gekennzeichnet, die bei 
Neugeborenen zu schweren und oft zum Tode fuhrenden Durchfallen fOhrt. Um die 
Beziehung zwischen Struktur und Funktion von EpCAM zu studieren ,  wurden die 
Auswirkungen der acht verschiedenen bisher identifizierten Mutationen auf das Protein 
und dessen subzellulare Lokalisierung untersucht. Die E rgebnisse zeigen ,  dass alle 
Mutationen zur Abwesenheit von EpCAM von der Zelloberflache fOhren, entweder 
aufgrund von Sekretion, Degradierung oder ER-Retention des mutierten Proteins. Dies 
erklart warum die verschiedenen Mutationen das gleiche Krankheitsbild hervorrufen.  
Unsere Ergebnisse unterstreichen, dass EpCAMs Lokalisieru ng in der Plasmamembran 
von entscheidender Bedeutung for die einwandfreie Funktion des Proteins sowie fur die 
normale Entwicklung des menschlichen Darms ist. 
Im Gegensatz zu den beschriebenen Ursachen und Folgen der Abwesenheit von 
EpCAM, ist eine Oberexpression von EpCAM in den Prozess der Zellproliferation und 
Tumorprogression involviert7 • 1 1 . Im Jahr 2009 wurden zwei Madelle zur EpCAM­
vermittelten Signaltransduktion vorgestellt. Das erste Modell basiert auf der Aktivierung 
der EpCAM-induzierten SignalObertragung durch regulierte lntramembranproteolyse 
(Regulated intramembrane proteolysis, RIP; siehe auch Kapitel 1 ,  Abbildung 6) 1 2 . Diese 
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Proteolyse von EpCAM fOhrt letztendlich zur Translokation der Zytoplasmadomane zum 
Zellkern, wodurch eine erhohte Transkription zellzyklus-beeinflussender Gene ausgelost 
wird. Das zweite Model! besagt, dass die EpCAM-vermittelte Signaltransduktion von der 
Bindung mit Claudin7 und der Lokalisierung in tetraspanin-angereicherten Mikrodomanen 
(Tetraspanin-enriched microdomains, TEMs) in der Plasmamembran abhangig ist, welche 
,, Signalisierungsplattformen" darstellen (siehe auch Kapitel 1 ,  Abbildung 8)1 3 . Die in den 
beiden Modellen vorgestellten Mechanismen ereignen sich moglicherweise unabhangig 
voneinander, konnten jedoch auch kombiniert sein (Hypothese Kapitel 5). 
Kap itel 4 befasst sich in erster Linie mit der Frage, wo und wann EpCAM proteolytisch 
gespalten wird, und bietet im Folgenden eine umfassende Charakterisierung aller 
Proteinfragmente. Gute Reagenzien sind hier von kritischer Bedeutung: Da EpCAM 
in einem Screen for Zelloberflachenproteine entdeckt wurde, sind die meisten anti­
EpCAM Antikorper gegen die extrazellulare Domane gerichtet. Um diese Domane 
von der intrazellularen Domane unterscheiden zu konnen, generierten wir zunachst 
einen Antikorper, der gegen den carboxyterminalen zytoplasmatischen Teil des Proteins 
gerichtet ist. Neben den bekannten Fragmenten, die aus dem RIP-Prozess sowie 
einer bereits frOher identifizierten Spaltung in der N-terminalen Region hervorgehen, 
identifizierten wir mit Hilfe des neuen Antikorpers mehrere zuvor noch nicht beschriebe 
C-terminale Fragmente, die moglicherweise die Funktion von EpCAM beeinflussen. 
Um der Rolle der einzelnen proteolytischen Ereignisse und der daraus resultierenden 
Proteinfragmente auf den Grund zu kommen, wurde versucht, die genauen Positionen 
der Spaltung in EpCAM mit Hilfe von Massenspektrometrie zu bestimmen. Diese Studie 
konnte leider im Rahmen dieser Arbeit nicht erfolgreich abgeschlossen werden. Die 
Ergebnisse in Kapitel 4 belegen, dass die Proteolyse von EpCAM ein entscheidendes 
Element in der Regulierung der EpCAM-Signalgebung darstellt. Als potentielle 
Kandidaten in diesem Prozess liefern die neu-entdeckten C-terminalen EpCAM­
Fragmente eine interessante Basis fur Folgestudien. 
Die Hypothese in Kapitel 5 kombiniert die beiden oben beschriebenen Modelle: Wird 
die Proteolyse von EpCAM durch dessen Lokalisierung in TEMs reguliert? Sowohl EpCAM 
als auch die Metalloprotease ADAM10 wurden in einem Komplex mit Tetraspanin CD9 
nachgewiesen und kommen somit in TE Ms vor 1 4 . Unsere Ergebnisse zeigen, dassADAM 1 0  
an der Proteolyse von EpCAM beteiligt ist und dass der Spaltungsprozess mit groBer 
Wahrscheinlichkeit in TEMs stattfindet. Die Tatsache, dass EpCAM eine Rolle in TEMs 
spielt, wirft die Frage auf, ob es sich bei EpCAM wirklich um ein ZelladhasionsmolekO I  
handelt. Obwohl der Name ,,EpCAM " eine bedeutende Rolle in  der Vermittlung der 
Zelladhasion in Epithelzellen nahelegt, kann EpCAM die durch klassische cadherine­
vermittelten Adharenzverbindungen destabilisieren und wirkt somit antiadhasiv1 5. Um 
die Zuordnung EpCAMs zu den klassischen ZelladhasionsmolekOlen zu OberprOfen, 
verglichen wir die Lokalisierung von EpCAM und dessen Dynamik mit der von junction­
assoziierten Proteinen. Unsere Studien zeigen, dass EpCAM in der Plasmamembran im 
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Vergleich zu klassischen Zelladhasionsmoleku!en auch auBerhalb von Ze! !-Ze! ! -Kontakten 
zu finden ist, und gleichzeitig eine hohere Beweglichkeit aufweist. Zusammenfassend 
ist somit festzustellen, dass EpCAM kein typisches Zelladhasionsmolekul, sondern in 
erster Linie ein zellproliferation-induzierendes/-mode!ierendes Signalprotein darstellt. 
ALLG EM EI N E  SCH LUSSFOLG ERUNG - EpCAM wurde vor mehr a!s drei Jahrzehnten 
als Tumormarker entdeckt und seither mit verschiedenen Erkrankungen sowie mit 
der Entwicklung und Aufrechterhaltung gesunder Gewebe in Verbindung gebracht. 
Wie und warum EpCAM jedoch in normalem Gewebe funktioniert und welcher 
Mechanismus der Regulation und der Dysfunktion zugrunde liegt war noch unbekannt. 
Das allgemeine Verstandnis der biologischen Rolle von EpCAM ist bis heute noch 
unvollstandig, und neben scheinbar widerspruchlichen Funktionen von EpCAM liegen 
auch kontroverse Erkenntnisse vor. 
Diese Arbeit zeigt, dass in der Zel lbiologie - dem Studium der lebenden Zelle -
oft Routine-Techniken verwendet werden die auf fixierten Zellen basieren, was zu 
Fehlinterpretationen fuhren kann. Durch revolutionare Methoden ist es zunehmend 
moglich, und deshalb essentiell, die Lokalisierung von Proteinen sowie biologische/ 
biochemische Prozesse in lebenden Zellen zu studieren. 
Die in dieser Arbeit vorgestellten Resultate leisten einen wichtigen Beitrag zur 
Aufdeckung der EpCAM-vermittelten Signalgebung und Funktionen. Unsere Ergebnisse 
zeigen, dass die Lokalisierung von EpCAM auf der Zel!oberflache eine entscheidende Rolle 
der fur dessen ordnungsgemaBe Funktion wahrend der Embryogenese spielt. Obwohl es 
paradox erscheint, ist offensichtlich, dass EpCAM-vermitte!te Funktionen von diversen 
proteolytischen Spaltungen beeinflusst/aktiviert wird. Wahrend andere Arbeitsgruppen 
gezeigt haben, dass dieses Phanomen unabhangig von Signa!isierungsplattformen wie 
TEMs stattfindet, belegt diese Arbeit, dass beide Madelle kombiniert sein konnten. Das 
genaue Verstandnis und die Manipulation der EpCAM-vermittelten Signa! transduktion 
werden in Zukunft zur Entwick! ung van Therapien diverser Krankheiten beitragen, nicht 
nur im Bereich der Krebstherapie sondern auch in der regenerativen Medizin. 
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